Scott Kopetz, M.D., Ph.D.

Peer-Reviewed Articles

1. VandenHeuvel, SN, Nash, LL, Clevenger, AJ, Collier, CA, Benavides, OR, Roy, S, Goggans, B, Salikhova, A, Tharakesh, A, Haricharan, S, Stratman, AN, Kopetz, S, Walsh, AJ, Raghavan, S. Decellularized Extracellular Matrix Scaffolds to Engineer the Dormant Landscape of Microscopic Colorectal Cancer Liver Metastasis. Advanced Healthcare Materials 15(8), 2026. e-Pub 2026. PMID: 41083747.
2. Wang, J, Minussi, DC, Davis, A, Wei, R, Ye, H, Sei, E, Schalck, A, Yan, Y, Wu, HJ, Bai, S, Peng, C, Hu, M, Casasent, A, Contreras, A, Chen, H, Hui, D, Damodaran, S, Edgerton, ME, Kopetz, S, Lim, B, Navin, N. Delineating the copy-number substructure of metastatic tumors with CopyKit. Molecular cell 86(2):407-422.e6, 2026. e-Pub 2026. PMID: 41534520.
3. Salem, ME, Puccini, A, Mauer, EA, Andre, T, George, TJ, Tabernero, J, Sinicrope, FA, Tie, J, Kopetz, S, Van Cutsem, E, Lonardi, S, Overman, MJ, Foureau, D. Impact of RAS/BRAFV600E Mutations on the Tumor Immune Microenvironment in Mismatch Repair–Deficient/Microsatellite Instability Colorectal Cancers. Clinical Cancer Research 32(2):417-427, 2026. e-Pub 2026. PMID: 41235954.
4. Galeano Niño, JL, Ponath, F, Ajisafe, VA, Becker, CR, Kempchinsky, AG, Zepeda Rivera, M, Gomez, JA, Wu, H, Terrazas, JG, Bouzek, H, Cromwell, E, Chanana, P, Wong, M, Damania, A, White, MG, You, YN, Kopetz, S, Ajami, NJ, Wargo, J, Johnston, CD, Bullman, S. Tumor-infiltrating bacteria disrupt cancer epithelial cell interactions and induce cell-cycle arrest. Cancer cell 44(1):166-186.e16, 2026. e-Pub 2026. PMID: 41106380.
5. Treekitkarnmongkol, W, Katayama, H, Sankaran, D, Tai, MC, Rauth, S, Chen, H, Nguyen, T, Kobayashi, K, Thege, F, Ponnusamy, MP, Batra, SK, Wang, H, Wistuba, II, Schmittgen, TD, Heymach, JV, Kopetz, S, Hu, T, Yao, W, Maitra, A, Sen, S. RASH3D19 mediates RAS activation through a positive feedback loop in KRAS-mutant cancer. Nature cell biology 28(1):197-206, 2026. e-Pub 2026. PMID: 41326795.
6. Lei, M, Overman, MJ, Yao, J, Andre, T, Lonardi, S, Lenz, HJ, Aglietta, M, Gelsomino, F, Mcdermott, R, Wong, KM, Morse, MA, Van Cutsem, E, Hendlisz, A, Cardin, D, Neyns, B, Hill, A, Krishnamurthy, A, Chen, F, Kochuparambil, ST, Jenq, RR, Abdullaev, S, He, B, Novosiadly, R, Kopetz, S. Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancer. Nature communications 16(1), 2025. e-Pub 2025. PMID: 41053075.
7. Pellatt, AJ, Barnett, RM, Gnerre, S, Edwards, K, Willis, JA, Overmann, MJ, Raghav, KS, Parseghian, C, Dasari, NV, Morelli, MP, Bent, AH, Eluri, M, Hornstein, N, Drusbosky, L, Kopetz, S, Morris, VK. Detection of oncogenic fusions in colorectal cancer using a partner-agnostic next-generation sequencing approach. BMC cancer 25(1), 2025. e-Pub 2025. PMID: 40696295.
8. Lapelusa, M, Qiao, W, Iorgulescu, B, San Lucas, FA, Patel, KP, Bhamidipati, D, Thomas, J, You, YN, Foo, WC, Maru, D, Thirumurthi, S, Morris, VK, Kopetz, S, Overman, MJ, Ludford, K. Long-Term Efficacy of Pembrolizumab and the Clinical Utility of ctDNA in Locally Advanced dMMR/MSI-H Solid Tumors. Nature communications 16(1), 2025. e-Pub 2025. PMID: 40374594.
9. Yazdani, A, Lenz, HJ, Pillonetto, G, Méndez-Giráldez, R, Yazdani, A, Sanoff, HK, Hadi, R, Samiei, E, Venook, AP, Ratain, MJ, Rashid, N, Vincent, BG, Qu, X, Wen, Y, Kosorok, M, Symmans, WF, Shen, JY, Lee, MS, Kopetz, S, Nixon, AB, Bertagnolli, MM, Perou, CM, Innocenti, F. Gene signatures derived from transcriptomic-causal networks stratify colorectal cancer patients for effective targeted therapy. Communications Medicine 5(1), 2025. e-Pub 2025. PMID: 39779996.
10. Maddalena G, der Pol YV, Villarreal OE, Coker O, Lee HM, Rivers Z, Covert W, Diao S, Lonardi S, Rogers JE, Dasari A, Guinney J, Kopetz S, Raghav K. Impact of KRAS codon-specific mutations on survival in metastatic CRC on trifluridine-tipiracil with/without bevacizumab. e-Pub 2025. PMID: 41455083.
11. Kopetz S, Tabernero J, Élez E. BREAKWATER Phase III: results for encorafenib and cetuximab plus mFOLFOX6 in first-line BRAF V600E-mutant metastatic colorectal cancer. Future Oncol. e-Pub 2025. PMID: 41230651.
12. Bild AH, Sangar MC, McQuerry JA, Ideker T, Kopetz S, Carey L, Nath A, Marcus D, Regier A, Rashid N, Barzilay R, Winer E, Salgia R, Malhotra J, Gentles A, Buetow K, Mahmood F, Markman DW, Eddy JA. The ADAPT learning cancer treatment system: ARPA-H's initiative to revolutionize cancer therapy. e-Pub 2025. PMID: 41512871.
13. Folkert IW, Mehran R, Sun R, Morris VK, Overman MJ, Kee B, Antonoff MB, Tzeng CW, Dasari A, Tran Cao H, Parseghian CM, Vilar E, Willis J, Newhook TE, Hofstetter W, Kopetz SE. Hepatectomy Plus Chemotherapy or Chemotherapy Alone for Resectable Liver and Unresectable Lung Metastases from Colorectal Adenocarcinoma (LUNA): A Randomized Phase II Trial. Annals of Surgical Oncology. e-Pub 2025. PMID: 41369813.
14. Alonso S, Raghav K, Morris VK, Alfaro-Munoz K, Bekaii-Saab T, Cannon TL, Corcoran RB, Duesbery N, George M, Hsu D, Lieu C, Maitra A, Maru D, McQuerry JA, Menter D, Mizrahi J, Ng K, Parikh A, Rai K, Sangar MC, Shaw KR, Shen JP, Strickler JH, Feehan AD, Tam AL, Vetere G, Yaeger R, Yuan Y, Shen X, Bild AH, Kopetz S. Framework for cancer evolution profiling and interception in colorectal cancer: ASCEND-CRC program. Cancer Cell. e-Pub 2025. PMID: 41512869.
15. Lin C, Gheorghe V, Chou J, Alibai S, Kim S, Nazanin EA, Xu Y, Ma X, Wilson LL, Moser RD, Kemp CJ, Chen J, Kopetz S, Hart T. Functional modules predict cancer-relevant genetic interactions in mammalian cells. e-Pub 2025. PMID: 41446269.
16. Maddalena, G, Zeineddine, F, Chowdhury, S, Zeineddine, MA, Yousef, A, Bergamo, F, Lonardi, S, Yap, TA, White, MG, Overman, MJ, Kopetz, S, Shen, JY. Prognosis and treatment response stratification according to loss of proofreading (LOP) POLE variants. Journal for immunotherapy of cancer 13(11), 2025. e-Pub 2025. PMID: 41253491.
17. Morris, VK, Parseghian, C, Bahrambeigi, V, Abdelfattah, N, Xiao, L, Agrawal, A, Lin, K, Raghav, KS, Wolff, RA, Dasari, NV, Huey, RW, Kee, BK, Overman, MJ, Willis, JA, Le, PH, Escano, M, Baig, YC, Pan, K, Menter, DG, Tam, AL, Foo, WC, Shen, L, Lee, HM, Gallup, T, Margain, C, Gallup, D, Rajapakshe, K, Guerrero, PA, Wang, J, Corcoran, RB, Maitra, A, Yun, K, Kopetz, S. Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAFV600E metastatic colorectal cancer. Cancer cell 43(11):2106-2118.e3, 2025. e-Pub 2025. PMID: 40882637.
18. Montierth MD, Yan H, Xie L, Nemeth K, Pan X, Li R, Ercan C, Yang P, Sinjab A, Zhou T, Peng F, Singh M, Wang L, Kopetz S, Kadara H, Yuan Y, Calin GA, Wang W. Deconvolution of Sparse-count RNA Sequencing Data for Tumor Cells Using Embedded Negative Binomial Distributions. e-Pub 2025. PMID: 41394660.
19. Jones, JC, Hegde, A, Huang, YJ, Manyam, GC, Srivastava, V, Song, JH, Cheng, Y, Krahe, R, Treekitkarnmongkol, W, Meltzer, SJ, Kopetz, S, Hamilton, SR, Katayama, H, Sen, S. Chromosome 20q gene signature associated with colorectal cancer progression. Oncology reports 54(4), 2025. e-Pub 2025. PMID: 40682849.
20. Kopetz, S, Boni, V, Kato, K, Raghav, KS, Vieito, M, Pallis, A, Habermehl, C, Siddiqui, A, Courlet, P, Sloot, W, Raab-Westphal, S, Hart, F, Rodriguez-Rivera, I. Precemtabart tocentecan, an anti-CEACAM5 antibody–drug conjugate, in metastatic colorectal cancer. Nature medicine 31(10):3504-3513, 2025. e-Pub 2025. PMID: 40739424.
21. Feng, T, Luo, Q, Liu, Y, Jin, Z, Skwarchuk, D, Lee, R, Nam, M, Asara, JM, Adye, DR, Lorenzi, PL, Tan, L, Pei, G, Zhao, Z, Zarrin-Khameh, N, Paulucci, A, Simons, BW, Lee, J, Kopetz, S, Yun, J. Fructose and glucose from sugary drinks enhance colorectal cancer metastasis via SORD. Nature Metabolism 7(10):2018-2032, 2025. e-Pub 2025. PMID: 40973819.
22. Theardy, MS, Takeda, M, Sorokin, A, Chen, S, Yang, Z, Wang, X, Kanikarla, PM, Coker, O, Nguyen, P, Wei, Y, Yao, J, Yan, L, Jin, Y, Cai, Y, Paku, M, Chen, Z, Li, KZ, Citron, F, Tomihara, H, Gao, S, Deem, AK, Zhao, J, Wang, H, Hanash, S, DePinho, RA, Maitra, A, Draetta, G, Ying, H, Kopetz, S, Yao, W. Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers. Cell Reports Medicine 6(8), 2025. e-Pub 2025. PMID: 40713971.
23. Cohen SA, Aushev VN, Laliotis G, Jabbal IS, Nagarajan A, Wang C, Fakih M, Sharif S, Alyunis F, Tejani MA, Alqahtani A, Marshall J, Chang J, Botta G, Manage K, George GV, Sharma S, Malhotra M, Chandana S, Mehler S, Somer BG, Babadi E, Wu C, Hanna D, Chidharla A, Kasi A, Vosoughi E, Dayyani F, Pedersen K, Briski RE, Azzi G, Katiyar V, Chan A, Sharma V, Shreenivas A, Chakrabarti S, Fuqua J, Malla M, Polite B, Bent AH, Rabinowitz M, Jurdi A, Liu MC, Aleshin A, Kopetz S. Real-world Monitoring of ctDNA Reliably Predicts Cancer Recurrence and Treatment Efficacy in Patients with Resected Stages I-III Colon Cancer. e-Pub 2025. PMID: 40772634.
24. Pellatt, AJ, Bent, AH, Hornstein, N, Parseghian, C, Huey, RW, Raghav, KS, Morris, VK, Overman, MJ, Morelli, P, Willis, JA, Le, PH, Shen, JY, Kee, BK, Eluri, M, Higbie, V, Alfaro-Munoz, KD, Aziz, KE, Kell, R, Sun, R, Kopetz, S, Dasari, NV. Phase II Trial of TAS-102 in Colorectal Cancer Patients With Circulating Tumor DNA-Defined Minimal Residual Disease After Adjuvant Therapy. JCO Precision Oncology 9, 2025. e-Pub 2025. PMID: 40669021.
25. Elez, E, Yoshino, T, Shen, L, Lonardi, S, Van Cutsem, E, Eng, C, Kim, TW, Wasan, H, Desai, J, Ciardiello, F, Yaeger, R, Maughan, TS, Morris, VK, Wu, CS, Usari, T, Laliberté, RJ, Dychter, SS, Zhang, X, Tabernero, J, Kopetz, S. Encorafenib, Cetuximab, and mFOLFOX6 in BRAF -Mutated Colorectal Cancer. New England Journal of Medicine 392(24):2425-2437, 2025. e-Pub 2025. PMID: 40444708.
26. Riedl, JM, Fece de la Cruz, F, Lin, JJ, Parseghian, C, Kim, JE, Matsubara, H, Barnes, H, Caughey, BA, Norden, BL, Morales-Giron, AA, Kushner, EW, Ehnstrom, S, Nakamura, H, Patel, PS, Ellis, H, Pappas, L, Vakaris, A, Gainor, J, Kopetz, S, Klempner, SJ, Parikh, AR, Hata, AN, Heist, RS, Corcoran, RB. Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors. Annals of Oncology 36(6):682-692, 2025. e-Pub 2025. PMID: 39914665.
27. Yazdani, A, Yazdani, A, Méndez-Giráldez, R, Pillonetto, G, Samiei, E, Hadi, R, Lenz, HJ, Venook, AP, Samiei, A, Nixon, AB, Lucci, JA, Kopetz, S, Bertagnolli, MM, Innocenti, F. Novel treatment-specific causal biomarkers for colorectal cancer by omics integration. NAR Genomics and Bioinformatics 7(2), 2025. e-Pub 2025. PMID: 40585306.
28. Odisio, BC, Albuquerque, J, Lin, YM, Anderson, BM, OConnor, C, Rigaud, B, Briones-Dimayuga, M, Jones, AK, Fellman, B, Huang, SY, Kuban, JD, Metwalli, ZA, Sheth, RA, Habibollahi, P, Patel, MN, Shah, KY, Cox, V, Kang, HC, Morris, VK, Kopetz, S, Javle, M, Kaseb, A, Tzeng, CW, Cao, HT, Newhook, TE, Chun, YS, Vauthey, JN, Gupta, S, Paolucci, I, Brock, K. Software-based versus visual assessment of the minimal ablative margin in patients with liver tumours undergoing percutaneous thermal ablation (COVER-ALL). The Lancet Gastroenterology and Hepatology 10(5):442-451, 2025. e-Pub 2025. PMID: 40090348.
29. White, MG, Ayabe, RI, Zeineddine, MA, Zeineddine, F, Yousef, A, Yousef, M, Galbraith, NJ, Iorgulescu, JB, Scally, CP, Fournier, KF, Newhook, TE, You, YN, Willis, JA, Kopetz, S, Chang, GJ, Shen, JY, Uppal, A. Tumoral and circulating genomic landscape inform survival differences in colorectal carcinomatosis. Translational Oncology 55, 2025. e-Pub 2025. PMID: 40184716.
30. Ciombor, KK, Bae, SW, Whisenant, JG, Ayers, GD, Quanghu, S, Peterson, TE, Smith, GT, Lin, K, Chowdhury, S, Kanikarla Marie, P, Sorokin, A, Cohen, A, Goff, LW, Cardin, D, Shen, JY, Kopetz, S, Eng, C, Shyr, Y, Berlin, J, Manning, HC. Results of the Phase I/II Study and Preliminary B-cell Gene Signature of Combined Inhibition of Glutamine Metabolism and EGFR in Colorectal Cancer. Clinical Cancer Research 31(8):1437-1448, 2025. e-Pub 2025. PMID: 39927885.
31. Raghav, KS, Guthrie, KA, Tan, BR, Denlinger, CS, Fakih, MG, Overman, MJ, Dasari, NV, Corum, LR, Hicks, LG, Patel, MS, Esparaz, BT, Kazmi, SM, Alluri, N, Colby, S, Gholami, S, Gold, PJ, Chiorean, EG, Kopetz, S, Hochster, HS, Philip, PA. Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With RAS/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613). Journal of Clinical Oncology 43(11):1348-1357, 2025. e-Pub 2025. PMID: 39761503.
32. Vailati Negrao, M, Paula, AG, Molkentine, D, Hover, LD, Nilsson, M, Vokes, N, Engstrom, LD, Calinisan, A, Briere, DM, Waters, L, Hallin, J, Diao, L, Altan, M, Blumenschein, GR, Skoulidis, F, Wang, J, Kopetz, S, Hong, DS, Gibbons, DL, Olson, P, Christensen, JG, Heymach, JV. Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial. Clinical Cancer Research 31(6):1069-1081, 2025. e-Pub 2025. PMID: 39804166.
33. Xu, C, Mannucci, A, Espósito, F, Oliveres, H, Alonso Orduña, V, Yubero, A, Fernández-Martos, C, Salud, A, Gallego, J, Martín-Richard, M, Fernández-Plana, J, Guillot, M, Aparicio, J, Fakih, MG, Kopetz, S, Feliu, J, Maurel, J, Goel, A. An Exosome-Based Liquid Biopsy Predicts Depth of Response and Survival Outcomes to Cetuximab and Panitumumab in Metastatic Colorectal Cancer. Clinical Cancer Research 31(6):1002-1015, 2025. e-Pub 2025. PMID: 39820673.
34. Kopetz, S, Yoshino, T, Van Cutsem, E, Eng, C, Kim, TW, Wasan, H, Desai, J, Ciardiello, F, Yaeger, R, Maughan, TS, Beyzarov, E, Zhang, X, Ferrier, G, Zhang, X, Tabernero, J. Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer. Nature medicine 31(3):901-908, 2025. e-Pub 2025. PMID: 39863775.
35. Bayraktar, R, Tang, Y, Dragomir, M, Ivan, C, Peng, X, Fabris, L, Zhang, J, Carugo, A, Aneli, S, Liu, J, Chen, MM, Srinivasan, S, Sahnoune, I, Bayraktar, E, Akdemir, KC, Chen, M, Narayanan, P, Huang, W, Ott, LF, Eterovic, AK, Villarreal, OE, Mohammad, MM, Peoples, M, Walsh, D, Hernandez, JA, Morgan, M, Shaw, KR, Davis, JS, Menter, DG, Tam, CS, Yeh, P, Dawson, SJ, Rassenti, LZ, Kipps, TJ, Kunej, T, Estrov, Z, Joosse, SA, Pagani, L, Alix-Panabières, C, Pantel, K, Ferajoli, A, Futreal, A, Wistuba, II, Radovich, M, Kopetz, S, Keating, M, Draetta, G, Mattick, JS, Liang, H, Calin, GA. The mutational landscape and functional effects of noncoding ultraconserved elements in human cancers. Science Advances 11(8), 2025. e-Pub 2025. PMID: 39970212.
36. Bayraktar, R, Tang, Y, Dragomir, M, Ivan, C, Peng, X, Fabris, L, Zhang, J, Carugo, A, Aneli, S, Liu, J, Chen, MM, Srinivasan, S, Sahnoune, I, Bayraktar, E, Akdemir, KC, Chen, M, Narayanan, P, Huang, W, Ott, LF, Eterovic, AK, Villarreal, OE, Mohammad, MM, Peoples, M, Walsh, D, Hernandez, JA, Morgan, M, Shaw, KR, Davis, JS, Menter, DG, Tam, CS, Yeh, P, Dawson, SJ, Rassenti, LZ, Kipps, TJ, Kunej, T, Estrov, Z, Joosse, SA, Pagani, L, Alix-Panabières, C, Pantel, K, Ferajoli, A, Futreal, A, Wistuba, II, Radovich, M, Kopetz, S, Keating, M, Draetta, G, Mattick, JS, Liang, H, Calin, GA. The mutational landscape and functional effects of noncoding ultraconserved elements in human cancers. Science Advances 11(8), 2025. e-Pub 2025. PMID: 39970212.
37. White, MG, Zeineddine, MA, Fallon, EA, Zeineddine, F, Dansby, J, Chowdhury, S, Hornstein, N, Yousef, A, Yousef, M, Bhutiani, N, Gu, Y, Kee, BK, Dasari, NV, Overman, MJ, Raghav, KS, Kopetz, S, Uppal, A, Taggart, MW, Newhook, TE, Fournier, KF, Helmink, BA, Drusbosky, L, Shen, JY. The Landscape of ctDNA in Appendiceal Adenocarcinoma. Clinical Cancer Research 31(3):551-560, 2025. e-Pub 2025. PMID: 39679931.
38. Clevenger, AJ, Collier, CA, Gorley, JM, Colijn, S, McFarlin, MK, Solberg, SC, Kopetz, S, Stratman, AN, Raghavan, S. Oncogenic KRAS Mutations Confer a Unique Mechanotransduction Response to Peristalsis in Colorectal Cancer Cells. Molecular Cancer Research 23(2):128-142, 2025. e-Pub 2025. PMID: 39485528.
39. Fox, DA, Bhamidipati, D, Kopetz, S, Hong, DS. Durable Remission After Targeted Therapy in BRAF V600E–Mutant Metastatic Colorectal Cancer. Journal of Immunotherapy and Precision Oncology 8(1):11-14, 2025. e-Pub 2025. PMID: 39811421.
40. Kopetz, S, Yoshino, T, Van Cutsem, E, Eng, C, Kim, TW, Wasan, H, Desai, J, Ciardiello, F, Yaeger, R, Maughan, TS, Beyzarov, E, Zhang, X, Ferrier, G, Zhang, X, Tabernero, J. The potential benefit of encorafenib plus cetuximab with chemotherapy compared with standard of care in people with BRAF V600E-mutant metastatic colorectal cancer in the BREAKWATER study. Future Oncology 21(13):1541-1552, 2025. e-Pub 2025. PMID: 40391894.
41. Guo, S, Liu, X, Cheng, X, Jiang, Y, Ji, S, Liang, Q, Koval, A, Li, Y, Owen, L, Kim, IK, Aparicio, A, Lee, S, Sood, AK, Kopetz, S, Shen, JY, Weinstein, JN, DeAngelis, MM, Chen, R, Wang, W. A deconvolution framework that uses single-cell sequencing plus a small benchmark data set for accurate analysis of cell type ratios in complex tissue samples. Genome research 35(1):147-161, 2025. e-Pub 2025. PMID: 39586714.
42. Yaeger, R, Martini, JF, Pasquina, LW, Tunquist, BJ, Zhang, X, Kaiser, F, Galicia, NP, Deng, S, Gong, S, Guo, C, Kiely, J, Ng, TV, Ferrier, G, Tabernero, J, Kopetz, S. Clinical Validity of FoundationOne Liquid CDx for Detection of BRAFV600E in Colorectal Cancer. Cancer Research Communications 5(9):1566-1573, 2025. e-Pub 2025. PMID: 40832988.
43. Bhutiani, N, Peacock, O, Uppal, A, Hu, C, Bednarski, BK, Taggart, MW, Dasari, NV, Morris, VK, Kaur, H, Kopetz, S, Holliday, EB, Das, P, You, YN, Chang, GJ. The prognostic impact of tumor deposits in colorectal cancer. Cancer 130(23):4052-4060, 2024. e-Pub 2024. PMID: 39306694.
44. Yousef, M, Yousef, A, Chowdhury, S, Fanaeian, M, Knafl, M, Peterson, J, Zeineddine, MA, Alfaro, KD, Zeineddine, F, Goldstein, D, Hornstein, N, Dasari, NV, Huey, RW, Johnson, B, Serpas Higbie, V, Bent, AH, Kee, BK, Lee, MS, Morelli, MP, Morris, VK, Halperin, DM, Overman, MJ, Parseghian, C, Vilar Sanchez, E, Wolff, RA, Raghav, KS, White, MG, Uppal, A, Sun, R, Wang, W, Kopetz, S, Willis, JA, Shen, JY. Molecular, Socioeconomic, and Clinical Factors Affecting Racial and Ethnic Disparities in Colorectal Cancer Survival. JAMA Oncology 10(11), 2024. e-Pub 2024. PMID: 39264607.
45. Lee, HM, Saw, AK, Morris, VK, Napolitano, S, Bristow, C, Srinivasan, S, Peoples, M, Sorokin, A, Kanikarla Marie, P, Schulz, J, Singh, A, Terranova, C, Coker, O, Jain, A, Kopetz, S, Rai, K. Epigenome Reprogramming Through H3K27 and H3K4 Trimethylation as a Resistance Mechanism to DNA Methylation Inhibition in BRAFV600E-Mutated Colorectal Cancer. Clinical Cancer Research 30(22):5166-5179, 2024. e-Pub 2024. PMID: 39269307.
46. Chowdhury, S, Xiu, J, Ribeiro, JR, Nicolaides, T, Zhang, J, Korn, WM, Poorman, K, Lenz, HJ, Marshall, JL, Oberley, MJ, Sledge, GW, Spetzler, D, Kopetz, S, Shen, JY. Consensus molecular subtyping of metastatic colorectal cancer expands biomarker-directed therapeutic benefit for patients with CMS1 and CMS2 tumors. British journal of cancer 131(8):1328-1339, 2024. e-Pub 2024. PMID: 39227409.
47. Margalit, O, Stemmer, A, Chapin, WJ, Shacham-Shmueli, E, Kopetz, S, Andre, T, Overman, MJ, Pietrantonio, F, Boursi, B. Duration of immunotherapy in dMMR/MSI-H metastatic colorectal cancer patients. European Journal of Cancer 212, 2024. e-Pub 2024. PMID: 39316932.
48. Segal, NH, Tie, J, Kopetz, S, Ducreux, M, Chen, EX, Dienstmann, R, Hollebecque, A, Reilley, MJ, Elez, E, Cosaert, J, Cain, J, Soo-Hoo, Y, Hewson, N, Cooper, Z, Kumar, R, Tabernero, J. COLUMBIA-1. British journal of cancer 131(6):1005-1013, 2024. e-Pub 2024. PMID: 39048638.
49. Ambrosini, M, Tougeron, D, Modest, DP, Guimbaud, R, Kopetz, S, Decraecker, M, Kim, S, Coutzac, C, Perkins, G, Alouani, E, Marmorino, F, Pernot, S, Sinicrope, FA, Elez, E, Parent, P, Cremolini, C, Pietrantonio, F, Lonardi, S, Gallois, C, Taieb, J. BRAF + EGFR +/- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancer. European Journal of Cancer 210, 2024. e-Pub 2024. PMID: 39216175.
50. Thatikonda, V, Lyu, H, Jurado, S, Kostyrko, K, Bristow, C, Albrecht, C, Alpar, D, Arnhof, H, Bergner, O, Bosch, K, Feng, N, Gao, S, Gerlach, D, Gmachl, M, Hinkel, M, Lieb, S, Jeschko, A, Machado, AA, Madensky, T, Marszalek, ED, Mahendra, M, Melo-Zainzinger, G, Molkentine, JM, Jaeger, PA, Peng, D, Schenk, RL, Sorokin, A, Strauss, S, Trapani, F, Kopetz, S, Vellano, CP, Petronczki, M, Kraut, N, Heffernan, TP, Marszalek, JR, Pearson, M, Waizenegger, IC, Hofmann, MH. Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance. Nature Cancer 5(9):1352-1370, 2024. e-Pub 2024. PMID: 39103541.
51. Whitehead, CE, Ziemke, E, Frankowski-McGregor, CL, Mumby, R, Chung, J, Li, J, Osher, N, Coker, O, Baladandayuthapani, V, Kopetz, S, Sebolt-Leopold, J. A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance. Nature Cancer 5(8):1250-1266, 2024. e-Pub 2024. PMID: 38992135.
52. Maddalena, G, Zeineddine, F, Rivero-Hinojosa, S, Aushev, VN, Chowdhury, S, Zeineddine, MA, Yousef, A, Yap, TA, EINaggar, AC, Liu, MC, White, MG, Overman, MJ, Kopetz, S, Shen, JY. Defining the subset of mutations in polymerase epsilon (POLE) associated with loss-of-proofreading (LOP) functionality. Annals of Oncology 35(7):678-680, 2024. e-Pub 2024. PMID: 38734075.
53. Klomp, JA, Klomp, JE, Stalnecker, CA, Bryant, KL, Edwards, AC, Drizyte-Miller, K, Hibshman, PS, Diehl, JN, Lee, YS, Morales, AJ, Taylor, KE, Peng, S, Tran, NL, Herring, LE, Prevatte, AW, Barker, NK, Hover, LD, Hallin, J, Chowdhury, S, Coker, O, Lee, HM, Goodwin, CM, Gautam, P, Olson, P, Christensen, JG, Shen, JY, Kopetz, S, Graves, LM, Lim, KH, Wang-Gillam, A, Wennerberg, K, Cox, AD, Der, CJ. Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers. Science 384(6700), 2024. e-Pub 2024. PMID: 38843331.
54. Yaeger R, Uboha NV, Pelster MS, Bekaii-Saab TS, Barve M, Saltzman J, Sabari JK, Peguero JA, Paulson AS, Jänne PA, Cruz-Correa M, Anderes K, Velastegui K, Yan X, Der-Torossian H, Klempner SJ, Kopetz SE. Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer. Cancer Discov 14(6):982-993, 2024. e-Pub 2024. PMID: 38587856.
55. Bahrambeigi, V, Lee, JJ, Branchi, V, Rajapakshe, K, Xu, Z, Kui, N, Henry, JT, Kun, W, Stephens, BM, Dhebat, S, Hurd, MW, Sun, R, Yang, P, Ruppin, E, Wang, W, Kopetz, S, Maitra, A, Guerrero, PA. Transcriptomic Profiling of Plasma Extracellular Vesicles Enables Reliable Annotation of the Cancer-Specific Transcriptome and Molecular Subtype. Cancer Research 84(10):1719-1732, 2024. e-Pub 2024. PMID: 38451249.
56. Pilie, PG, Giuliani, V, Wang, W, McGrail, DJ, Bristow, C, Ngoi, NY, Kyewalabye, K, Wani, K, Le, H, Campbell, E, Sánchez, N, Yang, D, Gheeya, J, Goswamy, R, Holla, V, Shaw, KR, Meric-Bernstam, F, Liu, CY, Ma, X, Feng, N, Machado, AA, Bardenhagen, J, Vellano, CP, Marszalek, JR, Rajendra, E, Piscitello, D, Johnson, TI, Likhatcheva, M, Elinati, E, Majithiya, J, Neves, J, Grinkevich, V, Ranzani, M, Luzarraga, MR, Boursier, M, Armstrong, L, Geo, L, Lillo, G, Tse, WY, Lazar, A, Kopetz, S, Do, MK, Lively, S, Johnson, MG, Robinson, HM, Smith, GC, Carroll, C, Di, MF, Jones, PH, Heffernan, TP, Yap, TA. Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types. Clinical Cancer Research 30(10):2121-2139, 2024. e-Pub 2024. PMID: 38416404.
57. Bolivar, AM, Duzagac, F, Deng, N, Reyes-Uribe, L, Chang, K, Wu, W, Bowen, CM, Taggart, MW, Thirumurthi, S, Lynch, PM, You, YN, Rodriguez-Pascual, J, Lipkin, SM, Kopetz, S, Scheet, PA, Lizee, GA, Reuben, A, Sinha, K, Vilar Sanchez, E. Genomic Landscape of Lynch Syndrome Colorectal Neoplasia Identifies Shared Mutated Neoantigens for Immunoprevention. Gastroenterology 166(5):787-801.e11, 2024. e-Pub 2024. PMID: 38244726.
58. Zhu, Y, Koleilat, MK, Roszik, J, Kwong, MK, Wang, Z, Maru, DM, Kopetz, S, Kwong, L. A Gold Standard-Derived Modular Barcoding Approach to Cancer Transcriptomics. Cancers 16(10), 2024. e-Pub 2024. PMID: 38791964.
59. Zhu Y, Koleilat MKI, Roszik J, Kwong MK, Wang Z, Maru DM, Kopetz S, Kwong LN. A Gold Standard-Derived Modular Barcoding Approach to Cancer Transcriptomics. Cancers (Basel) 16(10), 2024. e-Pub 2024. PMID: 38791964.
60. Xiang, K, Wang, E, Mantyh, J, Rupprecht, G, Negrete, M, Sanati, G, Hsu, C, Randon, PM, Dohlman, AB, Kretzschmar, K, Bose, S, Giroux, N, Ding, S, Wang, L, Balcazar, JP, Huang, Q, Sundaramoorthy, P, Xi, R, McCall, S, Wang, Z, Jiang, C, Kang, Y, Kopetz, S, Crawford, G, Lipkin, SM, Wang, XF, Clevers, H, Hsu, D, Shen, X. Chromatin Remodeling in Patient-Derived Colorectal Cancer Models. Advanced Science 11(16), 2024. e-Pub 2024. PMID: 38380561.
61. Lin K, Chowdhury S, Zeineddine MA, Zeineddine FA, Hornstein NJ, Villarreal OE, Maru DM, Haymaker CL, Vauthey JN, Chang GJ, Bogatenkova E, Menter D, Kopetz S, Shen JP. Identification of colorectal cancer cell stemness from single-cell RNA sequencing. Molecular Cancer Research 22(4), 2024. e-Pub 2024. PMID: 38156967.
62. Elez E, Kopetz S, Tabernero J, Bekaii-Saab T, Taieb J, Yoshino T, Manji G, Fernandez K, Abbattista A, Zhang X, Morris VK. SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR BRAFV600E-mutant mCRC. Future oncology (London, England) 20(11):653-663, 2024. e-Pub 2024. PMID: 37815847.
63. Yousef, A, Yousef, M, Zeineddine, MA, More, A, Fanaeian, M, Chowdhury, S, Knafl, M, Edelkamp, P, Ito, I, Gu, Y, Pattalachinti, V, Naini, ZA, Zeineddine, F, Peterson, J, Alfaro, KD, Foo, WC, Jin, J, Bhutiani, N, Higbie, V, Scally, CP, Kee, BK, Kopetz, S, Goldstein, D, Strach, M, Williamson, A, Aziz, O, Barriuso, J, Uppal, A, White, MG, Helmink, BA, Fournier, KF, Raghav, KS, Taggart, MW, Overman, MJ, Shen, JY. Serum Tumor Markers and Outcomes in Patients With Appendiceal Adenocarcinoma. JAMA Network Open 7(2):e240260, 2024. e-Pub 2024. PMID: 38416491.
64. Amaria, RN, Knisely, A, Vining, D, Kopetz, S, Overman, MJ, Javle, M, Antonoff, MB, Tzeng, CD, Wolff, RA, Pant, S, Lito, K, Rangel, KM, Fellman, B, Yuan, Y, Lu, KH, Sakellariou-Thompson, D, Haymaker, CL, Forget, MA, Hwu, P, Bernatchez, C, Jazaeri, AA. Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. Journal for immunotherapy of cancer 12(2), 2024. e-Pub 2024. PMID: 38309721.
65. Johnson, B, Morris, VK, Wang, X, Dasari, NV, Raghav, KS, Shen, JY, Lee, MS, Huey, RW, Parseghian, C, Willis, JA, Wolff, RA, Drusbosky, L, Overman, MJ, Kopetz, S. Comprehensive Landscape of BRAF Variant Classes, Clonalities, and Co-Mutations in Metastatic Colorectal Cancer Using ctDNA Profiling. Cancers 16(4), 2024. e-Pub 2024. PMID: 38398128.
66. Stemmer A, Margalit O, Serpas V, Strauss G, Thomas J, Shah P, Tau N, Levanon K, Shacham-Shmueli E, Kopetz S, Overman M, Boursi B. Immunotherapy in mismatch repair-deficient metastatic colorectal cancer - Outcome and novel predictive markers. European Journal of Cancer 198:113495, 2024. e-Pub 2024. PMID: 38157568.
67. Raghav KPS, Loree JM, Kopetz S. PRESSING need of precision care in HER2-positive CRC: The ELEPHANT in the room. Clinical Cancer Research 30(2):260-262, 2024. e-Pub 2024. PMID: 37975903.
68. Grabski IN, Heymach JV, Kehl KL, Kopetz S, Lau KS, Riely GJ, Schrag D, Yaeger R, Irizarry RA, Haigis KM. Effects of KRAS genetic interactions on outcomes in cancers of the lung, pancreas, and colorectum. Cancer Epidemiology Biomarkers and Prevention 33(1):158-169, 2024. e-Pub 2024. PMID: 37943166.
69. Bhutiani N, Yousef MMG, Yousef A, Zeineddine M, Knafl M, Ratliff O, Fernando UP, Turin A, Zeineddine FA, Jin J, Alfaro-Munoz K, Goldstein D, Chang GJ, Kopetz S, Shen JP, Uppal A. Automated, High-Throughput Platform to Generate a High-Reliability, Comprehensive Rectal Cancer Database. JCO Clin Cancer Inform 8, 2024. e-Pub 2024. PMID: 38759125.
70. Parseghian, C, Lee, J, Quintanilha, JC, Schrock, AB, Graf, RP, Pasquina, LW, Sivakumar, S, Oxnard, GR, Tukachinsky, H, Klempner, SJ, Kopetz, S. Novel potential mechanisms of acquired resistance to anti-EGFR monoclonal antibody (mAb) therapy detected in liquid biopsies (LBx) from patients (pts) with advanced colorectal cancer (CRC). Journal of Clinical Oncology 42(3_suppl):199, 2024. e-Pub 2024.
71. Higbie, V, Shah, P, Bent, AH, Dasari, NV, Huey, RW, Johnson, B, Kee, BK, Kopetz, S, Lee, MS, Ludford, K, Morelli, MP, Morris, VK, Parseghian, C, Raghav, KS, Shen, JY, Willis, JA, Wolff, RA, Overman, MJ. Natural history and patterns of progression for dMMR/MSI-H colorectal cancer treated with immune checkpoint blockade. Journal of Clinical Oncology 42(3), 2024. e-Pub 2024.
72. Lapelusa, M, San Lucas, FA, Iorgulescu, B, Patel, KP, You, YN, Foo, WC, Maru, DM, Kopetz, S, Ludford, K, Morris, VK, Overman, MJ. Circulating tumor DNA as a predictive biomarker for pathologic response after treatment with neoadjuvant immunotherapy for localized dMMR/MSI-H colorectal cancer. Journal of Clinical Oncology 42(16):3612, 2024. e-Pub 2024.
73. Kasi, PM, Aushev, VN, Ensor, J, Langer, N, Wang, CG, Cannon, TL, Berim, L, Feinstein, TM, Grothey, A, McCollom, JW, Kalmadi, S, Zakari, A, Dayyani, F, Gravenor, D, Meyer, JM, Sharif, S, Jurdi, A, Liu, MC, Aleshin, A, Kopetz, S. Circulating tumor DNA (ctDNA) for informing adjuvant chemotherapy (ACT) in stage II/III colorectal cancer (CRC). Journal of Clinical Oncology 42(3):1, 2024. e-Pub 2024.
74. Lieu, C, Yu, G, Kopetz, S, Puhalla, S, Lucas, PC, Sahin, IH, Deming, DA, Philip, PA, Hong, TS, Rojas-Khalil, Y, Loree, JM, Wolmark, N, Yothers, G, George, TJ, Dasari, NV. NRG-GI008. Journal of Clinical Oncology 42(3), 2024. e-Pub 2024.
75. Kopetz, S, Raghav, KS, Boni, V, Rivera, IR, Kato, K, Pallis, A, Habermehl, C, Galipelli, S, Courlet, P. First-in-human trial of M9140, an anti-CEACAM5 antibody drug conjugate (ADC) with exatecan payload, in patients (pts) with metastatic colorectal cancer (mCRC). Journal of Clinical Oncology 42(16), 2024. e-Pub 2024.
76. White, MG, Damania, A, Alshenaifi, J, Sahasrabhojane, P, Peacock, O, Losh, J, Wong, M, Berkova, Z, Nguyen, S, Chang, GJ, Wargo, J, Ajami, NJ, Kopetz, S, You, YN. Tumoral microbial and pathway alterations associated with young-onset rectal cancer and its response to therapy. Journal of Clinical Oncology 42(3):160, 2024. e-Pub 2024.
77. Bhutiani, N, Johnson, B, Kopetz, S, White, MG, Willis, JA, Morris, VK, Chang, GJ, Uppal, A. Immune checkpoint blockade combined with targeted therapies to provide disease control in mismatch repair-proficient colorectal cancer with peritoneal metastases. Journal of Clinical Oncology 42(3_suppl):133, 2024. e-Pub 2024.
78. Parikh, AR, Chiorean, EG, Atreya, CE, Zheng, L, Kopetz, S, Spira, AI, Spigel, D, Cui, Y, Osgood, R, Tran, R, Morris, SR, Ulahannan, SV. Updated results from ERAS-007 plus encorafenib and cetuximab (EC) in patients (pts) with EC-naïve metastatic BRAF V600E colorectal cancer (CRC) in the phase 1b/2 HERKULES-3 study. Journal of Clinical Oncology 42(16):3517, 2024. e-Pub 2024.
79. Pellatt, AJ, Maddalena, G, Bent, AH, Parseghian, C, Huey, RW, Raghav, KS, Morris, VK, Overman, MJ, Morelli, MP, Willis, JA, Le, PH, Shen, JY, Alfaro, KD, Aziz, KE, Kell, R, Sun, R, Kopetz, S, Dasari, NV. A phase II trial of TAS-102 in patients with colorectal cancer with ctDNA-defined minimal residual disease post-adjuvant therapy compared to synthetic control cohort. Journal of Clinical Oncology 42(16), 2024. e-Pub 2024.
80. Overman, MJ, Yothers, G, Jacobs, S, Sanoff, HK, Cohen, D, Guthrie, KA, Henry, NL, Ganz, PA, Kopetz, S, Lucas, PC, Blanke, CD, Hong, TS, Wolmark, N, Hochster, HS, George, TJ. Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study. Journal of Clinical Oncology 42(3), 2024. e-Pub 2024.
81. Kasi, PM, Rivero, S, Aushev, VN, Langer, N, Wang, CG, Cannon, TL, Berim, L, Feinstein, TM, Grothey, A, McCollom, JW, Kalmadi, S, Zakari, A, Dayyani, F, Gravenor, D, Meyer, JM, Sharif, S, Jurdi, A, Liu, MC, Aleshin, A, Kopetz, S. Patient-reported outcomes from the BESPOKE CRC study. Journal of Clinical Oncology 42(3):54, 2024. e-Pub 2024.
82. Morris, VK, Yothers, G, Kopetz, S, Puhalla, S, Lucas, PC, Iqbal, A, Boland, P, Deming, DA, Scott, AJ, Lim, HJ, Jacobs, S, Hong, TS, Wolmark, N, George, TJ. Phase II results of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer. Journal of Clinical Oncology 42(3):1, 2024. e-Pub 2024.
83. Kuboki Y, Fakih M, Strickler J, Yaeger R, Masuishi T, Kim EJ, Bestvina CM, Kopetz S, Falchook GS, Langer C, Krauss J, Puri S, Cardona P, Chan E, Varrieur T, Mukundan L, Anderson A, Tran Q, Hong DS. Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial. Nature medicine 30(1):265-270, 2024. e-Pub 2024. PMID: 38177853.
84. Eluri, M, Sun, R, Bubie, A, Alshenaifi, J, Zhang, N, Drusbosky, L, Parseghian, C, Raghav, KS, Kopetz, S. Characterization of mutational signatures demonstrating adaptive mutability post anti-EGFR therapy in a real-world metastatic colorectal cancer cohort. Journal of Clinical Oncology 42(16_suppl):3545, 2024. e-Pub 2024.
85. Maddalena, G, Pellatt, AJ, Eluri, M, Parseghian, C, Aziz, KE, Alfaro, KD, Kell, R, Bent, AH, Huey, RW, Uppal, A, Konishi, T, Overman, MJ, Morelli, MP, Willis, JA, Shen, JY, Raghav, KS, Newhook, TE, Morris, VK, Dasari, NV, Kopetz, S. INTERCEPT Program of circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) in colorectal cancer (CRC). Journal of Clinical Oncology 42(3_suppl):27, 2024. e-Pub 2024.
86. Wainberg, ZA, Han, SW, Lee, S, Lee, KW, Kopetz, S, Mizrahi, JD, Hong, YS, Ghiringhelli, F, Italiano, A, Tougeron, D, Beagle, BR, Boakye, M, Zhao, T, Rhee, J, Nuyten, DS, Cecchini, M. ARC-9. Journal of Clinical Oncology 42(16), 2024. e-Pub 2024.
87. Yousef, M, Yousef, A, Fanaeian, M, Chowdhury, S, Knafl, M, Alfaro, KD, Uppal, A, Sun, R, Wang, W, Raghav, KS, Willis, JA, Kopetz, S, Shen, JY. Understanding causes of racial/ethnic survival disparity in 47,178 patients with colorectal cancer. Journal of Clinical Oncology 42(3):1, 2024. e-Pub 2024.
88. Kopetz S, Murphy DA, Pu J, Ciardiello F, Desai J, Van Cutsem E, Wasan HS, Yoshino T, Saffari H, Zhang X, Hamilton P, Xie T, Yaeger R, Tabernero J. Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial. Nature Medicine 30(11):3261-3271, 2024. e-Pub 2024. PMID: 39313594.
89. Zeineddine FA, Zeineddine MA, Yousef A, Gu Y, Chowdhury S, Dasari A, Huey RW, Johnson B, Kee B, Lee MS, Morelli MP, Morris VK, Overman MJ, Parseghian C, Raghav K, Willis J, Wolff RA, Kawaguchi Y, Vauthey JN, Sun R, Kopetz S, Shen JP. Survival improvement for patients with metastatic colorectal cancer over twenty years. npj Precision Oncology 7(1):16, 2023. e-Pub 2023. PMID: 36781990.
90. Nelson BE, Tsimberidou AM, Fu X, Fu S, Subbiah V, Sood AK, Rodon J, Karp DD, Blumenschein G, Kopetz S, Pant S, Piha-Paul SA. A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors. Oncologist 28(12):e1100-e1292, 2023. e-Pub 2023. PMID: 37311055.
91. Simmons, K, Thomas, J, Ludford, K, Willis, JA, Serpas Higbie, V, Raghav, KS, Johnson, B, Dasari, NV, Kee, BK, Parseghian, C, Lee, MS, Le, PH, Morelli, MP, Shen, JY, Bent, AH, Vilar Sanchez, E, Wolff, RA, Kopetz, S, Overman, MJ, Morris, VK. Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination. Cancer Research Communications 3(12):2510-2517, 2023. e-Pub 2023. PMID: 38085001.
92. Hsu, WH, LaBella, KA, Lin, Y, Xu, P, Lee, R, Hsieh, CE, Yang, L, Zhou, A, Blecher, JM, Wu, C, Lin, K, Shang, X, Jiang, S, Spring, DJ, Xia, Y, Chen, P, Shen, JY, Kopetz, S, DePinho, RA. Oncogenic KRAS Drives Lipofibrogenesis to Promote Angiogenesis and Colon Cancer Progression. Cancer discovery 13(12):2652-2673, 2023. e-Pub 2023. PMID: 37768068.
93. Zhang X, Irajizad E, Hoffman KL, Fahrmann JF, Li F, Seo YD, Browman GJ, Dennison JB, Vykoukal J, Luna PN, Siu W, Wu R, Murage E, Ajami NJ, McQuade JL, Wargo JA, Long JP, Do KA, Lampe JW, Basen-Engquist KM, Okhuysen PC, Kopetz S, Hanash SM, Petrosino JF, Scheet P, Daniel CR. Modulating a prebiotic food source influences inflammation and immune-regulating gut microbes and metabolites: insights from the BE GONE trial. EBioMedicine 98:104873, 2023. e-Pub 2023. PMID: 38040541.
94. Zheng C, Wei Y, Zhang P, Lin K, He D, Teng H, Manyam G, Zhang Z, Liu W, Lee HRL, Tang X, He W, Islam N, Jain A, Chiu Y, Cao S, Diao Y, Meyer-Gauen S, Höök M, Malovannaya A, Li W, Hu M, Wang W, Xu H, Kopetz S, Chen Y. CRISPR-Cas9-based functional interrogation of unconventional translatome reveals human cancer dependency on cryptic non-canonical open reading frames. Nature Structural and Molecular Biology 30(12):1878-1892, 2023. e-Pub 2023. PMID: 37932451.
95. Ewa, PK, Giulia, N, Florent, D, Damarys, L, Patrick, P, Yi, X, Kopetz, S, Jennifer, D, Lucie, P, Catherine, RM, Philippe, S, Patrick, TC, Shaynoor, D. Global proteomic identifies multiple cancer-related signaling pathways altered by a gut pathobiont associated with colorectal cancer. Scientific reports 13(1), 2023. e-Pub 2023. PMID: 37696912.
96. Yazdani A, Lenz HJ, Pillonetto G, Mendez-Giraldez R, Yazdani A, Sanof H, Hadi R, Samiei E, Venook AP, Ratain MJ, Rashid N, Vincent BG, Qu X, Wen Y, Kosorok M, Symmans WF, JPYC S, Lee MS, Kopetz S, Nixon AB, Bertagnolli MM, Perou CM, Innocenti F. Gene signatures derived from transcriptomic-causal networks stratified colorectal cancer patients for effective targeted therapy. Res Sq, 2023. e-Pub 2023. PMID: 38168324.
97. Simmons K, Thomas JV, Ludford K, Willis JA, Higbie VS, Raghav KPS, Johnson B, Dasari A, Kee BK, Parseghian CM, Lee MS, Le PH, Morelli MP, Shen JP, Bent A, Vilar E, Wolff RA, Kopetz S, Overman MJ, Morris VK. Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination. Cancer Res Commun 3(12):2510-2517, 2023. e-Pub 2023. PMID: 38085001.
98. Fox DA, Bhamidipati D, Konishi T, Kaur H, You N, Raghav KPS, Ge PS, Messick C, Johnson B, Morris VK, Thomas JV, Shah P, Bednarski BK, Kopetz S, Chang GJ, Ludford K, Higbie VS, Overman MJ. Endoscopic and imaging outcomes of PD-1 therapy in localised dMMR colorectal cancer. European Journal of Cancer 194:113356, 2023. e-Pub 2023. PMID: 37827065.
99. Jiang L, Thall PF, Yan F, Kopetz S, Yuan Y. BASIC: A Bayesian adaptive synthetic-control design for phase II clinical trials. Clinical Trials 20(5):486-496, 2023. e-Pub 2023. PMID: 37313712.
100. White MG, Damania A, Alshenaifi J, Sahasrabhojane P, Peacock O, Losh J, Wong MC, Lutter-Berkova Z, Chang GJ, Futreal A, Wargo JA, Ajami NJ, Kopetz S, You YN. Young-onset Rectal Cancer: Unique Tumoral Microbiome and Correlation with Response to Neoadjuvant Therapy. Annals of surgery 278(4):538-548, 2023. e-Pub 2023. PMID: 37465976.
101. Khanduri I, Maki H, Verma A, Katkhuda R, Anandappa G, Pandurengan R, Zhang S, Mejia A, Tong Z, Soto LMS, Jadhav A, Wistuba II, Kopetz S, Parra ER, Vauthey JN, Maru DM. New Insights into Macrophage Polarization and its Prognostic Role in Patients with Colorectal Cancer Liver Metastasis. Res Sq, 2023. e-Pub 2023. PMID: 37886575.
102. Guo S, Liu X, Cheng X, Jiang Y, Ji S, Liang Q, Koval A, Li Y, Owen LA, Kim IK, Aparicio A, Shen JP, Kopetz S, Weinstein JN, DeAngelis MM, Chen R, Wang W. The DeMixSC deconvolution framework uses single-cell sequencing plus a small benchmark dataset for improved analysis of cell-type ratios in complex tissue samples. bioRxiv, 2023. e-Pub 2023. PMID: 37873318.
103. Napolitano S, Parikh AR, Henry J, Parseghian CM, Willis J, Raghav KP, Morris VK, Johnson B, Kee BK, Dasari AN, Overman MJ, Luthra R, Drusbosky LM, Corcoran RB, Kopetz S, Sun R. Novel Clinical Tool to Estimate Risk of False-Negative KRAS Mutations in Circulating Tumor DNA Testing. JCO Precis Oncol 7:e2300228, 2023. e-Pub 2023. PMID: 37824798.
104. Ghosh S, Fan F, Powell RT, Roszik J, Park Y, Stephan C, Sebastian M, Tan L, Sorokin AV, Lorenzi PL, Kopetz S, Ellis LM, Bhattacharya R. Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer. Molecular cancer therapeutics 22(8):962-975, 2023. e-Pub 2023. PMID: 37310170.
105. Chowdhury S, Gupta R, Millstein J, Lin K, Haridas V, Zeineddine MA, Parseghian C, Lenz HJ, Kopetz S, Shen JP. Transcriptional Profiling and Consensus Molecular Subtype Assignment to Understand Response and Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Colorectal Cancer. JCO Precis Oncol 7:e2200422, 2023. e-Pub 2023. PMID: 37487150.
106. Napolitano S, Woods M, Lee HM, De Falco V, Martini G, Della Corte CM, Martinelli E, Famiglietti V, Ciardiello D, Anderson A, Fowlkes NW, Villareal OE, Sorokin A, Kanikarla P, Coker O, Morris V, Altucci L, Tabernero J, Troiani T, Ciardiello F, Kopetz S. Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human BRAFV600E-Mutant Colorectal Cancer. Clinical Cancer Research 29(12):2299-2309, 2023. e-Pub 2023. PMID: 37040395.
107. Newhook TE, Overman MJ, Chun YS, Dasari A, Tzeng CD, Cao HST, Raymond V, Parseghian C, Johnson B, Nishioka Y, Kawaguchi Y, Uppal A, Vreeland TJ, Jaimovich A, Arvide EM, Cristo JV, Wei SH, Raghav KP, Morris VK, Lee JE, Kopetz S, Vauthey JN. Prospective Study of Perioperative Circulating Tumor DNA Dynamics in Patients Undergoing Hepatectomy for Colorectal Liver Metastases. Annals of surgery 277(5):813-820, 2023. e-Pub 2023. PMID: 35797554.
108. Ludford K, Ho WJ, Thomas JV, Raghav KPS, Murphy MB, Fleming ND, Lee MS, Smaglo BG, You YN, Tillman MM, Kamiya-Matsuoka C, Thirumurthi S, Messick C, Johnson B, Vilar E, Dasari A, Shin S, Hernandez A, Yuan X, Yang H, Foo WC, Qiao W, Maru D, Kopetz S, Overman MJ. Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors. Journal of Clinical Oncology 41(12):2181-2190, 2023. e-Pub 2023. PMID: 36623241.
109. You YN, Moskowitz J, Chang GJ, Mork M, Rodriguez-Bigas M, Bednarski BK, Messick C, Tillman M, Skibber J, Nguyen S, Kopetz S, Vilar E. Germline Cancer Risk Profiles of Young-Onset Colorectal Cancer Patients: Findings from a Prospective Universal Germline Testing and Tele-Genetics Program. Diseases of the colon and rectum 66(4):531-542, 2023. e-Pub 2023. PMID: 35195555.
110. Gouda MA, Duose DY, Lapin M, Zalles S, Huang HJ, Xi Y, Zheng X, Aldesoky AI, Alhanafy AM, Shehata MA, Wang J, Kopetz S, Meric-Bernstam F, Wistuba II, Luthra R, Janku F. Mutation-Agnostic Detection of Colorectal Cancer Using Liquid Biopsy-Based Methylation-Specific Signatures. Oncologist 28(4):368-372, 2023. e-Pub 2023. PMID: 36200910.
111. Fan F, Ghosh S, Powell R, Roszik J, Park Y, Sobieski M, Sorokin A, Stephan C, Kopetz S, Ellis LM, Bhattacharya R. Combining MEK and SRC inhibitors for treatment of colorectal cancer demonstrate increased efficacy in vitro but not in vivo. PLoS One 18(3):e0281063, 2023. e-Pub 2023. PMID: 36952536.
112. Pant S, Dragovich T, Lieu C, Jimeno A, Kundranda M, Menter D, Tchaparian E, Chen YC, Kopetz S. Phase 1 study of the safety, pharmacokinetics, and preliminary efficacy of CA102N as monotherapy and in combination with trifluridine-tipiracil in patients with locally advanced or metastatic solid tumors. Investigational New Drugs 41(1):25-34, 2023. e-Pub 2023. PMID: 36331676.
113. Spira A, Wertheim MS, Kim EJ, Tan B, Lenz HJ, Nikolinakos P, Rich PL, Jehl G, Machl A, Ito R, Gulley JL, Kopetz S. Bintrafusp Alfa: A Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with Pretreated Colorectal Cancer: Results from a Phase I Trial. Oncologist 28(2):e124-e127, 2023. e-Pub 2023. PMID: 36576431.
114. Paolucci I, Lin YM, Kawaguchi Y, Maki H, Jones AK, Calandri M, Kopetz S, Newhook TE, Brock KK, Vauthey JN, Odisio BC. Targeted exome-based predictors of patterns of progression of colorectal liver metastasis after percutaneous thermal ablation. British journal of cancer 128(1):130-136, 2023. e-Pub 2023. PMID: 36319850.
115. Parseghian CM, Sun R, Woods M, Napolitano S, Lee HM, Alshenaifi J, Willis J, Nunez S, Raghav KP, Morris VK, Shen JP, Eluri M, Sorokin A, Kanikarla P, Vilar E, Rehn M, Ang A, Troiani T, Kopetz S. Resistance Mechanisms to Anti-Epidermal Growth Factor Receptor Therapy in RAS/RAF Wild-Type Colorectal Cancer Vary by Regimen and Line of Therapy. Journal of Clinical Oncology 41(3):460-471, 2023. e-Pub 2023. PMID: 36351210.
116. Raghav K, Ou FS, Venook AP, Innocenti F, Sun R, Lenz HJ, Kopetz S. Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer: Circulating Tumor DNA Analysis of the CALGB/SWOG-80405 Trial (Alliance). Journal of Clinical Oncology 41(3):472-478, 2023. e-Pub 2023. PMID: 36067452.
117. Eluri M, Kopetz S, Parseghian CM. Truncal dynamics may trump: serial ctDNA to predict early therapeutic response. Clinical Cancer Research 29(2):OF1-OF10, 2023. e-Pub 2023. PMID: 36378102.
118. Thatikonda V, Lu H, Jurado S, Kostyrko K, Bristow CA, Bosch K, Feng N, Gao S, Gerlach D, Gmachl M, Lieb S, Jeschko A, Machado AA, Marszalek ED, Mahendra M, Jaeger PA, Sorokin A, Strauss S, Trapani F, Kopetz S, Vellano CP, Petronczki M, Kraut N, Heffernan TP, Marszalek JR, Pearson M, Waizenegger I, Hofmann MH. Combined KRAS G12C and SOS1 inhibition enhances and extends the anti-tumor response in KRAS G12C -driven cancers by addressing intrinsic and acquired resistance. bioRxiv, 2023. e-Pub 2023. PMID: 36747713.
119. Parseghian C, Eluri M, Kopetz S, Raghav K. Mechanisms of resistance to EGFR-targeted therapies in colorectal cancer: more than just genetics. Frontiers in Cell and Developmental Biology 11:1176657, 2023. e-Pub 2023. PMID: 37791069.
120. Pairawan, S, Akcakanat, A, Kopetz, S, Tapia, C, Zheng, X, Chen, H, Ha, MJ, Rizvi, YQ, Holla, V, Wang, J, Evans, KW, Zhao, M, Busaidy, NL, Fang, B, Roth, JA, Ileana Dumbrava, EE, Meric-Bernstam, F. Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations. Scientific reports 12(1), 2022. e-Pub 2022. PMID: 35075200.
121. Khan S, Wiegand J, Zhang P, Hu W, Thummuri D, Budamagunta V, Hua N, Jin L, Allegra CJ, Kopetz SE, Zajac-Kaye M, Kaye FJ, Zheng G, Zhou D. BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers. Journal of Hematology and Oncology 15(1):23, 2022. e-Pub 2022. PMID: 35260176.
122. Cao S, Wang JR, Ji S, Yang P, Dai Y, Guo S, Montierth MD, Shen JP, Zhao X, Chen J, Lee JJ, Guerrero PA, Spetsieris N, Engedal N, Taavitsainen S, Yu K, Livingstone J, Bhandari V, Hubert SM, Daw NC, Futreal PA, Efstathiou E, Lim B, Viale A, Zhang J, Nykter M, Czerniak BA, Brown PH, Swanton C, Msaouel P, Maitra A, Kopetz S, Campbell P, Speed TP, Boutros PC, Zhu H, Urbanucci A, Demeulemeester J, Van Loo P, Wang W. Estimation of tumor cell total mRNA expression in 15 cancer types predicts disease progression. Nature biotechnology 40(11):1624-1633, 2022. e-Pub 2022. PMID: 35697807.
123. Serpas Higbie V, Rogers J, Hwang H, Qiao W, Xiao L, Dasari A, Mola-Rudd K, Morris VK, Wolff RA, Raghav K, Huey R, Parseghian C, Willis J, Kopetz S, Overman MJ, Johnson B. Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience. Oncologist 27(11):952-957, 2022. e-Pub 2022. PMID: 35946836.
124. Davis JS, Chavez JC, Kok M, San Miguel Y, Lee HY, Henderson H, Overman MJ, Morris V, Kee B, Fogelman D, Advani SM, Johnson B, Parseghian C, Shen JP, Dasari A, Shaw KR, Vilar E, Raghav KP, Shureiqi I, Wolff RA, Meric-Bernstam F, Maru D, Menter DG, Kopetz S, Chang S. Association of Prediagnosis Obesity and Postdiagnosis Aspirin With Survival From Stage IV Colorectal Cancer. JAMA Network Open 5(10):e2236357, 2022. e-Pub 2022. PMID: 36239938.
125. Andre, T, Lonardi, S, Wong, KM, Lenz, HJ, Gelsomino, F, Aglietta, M, Morse, MA, Van Cutsem, E, Mcdermott, R, Hill, AG, Sawyer, MB, Hendlisz, A, Neyns, B, Abdullaev, S, Memaj, A, Lei, M, Dixon, M, Kopetz, S, Overman, MJ. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. Annals of Oncology 33(10):1052-1060, 2022. e-Pub 2022. PMID: 35764271.
126. Abu-Sbeih, H, Szafron, D, Elkafrawy, AA, Garcia-Rodriguez, V, Ma, W, Xu, A, Khurana, S, Numan, L, Chen, E, Goldstein, R, Tsen, A, Peng, Y, Blum Murphy, M, Kopetz, S, Ikoma, N, Shatila, M, Qiao, W, Raju, GS, Ross, WA, Ge, PS, Coronel, E, Wang, Y. Endoscopy for the diagnosis and treatment of gastrointestinal bleeding caused by malignancy. Journal of Gastroenterology and Hepatology (Australia) 37(10):1983-1990, 2022. e-Pub 2022. PMID: 35730192.
127. Kanikarla Marie P, Sorokin AV, Bitner LA, Aden R, Lam M, Manyam G, Woods MN, Anderson A, Capasso A, Fowlkes N, Overman MJ, Menter DG, Kopetz S. Autologous humanized mouse models to study combination and single-agent immunotherapy for colorectal cancer patient-derived xenografts. Front Oncol 12:994333, 2022. e-Pub 2022. PMID: 36212401.
128. Sorokin AV, Kanikarla Marie P, Bitner L, Syed M, Woods M, Manyam G, Kwong LN, Johnson B, Morris VK, Jones P, Menter DG, Lee MS, Kopetz S. Targeting RAS mutant colorectal cancer with dual inhibition of MEK and CDK4/6. Cancer Res 82(18):3335-3344, 2022. e-Pub 2022. PMID: 35913398.
129. Morris VK, Overman MJ, Lam M, Parseghian CM, Johnson B, Dasari A, Raghav K, Kee BK, Huey R, Wolff RA, Shen JP, Li J, Zorrilla I, Tzeng CD, Tran Cao HS, Chun YS, Newhook TE, Vauthey N, Duose D, Luthra R, Haymaker C, Kopetz S. Bintrafusp alfa, an anti-PD-L1:TGF-β trap fusion protein, in patients with ctDNA-positive, liver-limited metastatic colorectal cancer. Cancer Res Commun 2(9):979-986, 2022. e-Pub 2022. PMID: 36382087.
130. Johnson B, Haymaker CL, Parra ER, Soto LMS, Wang X, Thomas JV, Dasari A, Morris VK, Raghav K, Vilar E, Kee BK, Eng C, Parseghian CM, Wolff RA, Lee Y, Lorenzini D, Laberiano-Fernandez C, Verma A, Lang W, Wistuba II, Futreal A, Kopetz S, Overman MJ. Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). J Immunother Cancer 10(8), 2022. e-Pub 2022. PMID: 36007963.
131. Fakih M, Tu H, Hsu H, Aggarwal S, Chan E, Rehn M, Chia V, Kopetz S. Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer. Oncologist 27(8):663-674, 2022. e-Pub 2022. PMID: 35472176.
132. Dankner M, Wang Y, Fazelzad R, Johnson B, Nebhan CA, Dagogo-Jack I, Myall NJ, Richtig G, Bracht JWP, Gerlinger M, Shinozaki E, Yoshino T, Kotani D, Fangusaro JR, Gautschi O, Mazieres J, Sosman JA, Kopetz S, Subbiah V, Davies MA, Groover AL, Sullivan RJ, Flaherty KT, Johnson DB, Benedetti A, Cescon DW, Spreafico A, Zogopoulos G, Rose AAN. Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant Tumors. JCO Precis Oncol 6:e2200107, 2022. e-Pub 2022. PMID: 35977349.
133. VandenHeuvel SN, Farris HA, Noltensmeyer DA, Roy S, Donehoo DA, Kopetz S, Haricharan S, Walsh AJ, Raghavan S. Decellularized organ biomatrices facilitate quantifiable in vitro 3D cancer metastasis models. Soft Matter 18(31):5791-5806, 2022. e-Pub 2022. PMID: 35894795.
134. Chun YS, Passot G, Nishioka Y, Katkhuda R, Arvide EM, Benzerdjeb N, Lopez J, Kopetz SE, Maru DM, Vauthey JN. Colorectal Liver Micrometastases: Association with RAS/TP53 Co-Mutation and Prognosis after Surgery. J Am Coll Surg 235(1):8-16, 2022. e-Pub 2022. PMID: 35703957.
135. Thein KZ, Biter AB, Banks KC, Duda AW, Saam J, Roszik J, Janku F, Skoulidis F, Heymach JV, Kopetz S, Meric-Bernstam F, Hong DS. Identification of KRASG12C Mutations in Circulating Tumor DNA in Patients With Cancer. JCO Precis Oncol 6:e2100547, 2022. e-Pub 2022. PMID: 35862868.
136. Kasi PM, Fehringer G, Aleshin A, Kopetz S. Reply to F. Dayyani et al. JCO Precis Oncol 6:e2200275, 2022. e-Pub 2022. PMID: 35834757.
137. Ryan MB, Coker O, Sorokin A, Fella K, Barnes H, Wong E, Kanikarla P, Gao F, Zhang Y, Zhou L, Kopetz S, Corcoran RB. KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy. Cell Rep 39(12):110993, 2022. e-Pub 2022. PMID: 35732135.
138. Ding S, Hsu C, Wang Z, Natesh NR, Millen R, Negrete M, Giroux N, Rivera GO, Dohlman A, Bose S, Rotstein T, Spiller K, Yeung A, Sun Z, Jiang C, Xi R, Wilkin B, Randon PM, Williamson I, Nelson DA, Delubac D, Oh S, Rupprecht G, Isaacs J, Jia J, Chen C, Shen JP, Kopetz S, McCall S, Smith A, Gjorevski N, Walz AC, Antonia S, Marrer-Berger E, Clevers H, Hsu D, Shen X. Patient-derived micro-organospheres enable clinical precision oncology. Cell Stem Cell 29(6):905-917.e6, 2022. e-Pub 2022. PMID: 35508177.
139. Li X, Dowling EK, Yan G, Dereli Z, Bozorgui B, Imanirad P, Elnaggar JH, Luna A, Menter DG, Pilie PG, Yap TA, Kopetz S, Sander C, Korkut A. Precision combination therapies based on recurrent oncogenic co-alterations. Cancer Discov 12(6):1542-1559, 2022. e-Pub 2022. PMID: 35412613.
140. Kothari A, White MG, Peacock O, Kaur H, Palmquist SM, You N, Taggart M, Salem U, Overman M, Kopetz S, Chang GJ. Pathological response following neoadjuvant immunotherapy in mismatch repair-deficient/microsatellite instability-high locally advanced, non-metastatic colorectal cancer. Br J Surg 109(6):489-492, 2022. e-Pub 2022. PMID: 35576377.
141. Kopetz, S, Grothey, A, Van Cutsem, E, Yaeger, R, Wasan, H, Yoshino, T, Desai, J, Ciardiello, F, Loupakis, F, Hong, YS, Steeghs, N, Guren, T, Arkenau, HT, Garcia-Alfonso, P, Belani, A, Zhang, X, Tabernero, J. Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer. ESMO Open 7(3), 2022. e-Pub 2022. PMID: 35653981.
142. Orouji E, Raman AT, Singh AK, Sorokin A, Arslan E, Ghosh AK, Schulz J, Terranova C, Jiang S, Tang M, Maitituoheti M, Callahan SC, Barrodia P, Tomczak K, Jiang Y, Jiang Z, Davis JS, Ghosh S, Lee HM, Reyes-Uribe L, Chang K, Liu Y, Chen H, Azhdarinia A, Morris J, Vilar E, Carmon KS, Kopetz SE, Rai K. Chromatin state dynamics confers specific therapeutic strategies in enhancer subtypes of colorectal cancer. Gut 71(5):938-949, 2022. e-Pub 2022. PMID: 34059508.
143. Shen C, Tannenbaum D, Horn R, Rogers J, Eng C, Zhou S, Johnson B, Kopetz S, Morris V, Overman M, Parseghian C, Chang GJ, Lopez-Olivo MA, Kanwal R, Ellis LM, Dasari A. Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016: A Systematic Review. JAMA Netw Open 5(5):e2213588, 2022. e-Pub 2022. PMID: 35608860.
144. Parikh AR, Gonzalez-Gugel E, Smolyakova N, Jen MH, Toms N, Lin Y, Kim JS, Kopetz S. Efficacy and Safety of Cetuximab Dosing (biweekly vs weekly) in Patients with KRAS Wild-type Metastatic Colorectal Cancer: A Meta-analysis. Oncologist 27(5):371-379, 2022. e-Pub 2022. PMID: 35522557.
145. Morris V, Kee B, Overman M, Dasari A, Raghav K, Johnson B, Parseghian C, Wolff RA, Garg N, Eng C, Kopetz S. Clinical and pathologic features correlated with rare favorable survival in patients with BRAFV600E mutated colorectal cancer. J Gastrointest Oncol 13(2):647-656, 2022. e-Pub 2022. PMID: 35557581.
146. Nishioka Y, Chun YS, Overman MJ, Cao HST, Tzeng CD, Mason MC, Kopetz SW, Bauer TW, Vauthey JN, Newhook TE, Program MD. Effect of Co-mutation of RAS and TP53 on Postoperative ctDNA Detection and Early Recurrence after Hepatectomy for Colorectal Liver Metastases. J Am Coll Surg 234(4):474-483, 2022. e-Pub 2022. PMID: 35290266.
147. Kothari A, White MG, Peacock O, Kaur H, Palmquist SM, You N, Taggart M, Salem U, Overman M, Kopetz S, Chang GJ. Pathological response following neoadjuvant immunotherapy in mismatch repair-deficient/microsatellite instability-high locally advanced, non-metastatic colorectal cancer. Br J Surg. e-Pub 2022. PMID: 35373260.
148. Taku N, Yi-Qian YN, Chang GJ, Ludmir EB, Raghav KPS, Rodriguez-Bigas MA, Holliday EB, Smith GL, Minsky BD, Overman MJ, Messick C, Boyce-Fappiano D, Koong AC, Skibber JM, Koay EJ, Dasari A, Taniguchi CM, Bednarski BK, Morris VK, Kopetz S, Das P. Benchmarking Outcomes for Definitive Treatment of Young-Onset, Locally Advanced Rectal Cancer. Clin Colorectal Cancer 21(1):e28-e37, 2022. e-Pub 2022. PMID: 34794903.
149. Kawaguchi Y, Kopetz S, Panettieri E, Hwang H, Wang X, Cao HST, Tzeng CD, Chun YS, Aloia TA, Vauthey JN. Improved Survival over Time After Resection of Colorectal Liver Metastases and Clinical Impact of Multigene Alteration Testing in Patients with Metastatic Colorectal Cancer. J Gastrointest Surg 26(3):583-593, 2022. e-Pub 2022. PMID: 34506029.
150. Mu R, Xu J, Tang RS, Kopetz S, Yuan Y. A Bayesian phase I/II platform design for co-developing drug combination therapies for multiple indications. Stat Med 41(2):374-389, 2022. e-Pub 2022. PMID: 34730248.
151. Hu, J, Yang, Q, Zhang, W, Du, H, Chen, Y, Zhao, Q, Dao, L, Xia, X, Fowlkes, NW, Zhang, Z, Mahadeo, KM, Gorlick, R, Kopetz, S, Dotti, G, Li, S. Cell membrane-Anchored and tumor-Targeted IL-12 (attIL12)-T cell therapy for eliminating large and heterogeneous solid tumors. Journal for immunotherapy of cancer 10(1), 2022. e-Pub 2022. PMID: 35027427.
152. Fakih MG, Kopetz S, Kuboki Y, Kim TW, Munster PN, Krauss JC, Falchook GS, Han SW, Heinemann V, Muro K, Strickler JH, Hong DS, Denlinger CS, Girotto G, Lee MA, Henary H, Tran Q, Park JK, Ngarmchamnanrith G, Prenen H, Price TJ. Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial. Lancet Oncol 23(1):115-124, 2022. e-Pub 2022. PMID: 34919824.
153. Kasi PM, Fehringer G, Taniguchi H, Starling N, Nakamura Y, Kotani D, Powles T, Li BT, Pusztai L, Aushev VN, Kalashnikova E, Sharma S, Malhotra M, Demko ZP, Aleshin A, Rodriguez A, Billings PR, Grothey A, Taieb J, Cunningham D, Yoshino T, Kopetz S. Impact of Circulating Tumor DNA-Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors. JCO Precis Oncol 6:e2100181, 2022. e-Pub 2022. PMID: 35263168.
154. Sahin IH, Lin Y, Yothers G, Lucas PC, Deming D, George TJ, Kopetz S, Lieu CH, Dasari A. Minimal Residual Disease-Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer: CIRCULATE-US. Oncology (Williston Park) 36(10):604-608, 2022. e-Pub 2022. PMID: 36260786.
155. Morris, VK, Overman, MJ, Lam, MC, Parseghian, C, Johnson, B, Dasari, NV, Raghav, KS, Kee, BK, Huey, RW, Wolff, RA, Shen, JY, Li, J, Zorrilla, I, Tzeng, CD, Tran Cao, HS, Chun, YS, Newhook, TE, Vauthey, JN, Duose, D, Luthra, R, Haymaker, CL, Kopetz, S. Bintrafusp Alfa, an Anti-PD-L1:TGFβ Trap Fusion Protein, in Patients with ctDNA-positive, Liver-limited Metastatic Colorectal Cancer. Cancer Research Communications 2(9):979-986, 2022. e-Pub 2022. PMID: 36382087.
156. Fangman B, Raghav K, Kopetz S. Circulating Tumor DNA as a Marker of Minimal Residual Disease. Oncology (Williston Park) 36(10):600-603, 2022. e-Pub 2022. PMID: 36260787.
157. Bhamidipati D, Verma A, Sui D, Maru D, Mathew G, Lang W, Posadas J, Hein J, Kopetz S, Futreal A, Wistuba II, Gupta S, Lee JJ, Overman MJ, Tam AL. An analysis of research biopsy core variability from over 5000 prospectively collected core samples. NPJ Precis Oncol 5(1):94, 2021. e-Pub 2021. PMID: 34707215.
158. Tabernero J, Velez L, Trevino TL, Grothey A, Yaeger R, Van Cutsem E, Wasan H, Desai J, Ciardiello F, Yoshino T, Gollerkeri A, Maharry K, Christy-Bittel J, Kopetz S. Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study. ESMO Open 6(6), 2021. e-Pub 2021. PMID: 34896698.
159. Yu IS, Kopetz S. The emergence of targetable pathways in colorectal cancer. Clin Adv Hematol Oncol 19(12):774-783, 2021. e-Pub 2021. PMID: 34928933.
160. Sun, H, Cao, S, Mashl, RJ, Mo, CK, Zaccaria, S, Wendl, MC, Davies, S, Bailey, MH, Primeau, T, Hoog, J, Mudd, JL, Dean, DA, Patidar, R, Chen, L, Wyczalkowski, MA, Jayasinghe, R, Rodrigues, FM, Terekhanova, NV, Li, Y, Lim, KH, Wang-Gillam, A, Van Tine, BA, Ma, C, Aft, R, Fuh, KC, Schwarz, JK, Roth, JA, Akcakanat, A, Chen, H, Dai, B, Gibbons, DL, Ha, MJ, Jensen, VB, Kim, M, Kopetz, S, Menter, DG, Meraz, I, Sorokin, A, Tapia, C, Wang, J, Westin, SN, Xi, Y, Yang, F, Yap, TA, Yennu Nanda, VG, Zhang, X, Zheng, X, Davies, MA, Fang, B, Meric-Bernstam, F. Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment. Nature communications 12(1), 2021. e-Pub 2021. PMID: 34429404.
161. Liu Y, Baggerly KA, Orouji E, Manyam G, Chen H, Lam M, Davis JS, Lee MS, Broom BM, Menter DG, Rai K, Kopetz S, Morris JS. Methylation-eQTL Analysis in Cancer Research. Bioinformatics 37(22):4014-4022, 2021. e-Pub 2021. PMID: 34117863.
162. Raghav K, Liu S, Overman MJ, Willett AF, Knafl M, Fu SC, Malpica A, Prasad S, Royal RE, Scally CP, Mansfield PF, Wistuba II, Futreal AP, Maru DM, Solis Soto LM, Parra Cuentas ER, Chen H, Villalobos P, Verma A, Mahvash A, Hwu P, Cortazar P, McKenna E, Yun C, Dervin S, Schulze K, Darbonne WC, Morani AC, Kopetz S, Fournier KF, Woodman SE, Yao JC, Varadhachary GR, Halperin DM. Efficacy, Safety and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. Cancer Discov 11(11):2738-2747, 2021. e-Pub 2021. PMID: 34261675.
163. Nunez SK, Young CD, Griffen TL, Ohandjo AQ, McKinney LP, Kopetz S, Lillard JW. Identification of Gene Co-Expression Networks Associated with Consensus Molecular Subtype-1 of Colorectal Cancer. Cancers (Basel) 13(22), 2021. e-Pub 2021. PMID: 34830978.
164. Kopetz S, Bent A. Going With the Flow: The Promise of Plasma-Only Circulating Tumor DNA Assays. Clin Cancer Res 27(20):5449-5451, 2021. e-Pub 2021. PMID: 34389607.
165. Wang L, Wang E, Prado Balcazar J, Wu Z, Xiang K, Wang Y, Huang Q, Negrete M, Chen KY, Li W, Fu Y, Dohlman A, Mines R, Zhang L, Kobayashi Y, Chen T, Shi G, Shen JP, Kopetz S, Tata PR, Moreno V, Gersbach C, Crawford G, Hsu D, Huang E, Bu P, Shen X. Chromatin Remodeling of Colorectal Cancer Liver Metastasis is Mediated by an HGF-PU.1-DPP4 Axis. Adv Sci (Weinh) 8(19):e2004673, 2021. e-Pub 2021. PMID: 34378358.
166. Chowdhury S, Hofree M, Lin K, Maru D, Kopetz S, Shen JP. Implications of Intratumor Heterogeneity on Consensus Molecular Subtype (CMS) in Colorectal Cancer. Cancers (Basel) 13(19), 2021. e-Pub 2021. PMID: 34638407.
167. Dumbrava EI, Call SG, Huang HJ, Stuckett AL, Madwani K, Adat A, Hong DS, Piha-Paul SA, Subbiah V, Karp DD, Fu S, Naing A, Tsimberidou AM, Moulder SL, Koenig KH, Barcenas CH, Kee BK, Fogelman DR, Kopetz ES, Meric-Bernstam F, Janku F. PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers. ESMO Open 6(5):100230, 2021. e-Pub 2021. PMID: 34479035.
168. Kasi PM, Sawyer S, Guilford J, Munro M, Ellers S, Wulff J, Hook N, Krinshpun S, Koyen Malashevich A, Malhotra M, Rodriguez A, Moshkevich S, Grothey A, Kopetz S, Billings P, Aleshin A. BESPOKE study protocol: a multicentre, prospective observational study to evaluate the impact of circulating tumour DNA guided therapy on patients with colorectal cancer. BMJ Open 11(9):e047831, 2021. e-Pub 2021. PMID: 34561256.
169. Loree JM, Wang Y, Syed MA, Sorokin AV, Coker O, Xiu J, Weinberg BA, VanderWalde AM, Tesfaye A, Raymond VM, Miron B, Tarcic G, Zelichov O, Broaddus RR, Ng PKS, Jeong KJ, Tsang YH, Mills GB, Overman MJ, Grothey A, Marshall JL, Kopetz S. Clinical and functional characterization of atypical KRAS/NRAS mutations in metastatic colorectal cancer. Clin Cancer Res 27(16):4587-4598, 2021. e-Pub 2021. PMID: 34117033.
170. Kawaguchi Y, Kopetz S, Kwong L, Xiao L, Morris JS, Tran Cao HS, Tzeng CD, Chun YS, Lee JE, Vauthey JN. Genomic Sequencing and Insight into Clinical Heterogeneity and Prognostic Pathway Genes in Patients with Metastatic Colorectal Cancer. J Am Coll Surg 233(2):272-284.e13, 2021. e-Pub 2021. PMID: 34111531.
171. Kawaguchi Y, Kopetz S, Tran Cao HS, Panettieri E, De Bellis M, Nishioka Y, Hwang H, Wang X, Tzeng CD, Chun YS, Aloia TA, Hasegawa K, Guglielmi A, Giuliante F, Vauthey JN. Contour prognostic model for predicting survival after resection of colorectal liver metastases: development and multicentre validation study using largest diameter and number of metastases with RAS mutation status. Br J Surg 108(8):968-975, 2021. e-Pub 2021. PMID: 33829254.
172. Mason MC, Tzeng CD, Tran Cao HS, Aloia TA, Newhook TE, Overman MJ, Kopetz SE, Vauthey JN, Chun YS. Preliminary Analysis of Liquid Biopsy after Hepatectomy for Colorectal Liver Metastases. J Am Coll Surg 233(1):82-89.e1, 2021. e-Pub 2021. PMID: 33667566.
173. Inoue A, Robinson FS, Minelli R, Tomihara H, Rizi BS, Rose JL, Kodama T, Srinivasan S, Harris AL, Zuniga AM, Mullinax RA, Ma X, Seth S, Daniele JR, Peoples MD, Loponte S, Akdemir KC, Khor TO, Feng N, Roszik J, Sobieski MM, Brunell D, Stephan C, Giuliani V, Deem AK, Shingu T, Deribe YL, Menter DG, Heffernan TP, Viale A, Bristow CA, Kopetz S, Draetta GF, Genovese G, Carugo A. Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer. Gastroenterology 161(1):196-210, 2021. e-Pub 2021. PMID: 33745946.
174. Kanikarla Marie P, Haymaker C, Parra ER, Kim YU, Lazcano R, Gite S, Lorenzini D, Wistuba II, Tidwell RSS, Song X, Foo WC, Maru DM, Chun YS, Futreal A, Kee B, Menter D, Solis L, Tzeng CW, Parseghian C, Raghav K, Morris V, Chang CC, Jenq R, Tam A, Bernatchez C, Kopetz S, Vauthey JN, Overman MJ. Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases. Clin Cancer Res 27(11):3039-3049, 2021. e-Pub 2021. PMID: 33811152.
175. Cleary JM, Wang V, Heist RS, Kopetz ES, Mitchell EP, Zwiebel JA, Kapner KS, Chen HX, Li S, Gray RJ, McShane LM, Rubinstein LV, Patton DR, Meric-Bernstam F, Dillmon MS, Williams PM, Hamilton SR, Conley BA, Aguirre AJ, O'Dwyer PJ, Harris LN, Arteaga CL, Chen AP, Flaherty KT. Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors. Clin Cancer Res 27(11):2996-3004, 2021. e-Pub 2021. PMID: 33637626.
176. Advani SM, Swartz MD, Loree J, Davis JS, Sarsashek AM, Lam M, Lee MS, Bressler J, Lopez DS, Daniel CR, Morris V, Shureqi I, Kee B, Dasari A, Vilar E, Overman M, Hamilton S, Maru D, Braithwaite D, Kopetz S. Epidemiology and Molecular-Pathologic Characteristics of CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer. Clin Colorectal Cancer 20(2):137-147, 2021. e-Pub 2021. PMID: 33229221.
177. Zhao M, Scott S, Evans KW, Yuca E, Saridogan T, Zheng X, Wang H, Korkut A, Cruz Pico CX, Demirhan ME, Kirby B, Kopetz S, Diala I, Lalani AS, Piha-Paul S, Meric-Bernstam F. Combining neratinib with CDK4/6, mTOR and MEK inhibitors in models of HER2-positive cancer. Clin Cancer Res 27(6):1681-1694, 2021. e-Pub 2021. PMID: 33414137.
178. Malakorn S, Ouchi A, Hu CY, Sandhu L, Dasari A, You YN, Kopetz ES, Ellis LM, Chang GJ. Tumor Sidedness, Recurrence, and Survival After Curative Resection of Localized Colon Cancer. Clin Colorectal Cancer 20(1):e53-e60, 2021. e-Pub 2021. PMID: 33004292.
179. Mehrvarz Sarshekeh A, Alshenaifi J, Roszik J, Manyam G, Advani SM, Katkhuda R, Verma A, Lam M, Willis JA, Shen JP, Morris JS, Davis JS, Loree JM, Lee HM, Ajani JA, Maru DM, Overman MJ, Kopetz S. ARID1A mutation may define an immunologically active subgroup in patients with microsatellite-stable colorectal cancer. Clin Cancer Res 27(6):1663-1670, 2021. e-Pub 2021. PMID: 33414133.
180. Mendis S, Anand S, Karasinska JM, Dasari A, Unger JM, Gothwal A, Ellis LM, Varadhachary G, Kopetz S, Overman MJ, Raghav K, Loree JM. Sex Representation in Clinical Trials Associated with FDA Cancer Drug Approvals Differs Between Solid and Hematologic Malignancies. Oncologist 26(2):107-114, 2021. e-Pub 2021. PMID: 32960478.
181. Ludford K, Cohen R, Svrcek M, Foo WC, Colle R, Parc Y, Thomas JV, Morris VK, Kopetz S, Chang GJ, Overman M, Andre T. Pathological tumor response following immune checkpoint blockade for deficient mismatch repair advanced colorectal cancer. J Natl Cancer Inst 113(2):208-211, 2021. e-Pub 2021. PMID: 32294214.
182. Kopetz S, Guthrie KA, Morris VK, Lenz HJ, Magliocco AM, Maru D, Yan Y, Lanman R, Manyam G, Hong DS, Sorokin A, Atreya CE, Diaz LA, Allegra C, Raghav KP, Wang SE, Lieu CH, McDonough SL, Philip PA, Hochster HS. Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406) 39(4):285-294, 2021. e-Pub 2021. PMID: 33356422.
183. Tabernero J, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, Desai J, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Elez E, Gollerkeri A, Maharry K, Christy-Bittel J, Kopetz S. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. J Clin Oncol 39(4):273-284, 2021. e-Pub 2021. PMID: 33503393.
184. Henry JT, Coker O, Chowdhury S, Shen JP, Morris VK, Dasari A, Raghav K, Nusrat M, Kee B, Parseghian C, Pant S, Jeyakumar N, Zhu L, Nishioka Y, Fogelman D, Wolff RA, Hong D, Overman MJ, Vauthey J, Kopetz S, Johnson B. Comprehensive Clinical and Molecular Characterization of KRAS G12C-Mutant Colorectal Cancer. JCO Precis Oncol 5:613-621, 2021. e-Pub 2021. PMID: 34250391.
185. Loree JM, Dowers A, Tu D, Jonker DJ, Edelstein DL, Quinn H, Holtrup F, Price T, Zalcberg JR, Moore MJ, Karapetis CS, O'Callaghan CJ, Waring P, Kennecke HF, Hamilton SR, Kopetz S. Expanded Low Allele Frequency RAS and BRAF V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial. Clin Cancer Res 27(1):52-59, 2021. e-Pub 2021. PMID: 33087330.
186. Kawaguchi Y, Newhook TE, Tran Cao HS, Tzeng CD, Chun YS, Aloia TA, Dasari A, Kopetz S, Vauthey JN. Alteration of FBXW7 is Associated with Worse Survival in Patients Undergoing Resection of Colorectal Liver Metastases. J Gastrointest Surg 25(1):186-194, 2021. e-Pub 2021. PMID: 33205306.
187. Woo, XY, Giordano, J, Srivastava, A, Zhao, ZM, Lloyd, M, de Bruijn, R, Suh, YS, Patidar, R, Chen, L, Scherer, S, Bailey, M, Yang, CH, Cortes-Sanchez, E, Xi, Y, Wang, J, Wickramasinghe, JM, Kossenkov, AV, Rebecca, VW, Sun, H, Mashl, RJ, Davies, S, Jeon, R, Frech, C, Randjelovic, J, Rosains, J, Galimi, F, Bertotti, A, Lafferty, A, O’Farrell, AC, Modave, E, Lambrechts, D, Fang, B, Roth, JA, Meric-Bernstam, F, Davies, MA, Zheng, X, Zhang, X, Akcakanat, A, Yap, TA, Ha, MJ, Chen, H, Kopetz, S, Menter, DG, Westin, SN, Kim, M, Dai, B, Gibbons, DL, Jensen, VB, Yennu Nanda, VG, Mælandsmo, GM. Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nature Genetics 53(1):86-99, 2021. e-Pub 2021. PMID: 33414553.
188. Morris JS, Luthra R, Liu Y, Duose DY, Lee W, Reddy NG, Windham J, Chen H, Tong Z, Zhang B, Wei W, Ganiraju M, Broom BM, Alvarez HA, Mejia A, Veeranki O, Routbort MJ, Morris VK, Overman MJ, Menter D, Katkhuda R, Wistuba II, Davis JS, Kopetz S, Maru DM. Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting. Clin Cancer Res 27(1):120-130, 2021. e-Pub 2021. PMID: 33109741.
189. Chen B, Dragomir MP, Fabris L, Bayraktar R, Knutsen E, Liu X, Tang C, Li Y, Shimura T, Ivkovic TC, Cruz De Los Santos M, Anfossi S, Shimizu M, Shah MY, Ling H, Shen P, Multani AS, Pardini B, Burks JK, Katayama H, Reineke LC, Huo L, Syed M, Song S, Ferracin M, Oki E, Fromm B, Ivan C, Bhuvaneshwar K, Gusev Y, Mimori K, Menter D, Sen S, Matsuyama T, Uetake H, Vasilescu C, Kopetz S, Parker-Thornburg J, Taguchi A, Hanash SM, Girnita L, Slaby O, Goel A, Varani G, Gagea M, Li C, Ajani JA, Calin GA. The Long Noncoding RNA CCAT2 Induces Chromosomal Instability Through BOP1-AURKB Signaling. Gastroenterology 159(6):2146-2162.e33, 2020. e-Pub 2020. PMID: 32805281.
190. Kopetz S. Circulating tumor DNA as a marker of minimal residual disease in colorectal cancer. Clin Adv Hematol Oncol 18(12):791-792, 2020. e-Pub 2020. PMID: 33406055.
191. Kawaguchi Y, Kopetz S, Lillemoe HA, Hwang H, Wang X, Tzeng CD, Chun YS, Aloia TA, Vauthey JN. A New Surveillance Algorithm After Resection of Colorectal Liver Metastases Based on Changes in Recurrence Risk and RAS Mutation Status. J Natl Compr Canc Netw 18(11):1500-1508, 2020. e-Pub 2020. PMID: 33152698.
192. Bradley SD, Talukder AH, Lai I, Davis R, Alvarez H, Tiriac H, Zhang M, Chiu Y, Melendez B, Jackson KR, Katailiha A, Sonnemann HM, Li F, Kang Y, Qiao N, Pan BF, Lorenzi PL, Hurd M, Mittendorf EA, Peterson CB, Javle M, Bristow C, Kim M, Tuveson DA, Hawke D, Kopetz S, Wolff RA, Hwu P, Maitra A, Roszik J, Yee C, Lizée G. Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers. Nat Commun 11(1):5332, 2020. e-Pub 2020. PMID: 33087697.
193. Davis JS, Kanikarla-Marie P, Gagea M, Yu PL, Fang D, Sebastian M, Yang P, Hawk E, Dashwood R, Lichtenberger LM, Menter D, Kopetz S. Sulindac plus a phospholipid is effective for polyp reduction and safer than sulindac alone in a mouse model of colorectal cancer development. BMC Cancer 20(1):871, 2020. e-Pub 2020. PMID: 32912193.
194. Chu JE, Johnson B, Kugathasan L, Morris VK, Raghav K, Swanson L, Lim HJ, Renouf DJ, Gill S, Wolber R, Karsan A, Kopetz S, Schaeffer DF, Loree JM. Population-based Screening for BRAFV600E in Metastatic Colorectal Cancer Reveals Increased Prevalence and Poor Prognosis. Clin Cancer Res 26(17):4599-4605, 2020. e-Pub 2020. PMID: 32571791.
195. Lou E, Beg MS, Bergsland E, Eng C, Khorana AA, Kopetz S, Lubner S, Saltz L, Shankaran V, Zafar SY. Reply to S. Boutayeb et al. JCO Oncol Pract 16(8):525, 2020. e-Pub 2020. PMID: 32574129.
196. Lou E, Beg S, Bergsland E, Eng C, Khorana A, Kopetz S, Lubner S, Saltz L, Shankaran V, Zafar SY. Modifying Practices in GI Oncology in the Face of COVID-19: Recommendations From Expert Oncologists on Minimizing Patient Risk. JCO Oncol Pract 16(7):383-388, 2020. e-Pub 2020. PMID: 32352884.
197. Dasari A, Morris VK, Allegra CJ, Atreya C, Benson AB, Boland P, Chung K, Copur MS, Corcoran RB, Deming DA, Dwyer A, Diehn M, Eng C, George TJ, Gollub MJ, Goodwin RA, Hamilton SR, Hechtman JF, Hochster H, Hong TS, Innocenti F, Iqbal A, Jacobs SA, Kennecke HF, Lee JJ, Lieu CH, Lenz HJ, Lindwasser OW, Montagut C, Odisio B, Ou FS, Porter L, Raghav K, Schrag D, Scott AJ, Shi Q, Strickler JH, Venook A, Yaeger R, Yothers G, You YN, Zell JA, Kopetz S. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. Nat Rev Clin Oncol. e-Pub 2020. PMID: 32632268.
198. Lee JJ, Kopetz S, Vilar E, Shen JP, Chen K, Maitra A. Relative Abundance of SARS-CoV-2 Entry Genes in the Enterocytes of the Lower Gastrointestinal Tract. Genes (Basel) 11(6), 2020. e-Pub 2020. PMID: 32545271.
199. Jácome AA, Kee B, Fogelman D, Dasari A, Shureiqi I, Raghav K, Morris V, Johnson B, Overman M, Wolff R, Kopetz S, Rogers J, Ahmed SU, Mehdizadeh A, Rothschild N, Eng C. FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival. Clin Colorectal Cancer. e-Pub 2020. PMID: 32665092.
200. Yang J, Gong Y, Lam VK, Shi Y, Guan Y, Zhang Y, Ji L, Chen Y, Zhao Y, Qian F, Chen J, Li P, Zhang F, Wang J, Zhang X, Yang L, Kopetz S, Futreal PA, Zhang J, Yi X, Xia X, Yu P. Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer. Cell Death Dis 11(5):346, 2020. e-Pub 2020. PMID: 32393783.
201. Hayes-Jordan AA, Sandler G, Malakorn S, Xiao LC, Kopetz S, Rodriquez-Bigas M. Colon Cancer in Patients Under 25 Years Old: A Different Disease?. J Am Coll Surg 230(4):648-656, 2020. e-Pub 2020. PMID: 32092356.
202. McGrail DJ, Garnett J, Yin J, Dai H, Shih DJH, Lam TNA, Li Y, Sun C, Li Y, Schmandt R, Wu JY, Hu L, Liang Y, Peng G, Jonasch E, Menter D, Yates MS, Kopetz S, Lu KH, Broaddus R, Mills GB, Sahni N, Lin SY. Proteome Instability Is a Therapeutic Vulnerability in Mismatch Repair-Deficient Cancer. Cancer Cell 37(3):371-386.e12, 2020. e-Pub 2020. PMID: 32109374.
203. Advani SM, Shi Q, Overman MJ, Loree JM, Lam M, Morris V, Shureiqi I, Kee B, Dasari A, Vilar E, Sarshekeh AM, Lin HK, Manuel S, Hamilton S, Raghav K, Maru D, Kopetz S, Wang XS. Patient-reported Symptom Outcomes and Microsatellite Instability in Patients With Metastatic Colorectal Cancer. Clin Colorectal Cancer 19(1):48-56.e2, 2020. e-Pub 2020. PMID: 32008976.
204. Yu IS, Pereira AAL, Lee M, Korphaisarn K, Marshall J, Segelov E, O'Callaghan C, Lim HJ, Kopetz S, Loree JM. Medical Oncologists' Perspectives on How the Results of the IDEA Collaboration Impact the Adjuvant Treatment of Stage III Colon Cancer. Oncologist 25(3):229-234, 2020. e-Pub 2020. PMID: 32162828.
205. Wang Y, Janku F, Piha-Paul S, Hess K, Broaddus R, Liu L, Shi N, Overman M, Kopetz S, Subbiah V, Naing A, Hong D, Tsimberidou AM, Karp D, Yao J, Fu S. Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. Sci Rep 10(1):3080, 2020. e-Pub 2020. PMID: 32080210.
206. Yang RK, Qing Y, Jelloul FZ, Routbort MJ, Wang P, Shaw K, Zhang J, Lee J, Medeiros LJ, Kopetz S, Tetzlaff MT, Broaddus RR. Identification of biomarkers of immune checkpoint blockade efficacy in recurrent or refractory solid tumor malignancies. Oncotarget 11(6):600-618, 2020. e-Pub 2020. PMID: 32110280.
207. Mendis S, Alcaide M, Topham JT, Johnson B, Morin RD, Chu J, Bosdet I, Kopetz S, Karsan A, Gill S, Laskin J, Jones SJM, Marra MA, Schaeffer DF, Renouf DJ, Loree JM. Integration of Whole-Genome Sequencing With Circulating Tumor DNA Analysis Captures Clonal Evolution and Tumor Heterogeneity in Non-V600 BRAF Mutant Colorectal Cancer. Clin Colorectal Cancer. e-Pub 2020. PMID: 32151517.
208. Goswami S, Walle T, Cornish AE, Basu S, Anandhan S, Fernandez I, Vence L, Blando J, Zhao H, Yadav SS, Ott M, Kong LY, Heimberger AB, de Groot J, Sepesi B, Overman M, Kopetz S, Allison JP, Pe'er D, Sharma P. Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. Nat Med 26(1):39-46, 2020. e-Pub 2020. PMID: 31873309.
209. Willis J, Lefterova MI, Artyomenko A, Kasi PM, Nakamura Y, Mody K, Catenacci DVT, Fakih M, Barbacioru C, Zhao J, Sikora M, Fairclough SR, Lee H, Kim KM, Kim ST, Kim J, Gavino D, Benavides M, Peled N, Nguyen T, Cusnir M, Eskander RN, Azzi G, Yoshino T, Banks KC, Raymond VM, Lanman RB, Chudova DI, Talasaz A, Kopetz S, Lee J, Odegaard JI. Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel. Clin Cancer Res 25(23):7035-7045, 2019. e-Pub 2019. PMID: 31383735.
210. Zhang X, Browman G, Siu W, Basen-Engquist KM, Hanash SM, Hoffman KL, Okhuysen PC, Scheet P, Petrosino JF, Kopetz S, Daniel CR. The BE GONE trial study protocol: a randomized crossover dietary intervention of dry beans targeting the gut microbiome of overweight and obese patients with a history of colorectal polyps or cancer. BMC Cancer 19(1):1233, 2019. e-Pub 2019. PMID: 31852462.
211. Veeranki OL, Tong Z, Mejia A, Verma A, Katkhuda R, Bassett R, Kim TB, Wang J, Lang W, Mino B, Solis L, Kingsley C, Norton W, Tailor R, Wu JY, Krishnan S, Lin SH, Blum M, Hofstetter W, Ajani J, Kopetz S, Maru D. A novel patient-derived orthotopic xenograft model of esophageal adenocarcinoma provides a platform for translational discoveries. Dis Model Mech. e-Pub 2019. PMID: 31732509.
212. Alifrangis L, Schoemaker R, Skartved NJ, Hald R, Montagut C, Kopetz S, Tabernero J, Kragh M, Wade JR. Population pharmacokinetics and covariate analysis of Sym004, an antibody mixture against the epidermal growth factor receptor, in subjects with metastatic colorectal cancer and other solid tumors. J Pharmacokinet Pharmacodyn. e-Pub 2019. PMID: 31679083.
213. Mallampati S, Zalles S, Duose DY, Hu PC, Medeiros LJ, Wistuba II, Kopetz S, Luthra R. Development and Application of Duplex Sequencing Strategy for Cell-Free DNA-Based Longitudinal Monitoring of Stage IV Colorectal Cancer. J Mol Diagn 21(6):994-1009, 2019. e-Pub 2019. PMID: 31401123.
214. Advani SM, Advani PS, Brown DW, DeSantis SM, Korphaisarn K, VonVille HM, Bressler J, Lopez DS, Davis JS, Daniel CR, Sarshekeh AM, Braithwaite D, Swartz MD, Kopetz S. Global differences in the prevalence of the CpG island methylator phenotype of colorectal cancer. BMC Cancer 19(1):964, 2019. e-Pub 2019. PMID: 31623592.
215. Burke HB, Kopetz S. Is the Patient Cured?. JAMA Oncol. e-Pub 2019. PMID: 31621795.
216. Siravegna G, Mussolin B, Venesio T, Marsoni S, Seoane J, Dive C, Papadopoulos N, Kopetz S, Corcoran RB, Siu LL, Bardelli A. How liquid biopsies can change clinical practice in oncology. Ann Oncol 30(10):1580-1590, 2019. e-Pub 2019. PMID: 31373349.
217. Kawaguchi Y, Kopetz S, Newhook TE, De Bellis M, Chun YS, Tzeng CD, Aloia TA, Vauthey JN. Mutation Status of RAS, TP53, and SMAD4 is Superior to Mutation Status of RAS Alone for Predicting Prognosis after Resection of Colorectal Liver Metastases. Clin Cancer Res 25(19):5843-5851, 2019. e-Pub 2019. PMID: 31221662.
218. Yu IS, Pereira AAL, Lee M, Korphaisarn K, Marshall J, Segelov E, O'Callaghan C, Lim HJ, Kopetz S, Loree JM. Medical Oncologists' Perspectives on How the Results of the IDEA Collaboration Impact the Adjuvant Treatment of Stage III Colon Cancer. Oncologist. e-Pub 2019. PMID: 31641062.
219. Wang YN, Lu YX, Liu J, Jin Y, Bi HC, Zhao Q, Liu ZX, Li YQ, Hu JJ, Sheng H, Jiang YM, Zhang C, Tian F, Chen Y, Pan ZZ, Chen G, Zeng ZL, Liu KY, Ogasawara M, Yun JP, Ju HQ, Feng JX, Xie D, Gao S, Jia WH, Kopetz S, Xu RH, Wang F. AMPKα1 confers survival advantage of colorectal cancer cells under metabolic stress by promoting redox balance through the regulation of glutathione reductase phosphorylation. Oncogene. e-Pub 2019. PMID: 31530934.
220. Kawaguchi Y, Lillemoe HA, Panettieri E, Chun YS, Tzeng CD, Aloia TA, Kopetz S, Vauthey JN. Conditional Recurrence-Free Survival after Resection of Colorectal Liver Metastases: Persistent Deleterious Association with RAS and TP53 Co-Mutation. J Am Coll Surg 229(3):286-294.e1, 2019. e-Pub 2019. PMID: 31054911.
221. Shi X, Duose DY, Mehrotra M, Harmon MA, Hu P, Wistuba II, Kopetz S, Luthra R. Non-invasive genotyping of metastatic colorectal cancer using circulating cell free DNA. Cancer Genet 237:82-89, 2019. e-Pub 2019. PMID: 31447070.
222. Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Takayuki Y, Wasan H, Ciardiello F, Loupakis F, Yong H, Neeltje S, Guren T, Arkenau H, Alfonso-Garcia P, Pfeiffer P, Orlov S, Lonardi S, Elez E, Kim T, Schellens J, Guo C, Krishnan A, Dekervel J, Morris V, Ferrandiz A, Tarpgaard L, Braun M, Gollerkeri A, Keir C, Maharry K, Pickard M, Bittel-Christy J, Anderson L, Sandor V, Tabernero J. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. N Enggl J Med, 2019. e-Pub 2019. PMID: 31566309.
223. Korphaisarn K, Morris V, Davis JS, Overman MJ, Fogelman DR, Kee BK, Dasari A, Raghav KPS, Shureiqi I, Trupti M, Wolff RA, Eng C, Menter DG, Hamilton S, Kopetz S. Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma. Br J Cancer 121(6):505-510, 2019. e-Pub 2019. PMID: 31406299.
224. Arango NP, Brusco L, Shaw KRM, Chen K, Eterovic AK, Holla V, Johnson A, Litzenburger B, Khotskaya YB, Sanchez N, Bailey A, Zheng X, Horombe C, Kopetz S, Farhangfar CJ, Routbort M, Broaddus R, Bernstam EV, Mendelsohn J, Mills GB, Meric-Bernstam F. Correction: A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory. Oncotarget 10(50):5254, 2019. e-Pub 2019. PMID: 31497255.
225. Loree JM, Anand S, Dasari A, Unger JM, Gothwal A, Ellis LM, Varadhachary G, Kopetz S, Overman MJ, Raghav K. Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018. JAMA Oncol:e191870. e-Pub 2019. PMID: 31415071.
226. Kutahyalioglu M, Nguyen HT, Kwatampora L, Clarke C, Silva A, Ibrahim E, Waguespack SG, Cabanillas ME, Jimenez C, Hu MI, Sherman SI, Kopetz S, Broaddus R, Dadu R, Wanland K, Williams M, Zafereo M, Perrier N, Busaidy NL. Genetic profiling as a clinical tool in advanced parathyroid carcinoma. J Cancer Res Clin Oncol 145(8):1977-1986, 2019. e-Pub 2019. PMID: 31309300.
227. Margalit O, Mamtani R, Kopetz S, Yang YX, Lawrence YR, Abu-Gazala S, Reiss KA, Golan T, Halpern N, Aderka D, Giantonio B, Shacham-Shmueli E, Boursi B. Refining the Use of Adjuvant Oxaliplatin in Clinical Stage II or III Rectal Adenocarcinoma. Oncologist 24(8):e671-e676, 2019. e-Pub 2019. PMID: 30696723.
228. Wang J, Yi Y, Xiao Y, Dong L, Liang L, Teng L, Ying JM, Lu T, Liu Y, Guan Y, Pang J, Zhou L, Lu J, Zhang Z, Liu X, Liang X, Zeng X, Yi X, Zhou W, Xia X, Yang L, Zhang J, Kopetz S, Futreal PA, Wu H, Liang Z. Prevalence of recurrent oncogenic fusion in mismatch repair-deficient colorectal carcinoma with hypermethylated MLH1 and wild-type BRAF and KRAS. Mod Pathol 32(7):1053-1064, 2019. e-Pub 2019. PMID: 30723297.
229. Veeranki OL, Tong Z, Dokey R, Mejia A, Zhang J, Qiao Y, Singh PK, Katkhuda R, Mino B, Tailor R, Canales JR, Bassett R, Ajani J, Wu JY, Kopetz S, Blum M, Hofstetter W, Tetzlaff M, Krishnan S, Lin SH, Maru D. Targeting cyclin-dependent kinase 9 by a novel inhibitor enhances radiosensitization and identifies Axl as a novel downstream target in esophageal adenocarcinoma 10(45):4703-4718, 2019. e-Pub 2019. PMID: 31384397.
230. Van Cutsem E, Huijberts S, Grothey A, Yaeger R, Cuyle PJ, Elez E, Fakih M, Montagut C, Peeters M, Yoshino T, Wasan H, Desai J, Ciardiello F, Gollerkeri A, Christy-Bittel J, Maharry K, Sandor V, Schellens JHM, Kopetz S, Tabernero J. Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study. J Clin Oncol 37(17):1460-1469, 2019. e-Pub 2019. PMID: 30892987.
231. Willauer AN, Liu Y, Pereira AAL, Lam M, Morris JS, Raghav KPS, Morris VK, Menter D, Broaddus R, Meric-Bernstam F, Hayes-Jordan A, Huh W, Overman MJ, Kopetz S, Loree JM. Clinical and molecular characterization of early-onset colorectal cancer. Cancer 125(12):2002-2010, 2019. e-Pub 2019. PMID: 30854646.
232. Chun YS, Passot G, Yamashita S, Nusrat M, Katsonis P, Loree JM, Conrad C, Tzeng CD, Xiao L, Aloia TA, Eng C, Kopetz SE, Lichtarge O, Vauthey JN. Deleterious Effect of RAS and Evolutionary High-risk TP53 Double Mutation in Colorectal Liver Metastases. Ann Surg 269(5):917-923, 2019. e-Pub 2019. PMID: 28767562.
233. Morris V, Dasari A, Kopetz S. Can Circulating Tumor DNA in Early-Stage Colorectal Cancer Be More Than a Prognostic Biomarker?. JAMA Oncol. e-Pub 2019. PMID: 31070713.
234. Liao W, Overman MJ, Boutin AT, Shang X, Zhao D, Dey P, Li J, Wang G, Lan Z, Li J, Tang M, Jiang S, Ma X, Chen P, Katkhuda R, Korphaisarn K, Chakravarti D, Chang A, Spring DJ, Chang Q, Zhang J, Maru DM, Maeda DY, Zebala JA, Kopetz S, Wang YA, DePinho RA. KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer. Cancer Cell 35(4):559-572.e7, 2019. e-Pub 2019. PMID: 30905761.
235. Kopetz S. New therapies and insights into the changing landscape of colorectal cancer. Nat Rev Gastroenterol Hepatol 16(2):79-80, 2019. e-Pub 2019. PMID: 30575801.
236. Parseghian CM, Loree JM, Morris VK, Liu X, Clifton KK, Napolitano S, Henry JT, Pereira AA, Vilar E, Johnson B, Kee B, Raghav K, Dasari A, Wu J, Garg N, Raymond VM, Banks KC, Talasaz AA, Lanman RB, Strickler JH, Hong DS, Corcoran RB, Overman MJ, S K. Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR rechallenge. Ann Oncol 30(2):243-249, 2019. e-Pub 2019. PMID: 30462160.
237. Varkaris A, Katsiampoura A, Davis JS, Shah N, Lam M, Frias RL, Ivan C, Shimizu M, Morris J, Menter D, Overman M, Tran H, Heymach J, Chun YS, Vauthey JN, Calin G, Kopetz S. Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer. Br J Cancer 120(3):340-345, 2019. e-Pub 2019. PMID: 30636774.
238. Capasso A, Lang J, Pitts TM, Jordan KR, Lieu CH, Davis SL, Diamond JR, Kopetz S, Barbee J, Peterson J, Freed BM, Yacob BW, Bagby SM, Messersmith WA, Slansky JE, Pelanda R, Eckhardt SG. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts. J Immunother Cancer 7(1):37, 2019. e-Pub 2019. PMID: 30736857.
239. Zacharias NM, Ornelas A, Lee J, Hu J, Davis J, Uddin MN, Pudakalakatti S, Menter D, Karam JA, Wood CG, Hawk E, Kopetz S, Vilar E, Bhattacharya P, Millward S. Real-Time Interrogation of Aspirin Reactivity, Biochemistry, and Biodistribution by Hyperpolarized Magnetic Resonance Spectroscopy. Angew Chem Int Ed Engl. e-Pub 2019. PMID: 30680862.
240. Dumbrava EI, Brusco L, Daniels M, Wathoo C, Shaw K, Lu K, Zheng X, Strong L, Litton J, Arun B, Eterovic AK, Routbort M, Patel K, Qi Y, Piha-Paul S, Subbiah V, Hong D, Rodon J, Kopetz S, Mendelsohn J, Mills GB, Chen K, Meric-Bernstam F. Expanded analysis of secondary germline findings from matched tumor/normal sequencing identifies additional clinically significant mutations. JCO Precis Oncol 3, 2019. e-Pub 2019. PMID: 31517177.
241. Tong Z, Mejia A, Veeranki O, Verma A, Correa AM, Dokey R, Patel V, Solis LM, Mino B, Kathkuda R, Rodriguez-Canales J, Lin SH, Krishnan S, Kopetz S, Blum M, Ajani JA, Hofstetter WL, Maru DM. Targeting CDK9 and MCL-1 by a new CDK9/p-TEFb inhibitor with and without 5-fluorouracil in esophageal adenocarcinoma. Ther Adv Med Oncol 11:1758835919864850, 2019. e-Pub 2019. PMID: 31384313.
242. Dumbrava EEI, Balaji K, Raghav K, Hess K, Javle M, Blum-Murphy M, Ajani J, Kopetz S, Broaddus R, Routbort M, Demirhan M, Zheng X, Pant S, Tsimberidou AM, Subbiah V, Hong DS, Rodon J, Shaw KM, Piha-Paul SA, Meric-Bernstam F. Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications. JCO Precis Oncol 3, 2019. e-Pub 2019. PMID: 32923865.
243. Parseghian CM, Loree JM, Morris VK, Liu X, Clifton KK, Napolitano S, Henry JT, Pereira AA, Vilar E, Johnson B, Kee B, Raghav K, Dasari A, Wu J, Garg N, Raymond VM, Banks KC, Talasaz AA, Lanman RB, Strickler JH, Hong DS, Corcoran RB, Overman MJ, Kopetz S. Anti-EGFR Resistant Clones Decay Exponentially After Progression: Implications for Anti-EGFR Re-challenge. Ann Oncol. e-Pub 2018. PMID: 30462160.
244. Dasari A, Grothey A, Kopetz S. Circulating Tumor DNA-Defined Minimal Residual Disease in Solid Tumors: Opportunities to Accelerate the Development of Adjuvant Therapies. J Clin Oncol:JCO2018789032. e-Pub 2018. PMID: 30376428.
245. Advani SM, Advani P, DeSantis SM, Brown D, VonVille HM, Lam M, Loree JM, Mehrvarz Sarshekeh A, Bressler J, Lopez DS, Daniel CR, Swartz MD, Kopetz S. Clinical, Pathological, and Molecular Characteristics of CpG Island Methylator Phenotype in Colorectal Cancer: A Systematic Review and Meta-analysis. Transl Oncol 11(5):1188-1201, 2018. e-Pub 2018. PMID: 30071442.
246. Adam L, San Lucas FA, Fowler J, Yu Y, Wu W, Liu Y, Wang H, Menter DG, Tetzlaff MT, Ensor JE, Manyam G, Arold ST, Huff CD, Kopetz S, Scheet P, Overman MJ. DNA Sequencing of Small Bowel Adenocarcinomas Identifies Targetable Recurrent Mutations in the ERBB2 Signaling Pathway. Clin Cancer Res. e-Pub 2018. PMID: 30352910.
247. Jung YS, Jun S, Kim MJ, Lee SH, Suh HN, Lien EM, Jung HY, Lee S, Zhang J, Yang JI, Ji H, Wu JY, Wang W, Miller RK, Chen J, McCrea PD, Kopetz S, Park JI. TMEM9 promotes intestinal tumorigenesis through vacuolar-ATPase-activated Wnt/β-catenin signalling. Nat Cell Biol. e-Pub 2018. PMID: 30374053.
248. Mehrvarz Sarshekeh A, Xiong HQ, Iizuka K, Hochster HS, Kopetz S. Phase II study of DFP-10917, a deoxycytidine analog, given by 14-day continuous intravenous infusion for chemotherapy-refractory advanced colorectal cancer. Invest New Drugs 36(5):895-902, 2018. e-Pub 2018. PMID: 29948357.
249. Kanikarla-Marie P, Kopetz S, Hawk ET, Millward SW, Sood AK, Gresele P, Overman M, Honn K, Menter DG. Bioactive lipid metabolism in platelet "first responder" and cancer biology. Cancer Metastasis Rev 37(2-3):439-454, 2018. e-Pub 2018. PMID: 30112590.
250. Okuno M, Goumard C, Kopetz S, Vega EA, Joechle K, Mizuno T, Tzeng CD, Chun YS, Lee JE, Vauthey JN, Aloia TA, Conrad C. Loss of muscle mass during preoperative chemotherapy as a prognosticator for poor survival in patients with colorectal liver metastases. Surgery. e-Pub 2018. PMID: 30197278.
251. Goey KKH, Sørbye H, Glimelius B, Adams RA, André T, Arnold D, Berlin JD, Bodoky G, de Gramont A, Díaz-Rubio E, Eng C, Falcone A, Grothey A, Heinemann V, Hochster HS, Kaplan RS, Kopetz S, Labianca R, Lieu CH, Meropol NJ, Price TJ, Schilsky RL, Schmoll HJ, Shacham-Shmueli E, Shi Q, Sobrero AF, Souglakos J, Van Cutsem E, Zalcberg J, van Oijen MGH, Punt CJA, Koopman M. Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. Eur J Cancer 100:35-45, 2018. e-Pub 2018. PMID: 29936065.
252. Chang K, Taggart MW, Reyes-Uribe L, Borras E, Riquelme E, Barnett RM, Leoni G, San Lucas FA, Catanese MT, Mori F, Diodoro MG, You YN, Hawk ET, Roszik J, Scheet P, Kopetz S, Nicosia A, Scarselli E, Lynch PM, McAllister F, Vilar E. Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome. JAMA Oncol 4(8):1085-1092, 2018. e-Pub 2018. PMID: 29710228.
253. Mehrvarz Sarshekeh A, Overman MJ, Kopetz S. Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer. Future Oncol 14(18):1869-1874, 2018. e-Pub 2018. PMID: 29473436.
254. Okuno M, Goumard C, Kopetz S, Vega EA, Joechle K, Mizuno T, Omichi K, Tzeng CD, Chun YS, Vauthey JN, Conrad C. RAS Mutation is Associated with Unsalvageable Recurrence Following Hepatectomy for Colorectal Cancer Liver Metastases. Ann Surg Oncol 25(8):2457-2466, 2018. e-Pub 2018. PMID: 29786130.
255. Overman MJ, Ferrarotto R, Raghav K, George B, Qiao W, Machado KK, Saltz LB, Mazard T, Vauthey JN, Hoff PM, Hobbs B, Loyer EM, Kopetz S. The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia. J Natl Cancer Inst 110(8):888-894, 2018. e-Pub 2018. PMID: 29346573.
256. Kandimalla R, Gao F, Matsuyama T, Ishikawa T, Uetake H, Takahashi N, Yamada Y, Becerra C, Kopetz S, Wang X, Goel A. Genome-wide discovery and identification of a novel miRNA signature for recurrence prediction in stage II and III colorectal cancer. Clin Cancer Res 24(16):3867-3877, 2018. e-Pub 2018. PMID: 29514841.
257. Khan M, Loree JM, Advani SM, Ning J, Li W, Pereira AAL, Lam M, Raghav K, Morris VK, Broaddus R, Maru D, Overman MJ, Kopetz S. Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics. Clin Colorectal Cancer. e-Pub 2018. PMID: 30205948.
258. Parseghian CM, Patnana M, Bhosale P, Hess KR, Shih YT, Kim B, Kopetz S, Overman MJ, Varadhachary GR, Javle M, Naing A, Piha-Paul S, Hong D, Le H, Subbiah V, Pant S. Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy. J Immunother 41(6):284-291, 2018. e-Pub 2018. PMID: 29668571.
259. Lin SH, Raju GS, Huff C, Ye Y, Gu J, Chen JS, Hildebrandt MAT, Liang H, Menter DG, Morris J, Hawk E, Stroehlein JR, Futreal A, Kopetz S, Mishra L, Wu X. The somatic mutation landscape of premalignant colorectal adenoma. Gut 67(7):1299-1305, 2018. e-Pub 2018. PMID: 28607096.
260. Liu L, Toung JM, Jassowicz AF, Vijayaraghavan R, Kang H, Zhang R, Kruglyak KM, Huang HJ, Hinoue T, Shen H, Salathia NS, Hong DS, Naing A, Subbiah V, Piha-Paul SA, Bibikova M, Granger G, Barnes B, Shen R, Gutekunst K, Fu S, Tsimberidou AM, Lu C, Eng C, Moulder SL, Kopetz ES, Amaria RN, Meric-Bernstam F, Laird PW, Fan JB, Janku F. Targeted Methylation Sequencing of Plasma Cell-free DNA for Cancer Detection and Classification. Ann Oncol 29(6):1445-1453, 2018. e-Pub 2018. PMID: 29635542.
261. Mazard T, Boonsirikamchai P, Overman MJ, Asran MA, Choi H, Herron D, Eng C, Maru DM, Ychou M, Vauthey JN, Loyer EM, Kopetz S. Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab. Gut 67(6):1095-1102, 2018. e-Pub 2018. PMID: 29084828.
262. Mizuno T, Cloyd JM, Vicente D, Omichi K, Chun YS, Kopetz SE, Maru D, Conrad C, Tzeng CD, Wei SH, Aloia TA, Vauthey JN. SMAD4 gene mutation predicts poor prognosis in patients undergoing resection for colorectal liver metastases. Eur J Surg Oncol 44(5):684-692, 2018. e-Pub 2018. PMID: 29551247.
263. Kopetz S. How should BRAF V600E-mutated colorectal cancer be treated?. Clin Adv Hematol Oncol 16(5):333-335, 2018. e-Pub 2018. PMID: 29851929.
264. Okuno M, Goumard C, Mizuno T, Kopetz S, Omichi K, Tzeng CD, Chun YS, Lee JE, Vauthey JN, Conrad C. Prognostic impact of perihepatic lymph node metastases in patients with resectable colorectal liver metastases. Br J Surg. e-Pub 2018. PMID: 29664996.
265. Montagut C, Argilés G, Ciardiello F, Poulsen TT, Dienstmann R, Kragh M, Kopetz S, Lindsted T, Ding C, Vidal J, Clausell-Tormos J, Siravegna G, Sánchez-Martín FJ, Koefoed K, Pedersen MW, Grandal MM, Dvorkin M, Wyrwicz L, Rovira A, Cubillo A, Salazar R, Desseigne F, Nadal C, Albanell J, Zagonel V, Siena S, Fumi G, Rospo G, Nadler P, Horak ID, Bardelli A, Tabernero J. Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial. JAMA Oncol 4(4):e175245, 2018. e-Pub 2018. PMID: 29423521.
266. Sankhala K, Takimoto CH, Mita AC, Xiong H, Rodón J, Mehrvarz Sarshekeh A, Burns K, Iizuka K, Kopetz S. Two phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules. Invest New Drugs. e-Pub 2018. PMID: 29667134.
267. Lam M, Loree JM, Pereira AAL, Chun YS, Kopetz S. Correction to: Accelerating Therapeutic Development through Innovative Trial Design in Colorectal Cancer. Curr Treat Options Oncol 19(5):25, 2018. e-Pub 2018. PMID: 29687230.
268. Loree JM, Bailey AM, Johnson AM, Yu Y, Wu W, Bristow CA, Davis JS, Shaw KR, Broaddus R, Banks KC, Lanman RB, Meric-Bernstam F, Overman MJ, Kopetz S, Raghav K. Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer. J Natl Cancer Inst. e-Pub 2018. PMID: 29718453.
269. Loree JM, Pereira AAL, Lam M, Willauer AN, Raghav K, Dasari A, Morris VK, Advani S, Menter DG, Eng C, Shaw K, Broaddus R, Routbort MJ, Liu Y, Morris JS, Luthra R, Meric-Bernstam F, Overman MJ, Maru D, Kopetz S. Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and Consensus Molecular Subtypes. Clin Cancer Res 24(5):1062-1072, 2018. e-Pub 2018. PMID: 29180604.
270. Odisio BC, Yamashita S, Huang SY, Kopetz SE, Ahrar K, Mizuno T, Conrad C, Aloia TA, Chun YS, Gupta S, Vauthey JN. Impact of Prior Hepatectomy History on Local Tumor Progression after Percutaneous Ablation of Colorectal Liver Metastases. J Vasc Interv Radiol 29(3):395-403.e1, 2018. e-Pub 2018. PMID: 29395898.
271. Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill A, Sawyer MB, Hendlisz A, Neyns B, Svrcek M, Moss RA, Ledeine JM, Cao ZA, Kamble S, Kopetz S, André T. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. J Clin Oncol 36(8):773-779, 2018. e-Pub 2018. PMID: 29355075.
272. Yamashita S, Brudvik KW, Kopetz SE, Maru D, Clarke CN, Passot G, Conrad C, Chun YS, Aloia TA, Vauthey JN. Embryonic Origin of Primary Colon Cancer Predicts Pathologic Response and Survival in Patients Undergoing Resection for Colon Cancer Liver Metastases. Ann Surg 267(3):514-520, 2018. e-Pub 2018. PMID: 28002060.
273. Strickler JH, Loree JM, Ahronian LG, Parikh AR, Niedzwiecki D, Pereira AAL, McKinney M, Korn WM, Atreya CE, Banks KC, Nagy RJ, Meric-Bernstam F, Lanman RB, Talasaz A, Tsigelny IF, Corcoran RB, Kopetz S. Genomic landscape of cell-free DNA in patients with colorectal cancer. Cancer Discov 8(2):164-173, 2018. e-Pub 2018. PMID: 29196463.
274. Mehrotra M, Singh RR, Loghavi S, Duose DY, Barkoh BA, Behrens C, Patel KP, Routbort MJ, Kopetz S, Broaddus RR, Medeiros LJ, Wistuba II, Luthra R. Detection of somatic mutations in cell-free DNA in plasma and correlation with overall survival in patients with solid tumors. Oncotarget 9(12):10259-10271, 2018. e-Pub 2018. PMID: 29535804.
275. Möhrmann L, Huang HJ, Hong DS, Tsimberidou AM, Fu S, Piha-Paul SA, Subbiah V, Karp DD, Naing A, Krug A, Enderle D, Priewasser T, Noerholm M, Eitan E, Coticchia C, Stoll G, Jordan LM, Eng C, Kopetz ES, Skog J, Meric-Bernstam F, Janku F. Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA compared with Clinical Outcomes of Patients with Advanced Cancers. Clin Cancer Res 24(1):181-188, 2018. e-Pub 2018. PMID: 29051321.
276. Yoshino T, Arnold D, Taniguchi H, Pentheroudakis G, Yamazaki K, Xu RH, Kim TW, Ismail F, Tan IB, Yeh KH, Grothey A, Zhang S, Ahn JB, Mastura MY, Chong D, Chen LT, Kopetz S, Eguchi-Nakajima T, Ebi H, Ohtsu A, Cervantes A, Muro K, Tabernero J, Minami H, Ciardiello F, Douillard JY. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer; A JSMO - ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol 29(1):44-70, 2018. e-Pub 2018. PMID: 29155929.
277. Falcone A, Ohtsu A, Van Cutsem E, Mayer RJ, Buscaglia M, Bendell JC, Kopetz S, Bebeau P, Yoshino T. Integrated safety summary for trifluridine/tipiracil (TAS-102). Anticancer Drugs 29(1):89-96, 2018. e-Pub 2018. PMID: 29176395.
278. Bédard PL, Davies MA, Kopetz S, Juric D, Shapiro GI, Luke JJ, Spreafico A, Wu B, Castell C, Gomez C, Cartot-Cotton S, Mazuir F, Dubar M, Micallef S, Demers B, Flaherty KT. First-in-human trial of the PI3Kβ-selective inhibitor SAR260301 in patients with advanced solid tumors. Cancer 124(2):315-324, 2018. e-Pub 2018. PMID: 28976556.
279. Overman MJ, Adam L, Raghav K, Wang J, Kee B, Fogelman D, Eng C, Vilar E, Shroff R, Dasari A, Wolff R, Morris J, Karunasena E, Pisanic R, Azad N, Kopetz S. Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer. Ann Oncol 29(1):139-144, 2018. e-Pub 2018. PMID: 29069279.
280. Passot G, Kim BJ, Glehen O, Mehran RJ, Kopetz SE, Goere D, Overman MJ, Pocard M, Marchal F, Conrad C, Aloia TA, Vauthey JN, Chun YS, Group BW. Impact of RAS Mutations in Metastatic Colorectal Cancer After Potentially Curative Resection: Does Site of Metastases Matter?. Ann Surg Oncol 25(1):179-187, 2018. e-Pub 2018. PMID: 29071660.
281. Ock CY, Hwang JE, Keam B, Kim SB, Shim JJ, Jang HJ, Park S, Sohn BH, Cha M, Ajani JA, Kopetz S, Lee KW, Kim TM, Heo DS, Lee JS. Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. Nat Commun 8(1):1050, 2017. e-Pub 2017. PMID: 29051489.
282. Clarke CN, Lee MS, Wei W, Manyam G, Jiang ZQ, Lu Y, Morris J, Broom B, Menter D, Vilar-Sanchez E, Raghav K, Eng C, Chang GJ, Simon I, Bernards R, Overman M, Mills GB, Maru D, Kopetz S. Proteomic Features of Colorectal Cancer Identify Tumor Subtypes Independent of Oncogenic Mutations and Independently Predict Relapse-Free Survival. Ann Surg Oncol. e-Pub 2017. PMID: 28936799.
283. Conrad C, Vauthey JN, Masayuki O, Sheth RA, Yamashita S, Passot G, Bailey CE, Zorzi D, Kopetz S, Aloia TA, You YN. Individualized Treatment Sequencing Selection Contributes to Optimized Survival in Patients with Rectal Cancer and Synchronous Liver Metastases. Ann Surg Oncol. e-Pub 2017. PMID: 28929463.
284. Lee WC, Kopetz S, Wistuba II, Zhang J. Metastasis of cancer: when and how?. Ann Oncol 28(9):2045-2047, 2017. e-Pub 2017. PMID: 28911075.
285. Korphaisarn K, Loree JM, Nguyen V, Coulson R, Holla V, Litzenburger BC, Chen K, Mills GB, Maru DM, Meric-Bernstan F, Shaw KRM, Kopetz S. Genomic analysis of exceptional responder to regorafenib in treatment-refractory metastatic rectal cancer: a case report and review of the literature. Oncotarget 8(34):57882-57888, 2017. e-Pub 2017. PMID: 28915719.
286. Leung ML, Davis A, Gao R, Casasent A, Wang Y, Sei E, Vilar E, Maru D, Kopetz S, Navin NE. Single-cell DNA sequencing reveals a late-dissemination model in metastatic colorectal cancer. Genome Res 27(8):1287-1299, 2017. e-Pub 2017. PMID: 28546418.
287. Parseghian CM, Parikh NU, Wu JY, Jiang ZQ, Henderson L, Tian F, Pastor B, Ychou M, Raghav K, Dasari A, Fogelman DR, Katsiampoura AD, Menter DG, Wolff RA, Eng C, Overman MJ, Thierry AR, Gallick GE, Kopetz S. Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. Clin Cancer Res 23(15):4146-4154, 2017. e-Pub 2017. PMID: 28280091.
288. Thierry AR, Pastor B, Jiang ZQ, Katsiampoura AD, Parseghian C, Loree JM, Overman MJ, Sanchez C, Messaoudi SE, Ychou M, Kopetz S. Circulating DNA demonstrates convergent evolution and common resistance mechanisms during treatment of colorectal cancer 23(16):4578-4591, 2017. e-Pub 2017. PMID: 28400427.
289. Gunther JR, Chadha AS, Shin US, Park IJ, Kattepogu KV, Grant JD, Weksberg DC, Eng C, Kopetz SE, Das P, Delclos ME, Kaur H, Maru DM, Skibber JM, Rodriguez-Bigas MA, You YN, Krishnan S, Chang GJ. Preoperative radiation dose escalation for rectal cancer using a concomitant boost strategy improves tumor downstaging without increasing toxicity: A matched-pair analysis. Adv Radiat Oncol 2(3):455-464, 2017. e-Pub 2017. PMID: 29114614.
290. Fujii T, Barzi A, Sartore-Bianchi A, Cassingena A, Siravegna G, Karp DD, Piha-Paul SA, Subbiah V, Tsimberidou AM, Huang HJ, Veronese S, Di Nicolantonio F, Pingle S, Vibat CRT, Hancock S, Berz D, Melnikova VO, Erlander MG, Luthra R, Kopetz ES, Meric-Bernstam F, Siena S, Lenz HJ, Bardelli A, Janku F. Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. Clin Cancer Res 23(14):3657-3666, 2017. e-Pub 2017. PMID: 28096270.
291. Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, Goldberg MV, Cao ZA, Ledeine JM, Maglinte GA, Kopetz S, André T. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. e-Pub 2017. PMID: 28734759.
292. Mehrotra M, Singh RR, Chen W, Huang RSP, Almohammedsalim AA, Barkoh BA, Simien CM, Hernandez M, Behrens C, Patel KP, Routbort MJ, Broaddus RR, Medeiros LJ, Wistuba II, Kopetz S, Luthra R. Study of Preanalytic and Analytic Variables for Clinical Next-Generation Sequencing of Circulating Cell-Free Nucleic Acid. J Mol Diagn 19(4):514-524, 2017. e-Pub 2017. PMID: 28506684.
293. Kumar R, Herold JL, Schady D, Davis J, Kopetz S, Martinez-Moczygemba M, Murray BE, Han F, Li Y, Callaway E, Chapkin RS, Dashwood WM, Dashwood RH, Berry T, Mackenzie C, Xu Y. Streptococcus gallolyticus subsp. gallolyticus promotes colorectal tumor development. PLoS Pathog 13(7):e1006440, 2017. e-Pub 2017. PMID: 28704539.
294. Park IJ, You YN, Skibber JM, Rodriguez-Bigas MA, Das P, Eng C, Kopetz S, Wolff RA, Crane CH, Krishnan S, Minsky B, Hu CY, Nguyen S, Chang GJ. Oncologic and Functional Hazards of Obesity Among Patients With Locally Advanced Rectal Cancer Following Neoadjuvant Chemoradiation Therapy. Am J Clin Oncol 40(3):277-282, 2017. e-Pub 2017. PMID: 27028350.
295. Korphaisarn K, Morris VK, Overman MJ, Fogelman DR, Kee BK, Raghav KPS, Manuel S, Shureiqi I, Wolff RA, Eng C, Menter D, Hamilton SR, Kopetz S, Dasari A. FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. Oncotarget 8(24):39268-39279, 2017. e-Pub 2017. PMID: 28424412.
296. Long Y, Sanchez-Espiridion B, Lin M, White L, Mishra L, Raju GS, Kopetz S, Eng C, Hildebrandt MAT, Chang DW, Ye Y, Liang D, Wu X. Global and targeted serum metabolic profiling of colorectal cancer progression. Cancer. e-Pub 2017. PMID: 28640361.
297. Arango NP, Brusco L, Mills Shaw KR, Chen K, Eterovic AK, Holla V, Johnson A, Litzenburger B, Khotskaya YB, Sanchez N, Bailey A, Zheng X, Horombe C, Kopetz S, Farhangfar CJ, Routbort M, Broaddus R, Bernstam EV, Mendelsohn J, Mills GB, Meric-Bernstam F. A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory. Oncotarget 8(26):41806-41814, 2017. e-Pub 2017. PMID: 28415679.
298. Sundar R, Hong DS, Kopetz S, Yap TA. Targeting BRAF-Mutant Colorectal Cancer: Progress in Combination Strategies. Cancer Discov 7(6):558-560, 2017. e-Pub 2017. PMID: 28576843.
299. Yamashita S, Odisio BC, Huang SY, Kopetz SE, Ahrar K, Chun YS, Conrad C, Aloia TA, Gupta S, Harmoush S, Hicks ME, Vauthey JN. Embryonic origin of primary colon cancer predicts survival in patients undergoing ablation for colorectal liver metastases. Eur J Surg Oncol 43(6):1040-1049, 2017. e-Pub 2017. PMID: 28187878.
300. Ikoma N, You YN, Bednarski BK, Rodriguez-Bigas MA, Eng C, Das P, Kopetz S, Messick C, Skibber JM, Chang GJ. Impact of Recurrence and Salvage Surgery on Survival After Multidisciplinary Treatment of Rectal Cancer. J Clin Oncol:JCO2016721464. e-Pub 2017. PMID: 28657814.
301. Gulhati P, Raghav K, Shroff RT, Varadhachary GR, Kopetz S, Javle M, Qiao W, Wang H, Morris J, Wolff RA, Overman MJ. Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study. Cancer 123(6):1011-1017, 2017. e-Pub 2017. PMID: 27859010.
302. Janku F, Zhang S, Waters J, Liu L, Huang H, Subbiah V, Hong DS, Karp D, Fu S, Cai X, Ramzanali NM, Madwani K, Cabrilo G, Andrews DD, Zhao Y, Javle M, Kopetz S, Luthra R, Kim HJ, Gnerre S, Satya RV, Chuang HY, Kruglyak KM, Toung J, Zhao C, Shen R, Heymach J, Meric-Bernstam F, Mills GB, Fan JB, Salathia NS. Development and validation of an ultra-deep next-generation sequencing assay for testing of plasma cell-free DNA from patients with advanced cancer. Clin Cancer Res. e-Pub 2017. PMID: 28536309.
303. Katsiampoura A, Raghav K, Jiang ZQ, Menter DG, Varkaris A, Morelli MP, Manuel S, Wu J, Sorokin AV, Rizi BS, Bristow C, Tian F, Airhart S, Cheng M, Broom BM, Morris J, Overman MJ, Powis G, Kopetz S. Modeling of Patient Derived Xenografts in Colorectal Cancer. Mol Cancer Ther. e-Pub 2017. PMID: 28468778.
304. Rigoutsos I, Lee SK, Nam SY, Anfossi S, Pasculli B, Pichler M, Jing Y, Rodriguez-Aguayo C, Telonis AG, Rossi S, Ivan C, Catela Ivkovic T, Fabris L, Clark PM, Ling H, Shimizu M, Redis RS, Shah MY, Zhang X, Okugawa Y, Jung EJ, Tsirigos A, Huang L, Ferdin J, Gafà R, Spizzo R, Nicoloso MS, Paranjape AN, Shariati M, Tiron A, Yeh JJ, Teruel-Montoya R, Xiao L, Melo SA, Menter D, Jiang ZQ, Flores ER, Negrini M, Goel A, Bar-Eli M, Mani SA, Liu CG, Lopez-Berestein G, Berindan-Neagoe I, Esteller M, Kopetz S, Lanza G, Calin GA. N-BLR, a primate-specific non-coding transcript leads to colorectal cancer invasion and migration. Genome Biol 18(1):98, 2017. e-Pub 2017. PMID: 28535802.
305. Sepulveda AR, Hamilton SR, Allegra CJ, Grody W, Cushman-Vokoun AM, Funkhouser WK, Kopetz SE, Lieu C, Lindor NM, Minsky BD, Monzon FA, Sargent DJ, Singh VM, Willis J, Clark J, Colasacco C, Rumble RB, Temple-Smolkin R, Ventura CB, Nowak JA. Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline Summary From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. J Oncol Pract 13(5):JOP2017022152, 2017. e-Pub 2017. PMID: 28350513.
306. Odisio BC, Yamashita S, Huang SY, Harmoush S, Kopetz SE, Ahrar K, Shin Chun Y, Conrad C, Aloia TA, Gupta S, Hicks ME, Vauthey JN. Local tumour progression after percutaneous ablation of colorectal liver metastases according to RAS mutation status. Br J Surg 104(6):760-768, 2017. e-Pub 2017. PMID: 28240361.
307. Jones JC, Renfro LA, Al-Shamsi HO, Schrock AB, Rankin A, Zhang BY, Kasi PM, Voss JS, Leal AD, Sun J, Ross J, Ali SM, Hubbard JM, Kipp BR, McWilliams RR, Kopetz S, Wolff RA, Grothey A. Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer. J Clin Oncol:JCO2016714394. e-Pub 2017. PMID: 28486044.
308. Goldstein JB, Wu W, Borras E, Masand G, Cuddy A, Mork ME, Bannon SA, Lynch PM, Rodriguez-Bigas M, Taggart MW, Wu J, Scheet P, Kopetz S, You YN, Vilar E. Can Microsatellite Status of Colorectal Cancer Be Reliably Assessed after Neoadjuvant Therapy?. Clin Cancer Res. e-Pub 2017. PMID: 28522602.
309. Yamashita S, Chun YS, Kopetz SE, Maru D, Conrad C, Aloia TA, Vauthey JN. APC and PIK3CA Mutational Cooperativity Predicts Pathologic Response and Survival in Patients Undergoing Resection for Colorectal Liver Metastases. Ann Surg. e-Pub 2017. PMID: 28379870.
310. Subbiah V, Khawaja MR, Hong DS, Amini B, Yungfang J, Liu H, Johnson A, Schrock AB, Ali SM, Sun JX, Fabrizio D, Piha-Paul S, Fu S, Tsimberidou AM, Naing A, Janku F, Karp DD, Overman M, Eng C, Kopetz S, Meric-Bernstam F, Falchook GS. First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. JCI Insight 2(8). e-Pub 2017. PMID: 28422758.
311. Loree JM, Kopetz S. Why a One Size Fits All Approach to RAS Might Not Fit Colorectal Cancer. J Natl Compr Canc Netw 15(4):545-547, 2017. e-Pub 2017. PMID: 28404763.
312. Tong Z, Chatterjee D, Deng D, Veeranki O, Mejia A, Ajani JA, Hofstetter W, Lin S, Guha S, Kopetz S, Krishnan S, Maru D. Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinoma. Oncotarget. e-Pub 2017. PMID: 28404924.
313. Boutin AT, Liao WT, Wang M, Hwang SS, Karpinets TV, Cheung H, Chu GC, Jiang S, Hu J, Chang K, Vilar E, Song X, Zhang J, Kopetz S, Futreal A, Wang YA, Kwong LN, DePinho RA. Oncogenic Kras drives invasion and maintains metastases in colorectal cancer. Genes Dev 31(4):370-382, 2017. e-Pub 2017. PMID: 28289141.
314. Tao R, Tsai CJ, Jensen G, Eng C, Kopetz S, Overman MJ, Skibber JM, Rodriguez-Bigas M, Chang GJ, You YN, Bednarski BK, Minsky BD, Delclos ME, Koay E, Krishnan S, Crane CH, Das P. Hyperfractionated accelerated reirradiation for rectal cancer: An analysis of outcomes and toxicity. Radiother Oncol 122(1):146-151, 2017. e-Pub 2017. PMID: 28057329.
315. Zuo X, Xu W, Xu M, Tian R, Moussalli MJ, Mao F, Zheng X, Wang J, Morris JS, Gagea M, Eng C, Kopetz S, Maru DM, Rashid A, Broaddus R, Wei D, Hung MC, Sood AK, Shureiqi I. Metastasis regulation by PPARD expression in cancer cells. JCI Insight 2(1):e91419, 2017. e-Pub 2017. PMID: 28097239.
316. Khan M, Korphaisarn K, Saif A, Foo WC, Kopetz S. Early-Onset Signet-Ring Cell Adenocarcinoma of the Colon: A Case Report and Review of the Literature. Case Rep Oncol Med 2017:2832180, 2017. e-Pub 2017. PMID: 28326211.
317. Sarshekeh AM, Advani S, Overman MJ, Manyam G, Kee BK, Fogelman DR, Dasari A, Raghav K, Vilar E, Manuel S, Shureiqi I, Wolff RA, Patel KP, Luthra R, Shaw K, Eng C, Maru DM, Routbort MJ, Meric-Bernstam F, Kopetz S. Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. PLoS One 12(3):e0173345, 2017. e-Pub 2017. PMID: 28267766.
318. Korphaisarn K, Chou CK, Xia WY, Clarke CN, Katkhuda R, Davis JS, Raghav KP, Liao HW, Wu JY, Menter DG, Maru DM, Hung MC, Kopetz S. Arginine methylation of EGFR: a new biomarker for predicting resistance to anti-EGFR treatment. Am J Cancer Res 7(12):2587-2599, 2017. e-Pub 2017. PMID: 29312811.
319. Pereira AAL, Morelli MP, Overman M, Kee B, Fogelman D, Vilar E, Shureiqi I, Raghav K, Eng C, Manuel S, Crosby S, Wolff RA, Banks K, Lanman R, Talasaz A, Kopetz S, Morris V. Clinical utility of circulating cell-free DNA in advanced colorectal cancer. PLoS One 12(8):e0183949, 2017. e-Pub 2017. PMID: 28850629.
320. Al-Shamsi HO, Jones J, Fahmawi Y, Dahbour I, Tabash A, Abdel-Wahab R, Abousamra AO, Shaw KR, Xiao L, Hassan MM, Kipp BR, Kopetz S, Soliman AS, McWilliams RR, Wolff RA. Molecular spectrum of KRAS, NRAS, BRAF, PIK3CA, TP53, and APC somatic gene mutations in Arab patients with colorectal cancer: determination of frequency and distribution pattern. J Gastrointest Oncol 7(6):882-902, 2016. e-Pub 2016. PMID: 28078112.
321. Janku F, Huang HJ, Fujii T, Shelton DN, Madwani K, Fu S, Tsimberidou AM, Piha-Paul SA, Wheler JJ, Zinner RG, Naing A, Hong DS, Karp DD, Cabrilo G, Kopetz ES, Subbiah V, Luthra R, Kee BK, Eng C, Morris VK, Karlin-Neumann GA, Meric-Bernstam F. Multiplex KRASG12/G13 Mutation Testing of Unamplified Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using Droplet Digital Polymerase Chain Reaction. Ann Oncol. e-Pub 2016. PMID: 27993791.
322. Odisio BC, Yamashita S, Frota L, Huang SY, Kopetz SE, Ahrar K, Chun YS, Aloia TA, Hicks ME, Gupta S, Vauthey JN. Planned Treatment of Advanced Metastatic Disease with Completion Ablation After Hepatic Resection. J Gastrointest Surg. e-Pub 2016. PMID: 27882510.
323. Tao R, Tsai CJ, Eng C, Kopetz S, Overman M, Skibber J, Rodriguez-Bigas M, Chang G, You YN, Bednarski B, Minsky BD, Delclos ME, Koay EJ, Krishnan S, Crane CH, Das P. Hyperfractionated Accelerated Reirradiation for Rectal Cancer: A Large Single-Institution Retrospective Analysis. Int J Radiat Oncol Biol Phys 96(2S):S105, 2016. e-Pub 2016. PMID: 27675536.
324. Sun Y, Ji P, Chen T, Zhou X, Yang D, Guo Y, Liu Y, Hu L, Xia D, Liu Y, Multani AS, Shmulevich I, Kucherlapati R, Kopetz S, Sood AK, Hamilton SR, Sun B, Zhang W. MIIP haploinsufficiency induces chromosomal instability and promotes tumour progression in colorectal cancer. J Pathol. e-Pub 2016. PMID: 27741356.
325. Mise Y, Vauthey JN, Kopetz S. Addition of RAS Mutation Status May Strengthen the Predictive Model for Progression of Indeterminate Pulmonary Nodules. Ann Surg 264(2):e7, 2016. e-Pub 2016. PMID: 27414157.
326. Reyes ME, Ye Y, Zhou Y, Liang A, Kopetz S, Rodriquez MA, Wu X, Hildebrandt MA. Predictors of health-related quality of life and association with survival may identify colorectal cancer patients at high risk of poor prognosis. Qual Life Res. e-Pub 2016. PMID: 27492454.
327. Passot G, Denbo JW, Yamashita S, Kopetz SE, Chun YS, Maru D, Overman MJ, Brudvik KW, Conrad C, Aloia TA, Vauthey JN. Is hepatectomy justified for patients with RAS mutant colorectal liver metastases? An analysis of 524 patients undergoing curative liver resection. Surgery. e-Pub 2016. PMID: 27592215.
328. Raghav K, Morris V, Tang C, Morelli P, Amin HM, Chen K, Manyam GC, Broom B, Overman MJ, Shaw K, Meric-Bernstam F, Maru D, Menter D, Ellis LM, Eng C, Hong D, Kopetz S. MET amplification in metastatic colorectal cancer: An acquired response to EGFR inhibition, not a de novo phenomenon. Oncotarget. e-Pub 2016. PMID: 27421137.
329. Janku F, Huang HJ, Claes B, Falchook GS, Fu S, Hong D, Ramzanali NM, Nitti G, Cabrilo G, Tsimberidou AM, Naing A, Piha-Paul SA, Wheler JJ, Karp DD, Holley VR, Zinner RG, Subbiah V, Luthra R, Kopetz S, Overman MJ, Kee BK, Patel S, Devogelaere B, Sablon E, Maertens G, Mills GB, Kurzrock R, Meric-Bernstam F. BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. Mol Cancer Ther 15(6):1397-404, 2016. e-Pub 2016. PMID: 27207774.
330. Lee MS, McGuffey EJ, Morris JS, Manyam G, Baladandayuthapani V, Wei W, Morris VK, Overman MJ, Maru DM, Jiang ZQ, Hamilton SR, Kopetz S. Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer. Br J Cancer 114(12):1352-1361, 2016. e-Pub 2016. PMID: 27272216.
331. Denbo JW, Yamashita S, Passot G, Egger M, Chun YS, Kopetz SE, Maru D, Brudvik KW, Wei SH, Conrad C, Vauthey JN, Aloia TA. RAS Mutation Is Associated with Decreased Survival in Patients Undergoing Repeat Hepatectomy for Colorectal Liver Metastases. J Gastrointest Surg. e-Pub 2016. PMID: 27334313.
332. Korphaisarn K, Kopetz S. BRAF-Directed Therapy in Metastatic Colorectal Cancer. Cancer J 22(3):175-8, 2016. e-Pub 2016. PMID: 27341594.
333. Lee MS, Helms TL, Feng N, Gay J, Chang QE, Tian F, Wu JY, Toniatti C, Heffernan TP, Powis G, Kwong LN, Kopetz S. Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models. Oncotarget. e-Pub 2016. PMID: 27167191.
334. Tu SM, Bilen MA, Hess KR, Broaddus RR, Kopetz S, Wei C, Pagliaro LC, Karama JA, Ward JF, Wood CG, Rao P, Tu ZH, General R, Chen AH, Nieto YL, Yeung SJ, Lin SH, Logothetis CJ, Pisters LL. Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer. Cancer. e-Pub 2016. PMID: 27018785.
335. Brudvik KW, Mise Y, Chung MH, Chun YS, Kopetz SE, Passot G, Conrad C, Maru DM, Aloia TA, Vauthey JN. RAS Mutation Predicts Positive Resection Margins and Narrower Resection Margins in Patients Undergoing Resection of Colorectal Liver Metastases. Ann Surg Oncol. e-Pub 2016. PMID: 27016292.
336. Passot G, Chun YS, Kopetz SE, Overman MJ, Conrad C, Aloia TA, Vauthey JN. Prognostic factors after resection of colorectal liver metastases following preoperative second-line chemotherapy: Impact of RAS mutations. Eur J Surg Oncol. e-Pub 2016. PMID: 27358198.
337. You YN, Skibber JM, Hu CY, Crane CH, Das P, Kopetz ES, Eng C, Feig BW, Rodriguez-Bigas MA, Chang GJ. Impact of multimodal therapy in locally recurrent rectal cancer. Br J Surg. e-Pub 2016. PMID: 26933792.
338. Overman MJ, Morris V, Kee B, Fogelman D, Xiao L, Eng C, Dasari A, Shroff R, Mazard T, Shaw K, Vilar E, Raghav K, Shureiqi I, Liang L, Mills GB, Wolff RA, Hamilton S, Meric-Bernstam F, Abbruzzese J, Morris J, Maru D, Kopetz S. Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials. Ann Oncol. e-Pub 2016. PMID: 27045102.
339. Sun Y, Liu Y, Cogdell D, Calin GA, Sun B, Kopetz S, Hamilton SR, Zhang W. Examining plasma microRNA markers for colorectal cancer at different stages. Oncotarget. e-Pub 2016. PMID: 26863633.
340. Arcaroli JJ, Tai WM, McWilliams R, Bagby S, Blatchford PJ, Varella-Garcia M, Purkey A, Quackenbush KS, Song EK, Pitts TM, Gao D, Lieu C, McManus M, Tan AC, Zheng X, Zhang Q, Ozeck M, Olson P, Jiang ZQ, Kopetz S, Jimeno A, Keysar S, Eckhardt G, Messersmith WA. A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer. Int J Cancer 138(1):195-205, 2016. e-Pub 2016. PMID: 26152787.
341. Passot G, Chun YS, Kopetz SE, Zorzi D, Brudvik KW, Kim BJ, Conrad C, Aloia TA, Vauthey JN. Predictors of Safety and Efficacy of 2-Stage Hepatectomy for Bilateral Colorectal Liver Metastases. J Am Coll Surg. e-Pub 2016. PMID: 26968325.
342. Meric-Bernstam F, Brusco L, Daniels M, Wathoo C, Bailey A, Strong L, Shaw K, Lu K, Qi Y, Zhao H, Lara-Guerra H, Litton J, Arun B, Eterovic AK, Aytac U, Routbort M, Subbiah V, Janku F, Davies MA, Kopetz S, Mendelsohn J, Mills GB, Chen K. Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. Ann Oncol. e-Pub 2016. PMID: 26787237.
343. Daniel CR, Shu X, Ye Y, Gu J, Raju GS, Kopetz S, Wu X. Severe obesity prior to diagnosis limits survival in colorectal cancer patients evaluated at a large cancer centre. Br J Cancer 114(1):103-9, 2016. e-Pub 2016. PMID: 26679375.
344. Satelli A, Batth IS, Brownlee Z, Rojas C, Meng QH, Kopetz S, Li S. Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients. Sci Rep 6:28910, 2016. e-Pub 2016. PMID: 27363678.
345. Kopetz S, Desai J, Chan E, Hecht JR, O'Dwyer PJ, Maru D, Morris V, Janku F, Dasari A, Chung W, Issa JP, Gibbs P, James B, Powis G, Nolop KB, Bhattacharya S, Saltz L. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer. J Clin Oncol 33(34):4032-8, 2015. e-Pub 2015. PMID: 26460303.
346. Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, Bot BM, Morris JS, Simon IM, Gerster S, Fessler E, De Sousa E Melo F, Missiaglia E, Ramay H, Barras D, Homicsko K, Maru D, Manyam GC, Broom B, Boige V, Perez-Villamil B, Laderas T, Salazar R, Gray JW, Hanahan D, Tabernero J, Bernards R, Friend SH, Laurent-Puig P, Medema JP, Sadanandam A, Wessels L, Delorenzi M, Kopetz S, Vermeulen L, Tejpar S. The Consensus Molecular Subtypes of Colorectal Cancer. Nat Med 21(11):1350-6, 2015. e-Pub 2015. PMID: 26457759.
347. Liao HW, Hsu JM, Xia W, Wang HL, Wang YN, Chang WC, Arold ST, Chou CK, Tsou PH, Yamaguchi H, Fang YF, Lee HJ, Lee HH, Tai SK, Yang MH, Morelli MP, Sen M, Ladbury JE, Chen CH, Grandis JR, Kopetz S, Hung MC. PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response. J Clin Invest. e-Pub 2015. PMID: 26571401.
348. Denise C, Paoli P, Calvani M, Taddei ML, Giannoni E, Kopetz S, Kazmi SM, Pia MM, Pettazzoni P, Sacco E, Caselli A, Vanoni M, Landriscina M, Cirri P, Chiarugi P. 5-Fluorouracil resistant colon cancer cells are addicted to OXPHOS to survive and enhance stem-like traits. Oncotarget. e-Pub 2015. PMID: 26527315.
349. Brudvik KW, Kopetz ES, Li L, Conrad C, Aloia TA, Vauthey JN. Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases. Br J Surg 102(10):1175-83, 2015. e-Pub 2015. PMID: 26206254.
350. Chang GJ, Kopetz S. Coordination of care in colon cancer. Cancer 121(18):3201-2, 2015. e-Pub 2015. PMID: 26043269.
351. Hecht JR, Douillard JY, Schwartzberg L, Grothey A, Kopetz S, Rong A, Oliner KS, Sidhu R. Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer. Cancer Treat Rev 41(8):653-9, 2015. e-Pub 2015. PMID: 26220150.
352. Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, Hong DS, Holley VR, Cabrilo G, Wheler JJ, Piha-Paul SA, Zinner RG, Bedikian AY, Overman MJ, Kee BK, Kim KB, Kopetz ES, Luthra R, Diehl F, Meric-Bernstam F, Kurzrock R. Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget 6(27):24581, 2015. e-Pub 2015. PMID: 26405159.
353. Janku F, Claes B, Huang HJ, Falchook GS, Devogelaere B, Kockx M, Bempt IV, Reijans M, Naing A, Fu S, Piha-Paul SA, Hong DS, Holley VR, Tsimberidou AM, Stepanek VM, Patel SP, Kopetz ES, Subbiah V, Wheler JJ, Zinner RG, Karp DD, Luthra R, Roy-Chowdhuri S, Sablon E, Meric-Bernstam F, Maertens G, Kurzrock R. BRAF mutation testing with a rapid, fully integrated molecular diagnostics system. Oncotarget 6(29):26886-94, 2015. e-Pub 2015. PMID: 26330075.
354. Shah MS, Fogelman DR, Raghav KP, Heymach JV, Tran HT, Jiang ZQ, Kopetz S, Daniel CR. Joint prognostic effect of obesity and chronic systemic inflammation in patients with metastatic colorectal cancer. Cancer 121(17):2968-75, 2015. e-Pub 2015. PMID: 25975416.
355. Corcoran RB, Atreya CE, Falchook GS, Kwak EL, Ryan DP, Bendell JC, Hamid O, Messersmith WA, Daud A, Kurzrock R, Pierobon M, Sun P, Cunningham E, Little S, Orford K, Motwani M, Bai Y, Patel K, Venook AP, Kopetz S. Combined BRAF and MEK Inhibition with Dabrafenib and Trametinib in BRAF V600 Mutant Colorectal Cancer. J Clin Oncol. e-Pub 2015. PMID: 26392102.
356. Meric-Bernstam F, Brusco L, Shaw K, Horombe C, Kopetz S, Davies MA, Routbort M, Piha-Paul SA, Janku F, Ueno N, Hong D, De Groot J, Ravi V, Li Y, Luthra R, Patel K, Broaddus R, Mendelsohn J, Mills GB. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. J Clin Oncol 33(25):2753-62, 2015. e-Pub 2015. PMID: 26014291.
357. Reddy SM, Kopetz S, Morris J, Parikh N, Qiao W, Overman MJ, Fogelman D, Shureiqi I, Jacobs C, Malik Z, Jimenez CA, Wolff RA, Abbruzzese JL, Gallick G, Eng C. Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer. Invest New Drugs 33(4):977-84, 2015. e-Pub 2015. PMID: 26062928.
358. Meric-Bernstam F, Johnson A, Holla V, Bailey AM, Brusco L, Chen K, Routbort M, Patel KP, Zeng J, Kopetz S, Davies MA, Piha-Paul SA, Hong DS, Eterovic AK, Tsimberidou AM, Broaddus R, Bernstam EV, Shaw KR, Mendelsohn J, Mills GB. A decision support framework for genomically informed investigational cancer therapy. J Natl Cancer Inst 107(7), 2015. e-Pub 2015. PMID: 25863335.
359. Goswami RS, Patel KP, Singh RR, Meric-Bernstam F, Kopetz ES, Subbiah V, Alvarez RH, Davies MA, Jabbar KJ, Roy-Chowdhuri S, Lazar AJ, Medeiros LJ, Broaddus RR, Luthra R, Routbort MJ. Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors. Clin Cancer Res 21(11):2644-51, 2015. e-Pub 2015. PMID: 25695693.
360. Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, Hong DS, Holley VR, Cabrilo G, Wheler JJ, Piha-Paul SA, Zinner RG, Bedikian AY, Overman MJ, Kee BK, Kim KB, Kopetz ES, Luthra R, Diehl F, Meric-Bernstam F, Kurzrock R. Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget 6(14):12809-21, 2015. e-Pub 2015. PMID: 25980577.
361. Mise Y, Kopetz S, Mehran RJ, Aloia TA, Conrad C, Brudvik KW, Taggart MW, Vauthey JN. Is Complete Liver Resection Without Resection of Synchronous Lung Metastases Justified?. Ann Surg Oncol 22(5):1585-92, 2015. e-Pub 2015. PMID: 25373535.
362. Morelli MP, Overman MJ, Dasari A, Kazmi SM, Mazard T, Vilar E, Morris VK, Lee MS, Herron D, Eng C, Morris J, Kee BK, Janku F, Deaton FL, Garrett C, Maru D, Diehl F, Angenendt P, Kopetz S. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann Oncol 26(4):731-6, 2015. e-Pub 2015. PMID: 25628445.
363. Atreya CE, Corcoran RB, Kopetz S. Expanded RAS: Refining the Patient Population. J Clin Oncol 33(7):682-5, 2015. e-Pub 2015. PMID: 25584005.
364. Mise Y, Zimmitti G, Shindoh J, Kopetz S, Loyer EM, Andreou A, Cooper AB, Kaur H, Aloia TA, Maru DM, Vauthey JN. RAS Mutations Predict Radiologic and Pathologic Response in Patients Treated with Chemotherapy Before Resection of Colorectal Liver Metastases. Ann Surg Oncol 22(3):834-42, 2015. e-Pub 2015. PMID: 25227306.
365. Ling H, Pickard K, Ivan C, Isella C, Ikuo M, Mitter R, Spizzo R, Bullock MD, Braicu C, Pileczki V, Vincent K, Pichler M, Stiegelbauer V, Hoefler G, Almeida MI, Hsiao A, Zhang X, Primrose JN, Packham GK, Liu K, Bojja K, Gafà R, Xiao L, Rossi S, Song JH, Vannini I, Fanini F, Kopetz S, Zweidler-McKay P, Wang X, Ionescu C, Irimie A, Fabbri M, Lanza G, Hamilton SR, Berindan-Neagoe I, Medico E, Mirnezami AH, Calin GA, Nicoloso MS. The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis. Gut. e-Pub 2015. PMID: 25804630.
366. Bresalier RS, Kopetz S, Brenner DE. Blood-Based Tests for Colorectal Cancer Screening: Do They Threaten the Survival of the FIT Test?. Dig Dis Sci 60(3):664-71, 2015. e-Pub 2015. PMID: 25680874.
367. Chen ZY, Raghav K, Lieu CH, Jiang ZQ, Eng C, Vauthey JN, Chang GJ, Qiao W, Morris J, Hong D, Hoff P, Tran H, Menter DG, Heymach J, Overman M, Kopetz S. Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer. Br J Cancer 112(6):1088-97, 2015. e-Pub 2015. PMID: 25688736.
368. Chen K, Meric-Bernstam F, Zhao H, Zhang Q, Ezzeddine N, Tang LY, Qi Y, Mao Y, Chen T, Chong Z, Zhou W, Zheng X, Johnson A, Aldape KD, Routbort MJ, Luthra R, Kopetz S, Davies MA, de Groot J, Moulder S, Vinod R, Farhangfar CJ, Shaw KM, Mendelsohn J, Mills GB, Eterovic AK. Clinical Actionability Enhanced through Deep Targeted Sequencing of Solid Tumors. Clin Chem 61(3):544-53, 2015. e-Pub 2015. PMID: 25626406.
369. Cabanillas ME, Patel A, Danysh BP, Dadu R, Kopetz S, Falchook G. BRAF Inhibitors: Experience in Thyroid Cancer and General Review of Toxicity. Horm Cancer 6(1):21-36, 2015. e-Pub 2015. PMID: 25467940.
370. Pereira AA, Rego JF, Morris V, Overman MJ, Eng C, Garrett CR, Boutin AT, Ferrarotto R, Lee M, Jiang ZQ, Hoff PM, Vauthey JN, Vilar E, Maru D, Kopetz S. Association between KRAS mutation and lung metastasis in advanced colorectal cancer. Br J Cancer 112(3):424-8, 2015. e-Pub 2015. PMID: 25535726.
371. Satelli A, Mitra A, Brownlee Z, Xia X, Bellister S, Overman MJ, Kopetz S, Ellis LM, Meng QH, Li S. Epithelial-mesenchymal transitioned circulating tumor cells capture for detecting tumor progression. Clin Cancer Res 21(4):899-906, 2015. e-Pub 2015. PMID: 25516888.
372. Fan F, Bellister S, Lu J, Ye X, Boulbes DR, Tozzi F, Sceusi E, Kopetz S, Tian F, Xia L, Zhou Y, Bhattacharya R, Ellis LM. The requirement for freshly isolated human colorectal cancer (CRC) cells in isolating CRC stem cells. Br J Cancer 112(3):539-46, 2015. e-Pub 2015. PMID: 25535733.
373. Kopetz S, Tabernero J, Rosenberg R, Jiang ZQ, Moreno V, Bachleitner-Hofmann T, Lanza G, Stork-Sloots L, Maru D, Simon I, Capellà G, Salazar R. Genomic Classifier ColoPrint Predicts Recurrence in Stage II Colorectal Cancer Patients More Accurately Than Clinical Factors. Oncologist 20(2):127-33, 2015. e-Pub 2015. PMID: 25561511.
374. Lee KW, Lee SS, Kim SB, Sohn BH, Lee HS, Jang HJ, Park YY, Kopetz S, Kim SS, Oh SC, Lee JS. Significant Association of oncogene YAP1 with Poor Prognosis and Cetuximab Resistance in Colorectal Cancer Patients. Clin Cancer Res 21(2):357-64, 2015. e-Pub 2015. PMID: 25388162.
375. Liu X, George GC, Tsimberidou AM, Naing A, Wheler JJ, Kopetz S, Fu S, Piha-Paul SA, Eng C, Falchook GS, Janku F, Garrett C, Karp D, Kurzrock R, Zinner R, Raghav K, Subbiah V, Hess K, Meric-Bernstam F, Hong DS, Overman MJ. Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. BMC Cancer 15:713, 2015. e-Pub 2015. PMID: 26474549.
376. Lanman RB, Mortimer SA, Zill OA, Sebisanovic D, Lopez R, Blau S, Collisson EA, Divers SG, Hoon DS, Kopetz ES, Lee J, Nikolinakos PG, Baca AM, Kermani BG, Eltoukhy H, Talasaz A. Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA. PLoS One 10(10):e0140712, 2015. e-Pub 2015. PMID: 26474073.
377. San Lucas FA, Fowler J, Chang K, Kopetz S, Vilar E, Scheet P. Cancer in silico Drug Discovery: a systems biology tool for identifying candidate drugs to target specific molecular tumor subtypes. Mol Cancer Ther 13(12):3230-40, 2014. e-Pub 2014. PMID: 25349306.
378. Pecot CV, Wu SY, Bellister S, Filant J, Rupaimoole R, Hisamatsu T, Bhattacharya R, Maharaj A, Azam S, Rodriguez-Aguayo C, Nagaraja AS, Morelli MP, Gharpure KM, Waugh TA, Gonzalez-Villasana V, Zand B, Dalton HJ, Kopetz S, Lopez-Berestein G, Ellis LM, Sood AK. Therapeutic Silencing of KRAS using Systemically Delivered siRNAs. Mol Cancer Ther 13(12):2876-85, 2014. e-Pub 2014. PMID: 25281617.
379. Chen G, Chakravarti N, Aardalen K, Lazar AJ, Tetzlaff MT, Wubbenhorst B, Kim SB, Kopetz S, Ledoux AA, Gopal YN, Pereira CG, Deng W, Lee JS, Nathanson KL, Aldape KD, Prieto VG, Stuart D, Davies MA. Molecular Profiling of Patient-Matched Brain and Extracranial Melanoma Metastases Implicates the PI3K Pathway as a Therapeutic Target. Clin Cancer Res 20(21):5537-46, 2014. e-Pub 2014. PMID: 24803579.
380. Menter DG, Patterson SL, Logsdon CD, Kopetz S, Sood AK, Hawk ET. Convergence of nanotechnology and cancer prevention: are we there yet?. Cancer Prev Res (Phila) 7(10):973-92, 2014. e-Pub 2014. PMID: 25060262.
381. Zhou JH, Rosen D, Andreou A, Brouquet A, Abbott D, Loyer E, Gonzalez-Angulo AM, Kopetz S, Meric-Bernstam F, Kuerer H, Abdalla E, Vauthey JN, Sahin AA, Maru DM. Residual tumor thickness at the tumor-normal tissue interface predicts the recurrence-free survival in patients with liver metastasis of breast cancer. Ann Diagn Pathol 18(5):266-70, 2014. e-Pub 2014. PMID: 25205085.
382. Morris VK, Lucas FA, Overman MJ, Eng C, Morelli MP, Jiang ZQ, Luthra R, Meric-Bernstam F, Maru D, Scheet P, Kopetz S, Vilar E. Clinicopathologic Characteristics and Gene Expression Analyses of Non-KRAS 12/13, RAS-Mutated Metastatic Colorectal Cancer. Ann Oncol 25(10):2008-14, 2014. e-Pub 2014. PMID: 25009008.
383. Morris V, Overman MJ, Jiang ZQ, Garrett C, Agarwal S, Eng C, Kee B, Fogelman D, Dasari A, Wolff R, Maru D, Kopetz S. Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin Colorectal Cancer 13(3):164-71, 2014. e-Pub 2014. PMID: 25069797.
384. Aloia TA, Zimmitti G, Conrad C, Gottumukalla V, Kopetz S, Vauthey JN. Return to intended oncologic treatment (RIOT): A novel metric for evaluating the quality of oncosurgical therapy for malignancy. J Surg Oncol 110(2):107-14, 2014. e-Pub 2014. PMID: 24846705.
385. Goldstein J, Tran B, Ensor J, Gibbs P, Wong HL, Wong SF, Vilar E, Tie J, Broaddus R, Kopetz S, Desai J, Overman MJ. Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H) 25(5):1032-8, 2014. e-Pub 2014. PMID: 24585723.
386. Haynes AB, You YN, Hu CY, Eng C, Kopetz ES, Rodriguez-Bigas MA, Skibber JM, Cantor SB, Chang GJ. Postoperative chemotherapy use after neoadjuvant chemoradiotherapy for rectal cancer: Analysis of Surveillance, Epidemiology, and End Results-Medicare data, 1998-2007. Cancer 120(8):1162-70, 2014. e-Pub 2014. PMID: 24474245.
387. Gong J, Xie J, Bedolla R, Rivas P, Chakravarthy D, Freeman JW, Reddick R, Kopetz S, Peterson A, Wang H, Fischer SM, Kumar AP. Combined targeting of STAT3/NF-κB/COX-2/EP4 for effective management of pancreatic cancer. Clin Cancer Res 20(5):1259-73, 2014. e-Pub 2014. PMID: 24520096.
388. Menter DG, Tucker SC, Kopetz S, Sood AK, Crissman JD, Honn KV. Platelets and cancer: a casual or causal relationship: revisited. Cancer Metastasis Rev 33(1):231-69, 2014. e-Pub 2014. PMID: 24696047.
389. Das P, Eng C, Rodriguez-Bigas MA, Chang GJ, Skibber JM, You YN, Maru DM, Munsell MF, Clemons MV, Kopetz SE, Garrett CR, Shureiqi I, Delclos ME, Krishnan S, Crane CH. Preoperative Radiation Therapy With Concurrent Capecitabine, Bevacizumab, and Erlotinib for Rectal Cancer: A Phase 1 Trial. Int J Radiat Oncol Biol Phys 88(2):301-5, 2014. e-Pub 2014. PMID: 24315563.
390. Bailey AM, Zhan L, Maru D, Shureiqi I, Pickering CR, Kiriakova G, Izzo J, He N, Wei C, Baladandayuthapani V, Liang H, Kopetz S, Powis G, Guo GL. FXR Silencing in Human Colon Cancer by DNA methylation and KRAS Signaling. Am J Physiol Gastrointest Liver Physiol 306(1):G48-58, 2014. e-Pub 2014. PMID: 24177031.
391. Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C, Nagtegaal ID, Palmqvist R, Masucci GV, Botti G, Tatangelo F, Delrio P, Maio M, Laghi L, Grizzi F, Asslaber M, D'Arrigo C, Vidal-Vanaclocha F, Zavadova E, Chouchane L, Ohashi PS, Hafezi-Bakhtiari S, Wouters BG, Roehrl M, Nguyen L, Kawakami Y, Hazama S, Okuno K, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Wang Y, Kopetz S, Sinicrope FA, Scripcariu V, Ascierto PA, Marincola FM, Fox BA, Pagès F. Towards the introduction of the Immunoscore in the classification of malignant tumors. J Pathol 232(2):199-209, 2014. e-Pub 2014. PMID: 24122236.
392. Kopetz S, Morris VK, Parikh N, Overman MJ, Jiang ZQ, Maru D, Elvin P, Gallick G. Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer. BMC Cancer 14:660, 2014. e-Pub 2014. PMID: 25208577.
393. Agarwal A, Chang GJ, Hu CY, Taggart M, Rashid A, Park IJ, You YN, Das P, Krishnan S, Crane CH, Rodriguez-Bigas M, Skibber J, Ellis L, Eng C, Kopetz S, Maru DM. Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy. Cancer 119(24):4231-41, 2013. e-Pub 2013. PMID: 24089344.
394. Morris V, Kopetz S. Clinical biomarkers in colorectal cancer. Clin Adv Hematol Oncol 11(12):768-76, 2013. e-Pub 2013. PMID: 24893280.
395. Ganesan P, Janku F, Naing A, Hong DS, Tsimberidou AM, Falchook GS, Wheler JJ, Piha-Paul SA, Fu S, Stepanek VM, Lee JJ, Luthra R, Overman MJ, Kopetz ES, Wolff RA, Kurzrock R. Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Colorectal Cancer and PIK3CA Mutations. Mol Cancer Ther 12(12):2857-63, 2013. e-Pub 2013. PMID: 24092809.
396. Vauthey JN, SE K. From multidisciplinary to personalized treatment of colorectal liver metastases: 4 reasons to consider RAS. Cancer 119(23):4083-5, 2013. e-Pub 2013. PMID: 24105015.
397. Vauthey JN, Zimmitti G, Kopetz SE, Shindoh J, Chen SS, Andreou A, Curley SA, Aloia TA, Maru DM. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg 258(4):619-26; discussion 626-7, 2013. e-Pub 2013. PMID: 24018645.
398. Ling H, Spizzo R, Atlasi Y, Nicoloso M, Shimizu M, Redis RS, Nishida N, Gafà R, Song J, Guo Z, Ivan C, Barbarotto E, De Vries I, Zhang X, Ferracin M, Churchman M, van Galen JF, Beverloo BH, Shariati M, Haderk F, Estecio MR, Garcia-Manero G, Patijn GA, Gotley DC, Bhardwaj V, Shureiqi I, Sen S, Multani AS, Welsh J, Yamamoto K, Taniguchi I, Song MA, Gallinger S, Casey G, Thibodeau SN, Le Marchand L, Tiirikainen M, Mani SA, Zhang W, Davuluri RV, Mimori K, Mori M, Sieuwerts AM, Martens JW, Tomlinson I, Negrini M, Berindan-Neagoe I, Foekens JA, Hamilton SR, Lanza G, Kopetz S, Fodde R, Calin GA. CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Res 23(9):1446-61, 2013. e-Pub 2013. PMID: 23796952.
399. Jiang ZQ, Varadhachary G, Wang X, Kopetz S, Lee JE, Wang H, Shroff R, Katz M, Wolff RA, Fleming J, Overman MJ. A retrospective study of ampullary adenocarcinomas: overall survival and responsiveness to fluoropyrimidine-based chemotherapy 24(9):2349-53, 2013. e-Pub 2013. PMID: 23704197.
400. Brouquet A, Zimmitti G, Kopetz S, Stift J, Julié C, Lemaistre AI, Agarwal A, Patel V, Benoist S, Nordlinger B, Gandini A, Rivoire M, Stremitzer S, Gruenberger T, Vauthey JN, Maru DM. Multicenter validation study of pathologic response and tumor thickness at the tumor-normal liver interface as independent predictors of disease-free survival after preoperative chemotherapy and surgery for colorectal liver metastases. Cancer 119(15):2778-88, 2013. e-Pub 2013. PMID: 23868456.
401. Andreou A, Aloia TA, Brouquet A, Dickson PV, Zimmitti G, Maru DM, Kopetz S, Loyer EM, Curley SA, Abdalla EK, Vauthey JN. Margin Status Remains an Important Determinant of Survival After Surgical Resection of Colorectal Liver Metastases in the Era of Modern Chemotherapy. Ann Surg 257(6):1079-88, 2013. e-Pub 2013. PMID: 23426338.
402. Clary BM, Grothey A, Kopetz S, Marsh RD. Systemic cytotoxic and biologic therapies for colorectal cancer liver metastases: expert consensus statement. HPB (Oxford) 15(2):116-8, 2013. e-Pub 2013. PMID: 23297722.
403. Mao M, Tian F, Mariadason JM, Tsao CC, Lemos R, Dayyani F, Gopal YN, Jiang ZQ, Wistuba II, Tang XM, Bornman WG, Bollag G, Mills GB, Powis G, Desai J, Gallick GE, Davies MA, Kopetz S. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with P13K inhibition or demethylating agents. Clin Cancer Res 19(3):657-667, 2013. e-Pub 2013. PMID: 23251002.
404. Overman MJ, Modak J, Kopetz ES, Murthy R, Yao JC, Hicks ME, Abbruzzese JL, Tam AL. Use of Research Biopsies in Clinical Trials: Are Risks and Benefits Adequately Discussed?. J Clin Oncol 31(1):17-22, 2013. e-Pub 2013. PMID: 23129736.
405. Conte B, Kopetz S. Challenges and strategies for identifying biomarkers for colorectal cancer. Colorectal Cancer 2(6):487-489, 2013. e-Pub 2013. PMID: 25598846.
406. Park YY, Lee SS, Lim JY, Kim SC, Kim SB, Sohn BH, Chu IS, Oh SC, Park ES, Jeong W, Kim SS, Kopetz S, Lee JS. Comparison of prognostic genomic predictors in colorectal cancer. PLoS One 8(4):e60778, 2013. e-Pub 2013. PMID: 23626670.
407. Morris V, Kopetz S. BRAF inhibitors in clinical oncology. F1000Prime Rep 5:11, 2013. e-Pub 2013. PMID: 23585929.
408. Kopetz S. "Right drug for the right patient". Am Soc Clin Oncol Educ Book 2013:115-20, 2013. e-Pub 2013. PMID: 23714474.
409. Overman MJ, Zhang J, Kopetz S, Davies M, Zhi-Qin J, Stemke-Hale K, Rümmele P, Pilarsky C, Grützmann R, Hamilton S, Hwang R, Abbruzzese JL, Varadhachary G, Broom B, Wang H. Gene expression profiling of ampullary carcinomas classifies ampullary carcinomas into biliary-like and intestinal-like subtypes that are prognostic of outcome. PLoS One 8(6):e65144, 2013. e-Pub 2013. PMID: 23776447.
410. Park YY, Lee SS, Lim JY, Kim SC, Kim SB, Sohn BH, Chu IS, Oh SC, Park ES, Jeong W, Kim SS, Kopetz S, Lee JS. Correction: Comparison of Prognostic Genomic Predictors in Colorectal Cancer. PLoS One 8(12), 2013. e-Pub 2013. PMID: 24358104.
411. Shindoh J, Loyer EM, Kopetz S, Boonsirikamchai P, Maru DM, Chun YS, Zimmitti G, Curley SA, Charnsangavej C, Aloia TA, Vauthey JN. Optimal Morphologic Response to Preoperative Chemotherapy: An Alternate Outcome End Point Before Resection of Hepatic Colorectal Metastases. J Clin Oncol 30(36):4566-72, 2012. e-Pub 2012. PMID: 23150701.
412. Hong DS, Patel JC, Wheler J, Naing A, Garrido-Laguna I, Falchook G, Fu S, Tsimberidou AM, Kopetz ES, Win S, Kurzrock R. Outcomes in 144 Patients With Colorectal Cancer Treated in a Phase I Clinic: the MD Anderson Cancer Center Experience. Clin Colorectal Cancer 11(4):297-303, 2012. e-Pub 2012. PMID: 22537607.
413. Vauthey JN, Kopetz S, Aloia TA, Andreou A. KRAS mutation in colorectal cancer metastases after adjuvant FOLFOX for the primary. Br J Cancer 107(8):1442-3, 2012. e-Pub 2012. PMID: 23018559.
414. Andreou A, Kopetz S, Maru DM, Chen SS, Zimmitti G, Brouquet A, Shindoh J, Curley SA, Garrett C, Overman MJ, Aloia TA, Vauthey JN. Adjuvant Chemotherapy With FOLFOX for Primary Colorectal Cancer Is Associated With Increased Somatic Gene Mutations and Inferior Survival in Patients Undergoing Hepatectomy for Metachronous Liver Metastases. Ann Surg 256(4):642-50, 2012. e-Pub 2012. PMID: 22968062.
415. Oh SC, Park YY, Park ES, Lim JY, Kim SM, Kim SB, Kim J, Kim SC, Chu IS, Smith JJ, Beauchamp RD, Yeatman TJ, Kopetz S, Lee JS. Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer. Gut 61(9):1291-8, 2012. e-Pub 2012. PMID: 21997556.
416. Garrett CR, George B, Viswanathan C, Bhadkamkar NA, Wen S, Baladandayuthapani V, You YN, Kopetz ES, Overman MJ, Kee BK, Eng C. Survival Benefit Associated With Surgical Oophorectomy in Patients With Colorectal Cancer Metastatic to the Ovary. Clin Colorectal Cancer 11(3):191-4, 2012. e-Pub 2012. PMID: 22280844.
417. Dai J, Gu J, Huang M, Eng C, Kopetz ES, Ellis LM, Hawk E, Wu X. GWAS-identified colorectal cancer susceptibility loci associated with clinical outcomes. Carcinogenesis 33(7):1327-31, 2012. e-Pub 2012. PMID: 22505654.
418. Overman MJ, Hu CY, Kopetz ES, Abbruzzese JL, Wolff RA, Chang GJ. A Population-Based Comparison of Adenocarcinoma of the Large and Small Intestine: Insights Into a Rare Disease. Ann Surg Oncol 19(5):1439-45, 2012. e-Pub 2012. PMID: 22187121.
419. Ferrarotto R, Machado K, Mak MP, Shah N, Takahashi TK, Costa FP, Overman MJ, Kopetz S, Hoff PM. A multicenter, multinational analysis of mitomycin C in refractory metastatic colorectal cancer 48(6):820-6, 2012. e-Pub 2012. PMID: 22330318.
420. Yang H, Higgins B, Kolinsky K, Packman K, Bradley WD, Lee RJ, Schostack K, Simcox ME, Kopetz S, Heimbrook D, Lestini B, Bollag G, Su F. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Res 72(3):779-89, 2012. e-Pub 2012. PMID: 22180495.
421. Galon J, Pagès F, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, Kreiter S, Chouchane L, Delrio P, Arndt H, Asslaber M, Maio M, Masucci GV, Mihm M, Vidal-Vanaclocha F, Allison JP, Gnjatic S, Hakansson L, Huber C, Singh-Jasuja H, Ottensmeier C, Zwierzina H, Laghi L, Grizzi F, Ohashi PS, Shaw PA, Clarke BA, Wouters BG, Kawakami Y, Hazama S, Okuno K, Wang E, O'Donnell-Tormey J, Lagorce C, Pawelec G, Nishimura MI, Hawkins R, Lapointe R, Lundqvist A, Khleif SN, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Palmqvist R, Nagtegaal ID, Wang Y, D'Arrigo C, Kopetz S, Sinicrope FA, Trinchieri G, Gajewski TF, Ascierto PA, Fox BA. Cancer classification using the Immunoscore: a worldwide task force 10(1):205, 2012. e-Pub 2012. PMID: 23034130.
422. Boonsirikamchai P, Asran MA, Maru DM, Vauthey JN, Kaur H, Kopetz ES, Loyer EM. CT Findings of Response and Recurrence, Independent of Change in Tumor Size, in Colorectal Liver Metastasis Treated With Bevacizumab. AJR Am J Roentgenol 197(6):W1060-6, 2011. e-Pub 2011. PMID: 22109320.
423. Angelo LS, Wu JY, Meng F, Sun M, Kopetz S, McCutcheon IE, Slopis JM, Kurzrock R. Combining curcumin (diferuloylmethane) and heat shock protein inhibition for neurofibromatosis 2 treatment: analysis of response and resistance pathways. Mol Cancer Ther 10(11):2094-103, 2011. e-Pub 2011. PMID: 21903608.
424. Lieu C, Heymach J, Overman M, Tran H, Kopetz S. Beyond VEGF: Inhibition of the Fibroblast Growth Factor Pathway and Antiangiogenesis. Clin Cancer Res 17(19):6130-9, 2011. e-Pub 2011. PMID: 21953501.
425. Brouquet A, Overman MJ, Kopetz ES, Maru DM, Loyer EM, Andreou A, Cooper A, Curley SA, Garrett CR, Abdalla EK, Vauthey JN. Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?. Cancer 117(19):4484-92, 2011. e-Pub 2011. PMID: 21446046.
426. Ferrarotto R, Pathak P, Maru D, Agarwal A, Overman M, Hoff PM, Kopetz ES. Durable complete responses in metastatic colorectal cancer treated with chemotherapy alone. Clin Colorectal Cancer 10(3):178-82, 2011. e-Pub 2011. PMID: 21855039.
427. George B, Kopetz ES. Predictive and Prognostic Markers in Colorectal Cancer. (Invited). Curr Oncol Rep 13(3):206-15, 2011. e-Pub 2011. PMID: 21373987.
428. Fogelman DR, Wolff RA, Kopetz ES, Javle M, Bradley C, Mok I, Cabanillas F, Abbruzzese JL. Evidence for the Efficacy of Iniparib, a PARP-1 Inhibitor, in BRCA2-associated Pancreatic Cancer. Anticancer Res 31(4):1417-20, 2011. e-Pub 2011. PMID: 21508395.
429. Brouquet A, Abdalla EK, Kopetz ES, Garrett CR, Overman MJ, Eng C, Andreou A, Loyer EM, Madoff DC, Curley SA, Vauthey JN. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol 29(8):1083-90, 2011. e-Pub 2011. PMID: 21263087.
430. Tran B, Kopetz ES, Tie J, Gibbs P, Jiang ZQ, Lieu CH, Agarwal A, Maru DM, Sieber O, Desai J. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer. e-Pub 2011. PMID: 21456008.
431. Kim MP, Fleming JB, Wang H, Abbruzzese JL, Choi W, Kopetz ES, McConkey DJ, Evans DB, Gallick GE. ALDH Activity Selectively Defines an Enhanced Tumor-Initiating Cell Population Relative to CD133 Expression in Human Pancreatic Adenocarcinoma. PLoS One 6(6):e20636, 2011. e-Pub 2011. PMID: 21695188.
432. Silberfein EJ, Kattepogu KM, Hu CY, Skibber JM, Rodriguez-Bigas MA, Feig B, Das P, Krishnan S, Crane C, Kopetz S, Eng C, Chang GJ. Long-term Survival and Recurrence Outcomes Following Surgery for Distal Rectal Cancer. Ann Surg Oncol 17(11):2863-9, 2010. e-Pub 2010. PMID: 20552409.
433. Maru DM, Kopetz S, Boonsirikamchai P, Agarwal A, Chun YS, Wang H, Abdalla EK, Kaur H, Charnsangavej C, Vauthey JN, Loyer EM. Tumor Thickness at the Tumor-normal Interface: A Novel Pathologic Indicator of Chemotherapy Response in Hepatic Colorectal Metastases 34(9):1287-1294, 2010. e-Pub 2010. PMID: 20697255.
434. Kishi Y, Zorzi D, Contreras CM, Maru DM, Kopetz S, Ribero D, Motta M, Ravarino N, Risio M, Curley SA, Abdalla EK, Capussotti L, Vauthey JN. Extended Preoperative Chemotherapy Does Not Improve Pathologic Response and Increases Postoperative Liver Insufficiency After Hepatic Resection for Colorectal Liver Metastases. Ann Surg Oncol 17(11):2870-6. e-Pub 2010. PMID: 20567921.
435. Brouquet A, Mortenson MM, Vauthey JN, Rodriguez-Bigas MA, Overman MJ, Chang GJ, Kopetz S, Garrett C, Curley SA, Abdalla EK. Surgical Strategies for Synchronous Colorectal Liver Metastases in 156 Consecutive Patients: Classic, Combined or Reverse Strategy?. J Am Coll Surg 210(6):934-41, 2010. e-Pub 2010. PMID: 20510802.
436. Overman MJ, Kopetz S, Lin E, Abbruzzese JL, Wolff RA. Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine. Acta Oncol 49(4):474-9, 2010. e-Pub 2010. PMID: 20397775.
437. Overman MJ, Maru DM, Charnsangavej C, Loyer EM, Wang H, Pathak P, Eng C, Hoff PM, Vauthey JN, Wolff RA, Kopetz S. Oxaliplatin-Mediated Increase in Spleen Size As a Biomarker for the Development of Hepatic Sinusoidal Injury. J Clin Oncol 28(15):2549-2555, 2010. e-Pub 2010. PMID: 20406923.
438. Lieu C, Kopetz S. The SRC family of protein tyrosine kinases: A new and promising target for colorectal cancer therapy. (Peer-reviewed Review). Clin Colorectal Cancer 9(2):89-94, 2010. e-Pub 2010. PMID: 20378502.
439. Vauthey JN, Nordlinger B, Kopetz S, Poston G. Sequenced Chemotherapy and Surgery for Potentially Resectable Colorectal Liver Metastases: A Debate Over Goals of Research and an Approach While the Jury Remains Out. Ann Surg Oncol 17(8):1983-1986, 2010. e-Pub 2010. PMID: 20232164.
440. Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, Adinin R, Overman MJ, Valero V, Wen S, Lieu C, Yan S, Tran HT, Ellis LM, Abbruzzese JL, Heymach JV. Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance. J Clin Oncol 28(3):453-9, 2010. e-Pub 2010. PMID: 20008624.
441. Overman MJ, Pozadzides J, Kopetz S, Wen S, Abbruzzese JL, Wolff RA, Wang H. Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine 102(1):144-50, 2010. e-Pub 2010. PMID: 19935793.
442. Chun YS, Vauthey JN, Boonsirikamchai P, Maru DM, Kopetz S, Palavecino M, Curley SA, Abdalla EK, Charnsangavej C, Loyer EM. Association of Computed Tomography Morphologic Criteria With Pathologic Response and Survival in Patients Treated With Bevacizumab for Colorectal Liver Metastases. JAMA 302(21):2338-2344, 2009. e-Pub 2009. PMID: 19952320.
443. Slade JH, Alattar ML, Fogelman DR, Overman MJ, Agarwal A, Maru DM, Coulson RL, Charnsangavej C, Vauthey JN, Wolff RA, Kopetz S. Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury. Clin Colorectal Cancer 8(4):225-30, 2009. e-Pub 2009. PMID: 19822514.
444. Kopetz S, Chang G, Overman M, Eng C, Larson DW, Grothey A, Vauthey JN, Sargent D, McWilliams R. Improved Survival in Metastatic Colorectal Cancer is Associated with Sequential Adoption of Hepatic Resection and Improved Chemotherapy. J Clin Oncol 27(22):3677-83, 2009. e-Pub 2009. PMID: 19470929.
445. Herman MP, Kopetz S, Bhosale PR, Eng C, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Delclos ME, Krishnan S, Crane CH, Das P. Sacral Insufficiency Fractures After Preoperative Chemoradiation for Rectal Cancer: Incidence, Risk Factors, and Clinical Course. Int J Radiat Oncol Biol Phys 74(3):818-23, 2009. e-Pub 2009. PMID: 19147305.
446. Overman MJ, Varadhachary GR, Kopetz S, Adinin R, Lin E, Morris JS, Eng C, Abbruzzese JL, Wolff RA. Phase II study of Capecitabine and Oxaliplatin for Advanced Adenocarcinoma of the Small Bowel and Ampulla of Vater. J Clin Oncol 26(15S):4538, 2009. e-Pub 2009. PMID: 19164203.
447. Rossi S, Kopetz S, Davuluri R, Hamilton SR, Calin GA. MicroRNAs, ultraconserved genes and colorectal cancers. (Invited). Int J Biochem Cell Biol 42(8):1291-1297, 2009. e-Pub 2009. PMID: 19497386.
448. Kopetz S, Lesslie DP, Dallas NA, Park SI, Johnson M, Parikh NU, Kim MP, Abbruzzese JL, Ellis LM, Chandra J, Gallick GE. Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res 69(9):3842-9, 2009. e-Pub 2009. PMID: 19383922.
449. Kishi Y, Kopetz S, Chun YS, Palavecino M, Abdalla EK, Vauthey JN. Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann Surg Oncol 16(3):614-22, 2009. e-Pub 2009. PMID: 19130139.
450. Chang DZ, Kumar V, Ma Y, Li K, Kopetz S. Individualized Therapies in Colorectal Cancer: KRAS as a Marker for Response to EGFR-targeted Therapy (Invited Editorial). J Hematol Oncol 2(18):18, 2009. e-Pub 2009. PMID: 19386128.
451. Fogelman DR, Kopetz S, Eng C. Emerging Drugs for Colorectal Cancer (Invited). Expert Opin Emerg Drugs 13(4):629-42, 2008. e-Pub 2008. PMID: 19046131.
452. Blazer DG, Kish U, Maru DM, Kopetz S, Overman M, Fogelman D, Eng C, Chang DZ, Wang H, Zorzi D, Ribero D, Ellis LM, Glover K, Wolff RA, Curley SA, Abdalla EK, Vauthey JN. Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point after Resection of Hepatic Colorectal Metastases. J Clin Oncol 59(33):5344-51, 2008. e-Pub 2008. PMID: 18936472.
453. Kesmodel SB, Ellis LM, Lin E, Chang GJ, Abdalla EK, Kopetz S, Vauthey JN, Rodriguez-Bigas MA, Curley SA, Feig BW. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol 26(32):5254-60, 2008. e-Pub 2008. PMID: 18854565.
454. Overman MJ, Kopetz S, Wen S, Hoff PM, Fogelman D, Morris J, Abbruzzese JL, Ajani JA, Wolff RA. Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma. Cancer 113(8):2038-45, 2008. e-Pub 2008. PMID: 18759326.
455. Overman MJ, Varadhachary G, Kopetz S, Thomas MB, Fukushima M, Kuwata K, Mita A, Wolff RA, Hoff PM, Xiong H, Abbrizzese JL. Phase I study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. Invest. New Drugs 26(5), 2008. e-Pub 2008. PMID: 18528634.
456. Overman MJ, Kopetz S, Varadhachary G, Fukushima M, Kuwata K, Mita A, Wolff RA, Hoff P, Xiong H, Abbruzzese JL. Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. Cancer Invest 26(8):794-9, 2008. e-Pub 2008. PMID: 18798063.
457. Overman MJ, Fogelman D, Al-Kali A, Crane CH, Evans D, Abdalla EK, Pisters P, Kopetz S, Eng C, Wolff RA. Aggressive combined modality therapy for recurrent colorectal cancer involving the duodenum and pancreas: a report of 5 cases. Clin Colorectal Cancer 7(5):338-42, 2008. e-Pub 2008. PMID: 18794067.
458. Hoff PM, Kopetz S, Thomas MB, Langleben A, Rinaldi D, Anthony L, Wolff RA, Lassere Y, Abbruzzese JL. A phase II study of UFT with leucovorin administered as a twice daily schedule in the treatment of patients with metastatic colorectal cancer. Br J Cancer 99(5):722-6, 2008. e-Pub 2008. PMID: 18728662.
459. Kauffman CR, Mahvash A, Kopetz S, Wolff RA, Ensor J, Wallace MJ. Partial splenic embolization for cancer patients with thrombocytopenia requiring systemic chemotherapy. Cancer 14(10):2283-8, 2008. e-Pub 2008. PMID: 18344210.
460. Kopetz S, Overman M, Chang DZ, Glover KY, Shureiqi I, Wolff RA, Abbruzzese JL, Eng C. Systematic Survey of Therapeutic Trials for Metastatic Colorectal Cancer: Room for Improvement in the Critical Pathway. J Clin Oncol 26(12):2000-5, 2008. e-Pub 2008. PMID: 18421052.
461. Dhillon N, Kopetz S, Pei BL, Fabbro ED, Zhang T, Bruera E. Clinical findings of a palliative care consultation team at a comprehensive cancer center. J Palliat Med 11(2):191-7, 2008. e-Pub 2008. PMID: 18333733.
462. Kopetz S, Freitas D, Calabrichi A, Hoff PM. Adjuvant Chemotherapy for Stage II Colon Cancer (Peer-Reviewed Review). Oncology 22(3):260-70, 2008. e-Pub 2008. PMID: 18494354.
463. Politano S, Overman M, Pathak P, Chadha R, Glover K, Chang DZ, Wolff RA, Hoff PM, Abbruzzese J, Eng C, Kopetz S. Second-Line Chemotherapy Use in Metastatic Colon Cancer Varies by Disease Responsiveness. Clin Colorectal Cancer 1(1):55-9, 2008. e-Pub 2008. PMID: 18279578.
464. Chun YS, Vauthey JN, Ribero D, Donadon M, Mullen JT, Eng C, Madoff DC, Chang DZ, Ho L, Kopetz S, Wei SH, Curley SA, Abdalla EK. Systemic Chemotherapy and Two-Stage Hepatectomy for Extensive Bilateral Colorectal Liver Metastases: Perioperative Safety and Survival. J Gastrointest Surg 11(11):1498-1505, 2007. e-Pub 2007. PMID: 17849166.
465. Kopetz S, Jimenez C, Tu SM, Sharma P. Pulmonary arteriovenous fistula in a patient with renal cell carcinoma. Eur Respir J 29(4):813-5, 2006. e-Pub 2006. PMID: 17400880.
466. Kopetz S. Endothelin-1 as a Target For Therapeutic Intervention in Prostate Cancer (Invited). Invest New Drugs 20:173-82, 2002. e-Pub 2002. PMID: 12099577.
467. Kopetz ES, Magnuson TH, Duncan MD, Bender JS, Lillemoe KD, Gordon TA, Cameron JL, Harmon JW. Complications of neglected cholelithiasis account for significant surgical mortality in the elderly. Surg Forum(52):489-91, 2000. e-Pub 2000.
468. Kopetz S, Steele CD, Brandt J, Baker A, Kronberg M, Galik E, Steinberg M, Warren A, Lyketsos CG. Characteristics and outcomes of dementia residents in an assisted living facility. Int J Geriatr Psychiatry 15(7):586-93, 2000. e-Pub 2000. PMID: 10918338.
469. Cheng MD, Nash TM, Kopetz ES. Retrieval of Aerosol Optical Thickness by Means of the Least-Median-Squares Robust Algorithm. Journal of Aerosol Science 30:805-17, 1999. e-Pub 1999.
470. Walczak WJ, Xiao JM, Kopetz ES, Lease K, Grau H, Lee SP, Han MK, and Knutson JR. Golden Ruler: Very Long-Range Resonance Energy Transfer to Surface Plasmon Acceptors. Biophysical Journal, 72:367, 1997. e-Pub 1997.

Invited Articles

1. Kopetz S. Novel Targets for Systemic Therapy of Colorectal Cancer. Clin Adv Hematol Oncol 6(1):38-40, 2008. e-Pub 2008. PMID: 18322439.
2. Kopetz S. Targeting Src and Epidermal Growth Factor Receptor in Colorectal Cancer: Rationale and Progress Into the Clinic. Gastrointestinal Cancer Research 1:S37-41, 2007. e-Pub 2007.
3. Kopetz S, Hoff PM. Cytotoxic chemotherapy for advanced colorectal cancer. Recent advances in management. Oncology (Williston Park) 19(13 Suppl 6):11-7, 2005. e-Pub 2005. PMID: 16502665.
4. Kopetz S, Kim ES. Adjuvant Chemotherapy in Non-Small Cell Lung Cancer. American Journal of Oncology Review (Pulmonary Supplement):1-4, 2005. e-Pub 2005.

Review Articles

1. Marasco, M, Kumar, D, Garcia Borrego, S, Seale, T, Maddalena, G, Mezzadra, R, Belanger, K, Cole, S, Perez, B, Luan, W, Mukherjee, R, Aricescu, I, Markov, V, Zhu, Y, Arena, S, Bardelli, A, De Stanchina, E, Lowe, SW, Burkhart, RA, Zimmerman, JW, Yaeger, R, Kopetz, S, Rosen, N, Misale, S. Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations. Cancer discovery 15(7):1392-1409, 2025. e-Pub 2025. PMID: 40294008.
2. Singh M, Morris VK, Bandey IN, Hong DS, Kopetz S. Advancements in combining targeted therapy and immunotherapy for colorectal cancer. Trends Cancer 10(7):598-609, 2024. e-Pub 2024. PMID: 38821852.
3. Loree, JM, Dasari, NV, Willis, JA, Gothwal, H, Shaheed, M, Singh, K, Shaheed, H, Mangal, R, Gothwal, S, Pant, A, Overman, MJ, Kopetz, S, Raghav, KS. Racial/ethnic representation and disparities in preclinical cancer models. Journal of Clinical Oncology 42:1601, 2024. e-Pub 2024.
4. Morris, VK, Guthrie, KA, Kopetz, S, Breakstone, R, Karasic, TB, Hu, Z, Colby, S, Fakih, MG, Gholami, S, Gold, PJ, Philip, PA. SWOG S2107. Journal of Clinical Oncology 42:TPS234-TPS234, 2024. e-Pub 2024.
5. Loree, JM, Bubie, A, Eluri, M, Parseghian, C, Overman, MJ, Zhang, N, Drusbosky, L, Kopetz, S, Raghav, KS. Clinical utility of serial circulating tumor DNA (ctDNA) to identify acquired resistance to anti-EGFR antibodies in metastatic colorectal cancer (mCRC). Journal of Clinical Oncology 42:158, 2024. e-Pub 2024.
6. Maddalena, G, van der Pol, Y, Rivers, Z, Dasari, NV, Rogers, JE, Guinney, J, Kopetz, S, Raghav, KS. Impact of KRAS codon-specific mutations on survival of patients with metastatic CRC (mCRC) treated with trifluridine-tipiracil (TAS) plus bevacizumab (Bev). Journal of Clinical Oncology 42:201, 2024. e-Pub 2024.
7. Pellatt, AJ, Maddalena, G, Eluri, M, Parseghian, C, Aziz, KE, Alfaro, KD, Kell, R, Bent, AH, Huey, RW, Uppal, A, Konishi, T, Overman, MJ, Morelli, MP, Willis, JA, Shen, JY, Raghav, KS, Newhook, TE, Morris, VK, Dasari, NV, Kopetz, S. Redefining the prognostic significance of RAS and BRAF V600E mutations on disease free survival in patients with colorectal cancer in the era of ct-DNA defined minimal residual disease. Journal of Clinical Oncology 42:196, 2024. e-Pub 2024.
8. Uppal, A, Bhutiani, N, Shen, JY, Alfaro, KD, Kell, R, Yousef, M, Yousef, A, Konishi, T, Holliday, EB, Morris, VK, Dasari, NV, Willis, JA, Newhook, TE, Bednarski, BK, You, YN, Peacock, O, Messick, C, Das, P, Chang, GJ, Kopetz, S. Association of pathologic nodal status with minimal residual disease after neoadjuvant treatment and resection of locally advanced rectal cancer. Journal of Clinical Oncology 42:205, 2024. e-Pub 2024.
9. Bhamidipati, D, Haro-Silerio, JI, Ileana Dumbrava, EE, Fu, S, Hong, DS, Karp, DD, Naing, A, Pant, S, Piha-Paul, SA, Rodon Ahnert, J, Tsimberidou, AM, Johnson, A, Lee, MS, Dasari, NV, Raghav, KS, Morris, VK, Overman, MJ, Kopetz, S, Meric-Bernstam, F, Yap, TA. Clinical characterization and therapeutic outcomes of patients (pts) with colorectal cancer (CRC) harboring somatic BRCA1/2 mutations. Journal of Clinical Oncology 42:134, 2024. e-Pub 2024.
10. Villarreal OE, Kopetz S. EMP1+ tumor cells drive metastatic relapse. Cell research 33(5):337-338, 2023. e-Pub 2023. PMID: 36646758.
11. Bose S, Barroso M, Chheda MG, Clevers H, Elez E, Kaochar S, Kopetz SE, Li XN, Meric-Bernstam F, Meyer CA, Mou H, Naegle KM, Pera MF, Perova Z, Politi KA, Raphael BJ, Robson P, Sears RC, Tabernero J, Tuveson DA, Welm AL, Welm BE, Willey CD, Salnikow K, Chuang JH, Shen X. A path to translation: How 3D patient tumor avatars enable next generation precision oncology. Cancer Cell 40(12):1448-1453, 2022. e-Pub 2022. PMID: 36270276.
12. Morris VK, Kopetz S. Don't blame the messenger: lessons learned for cancer mRNA vaccines during the COVID-19 pandemic. Nat Rev Cancer 22(6):317-318, 2022. e-Pub 2022. PMID: 35277674.
13. Bent A, Raghavan S, Dasari A, Kopetz S. The Future of ctDNA-Defined Minimal Residual Disease: Personalizing Adjuvant Therapy in Colorectal Cancer. Clin Colorectal Cancer 21(2):89-95, 2022. e-Pub 2022. PMID: 35450837.
14. Menter DG, Afshar-Kharghan V, Shen JP, Martch SL, Maitra A, Kopetz S, Honn KV, Sood AK. Of vascular defense, hemostasis, cancer, and platelet biology: an evolutionary perspective. Cancer Metastasis Rev 41(1):147-172, 2022. e-Pub 2022. PMID: 35022962.
15. Wan JCM, Mughal TI, Razavi P, Dawson SJ, Moss EL, Govindan R, Tan IB, Yap YS, Robinson WA, Morris CD, Besse B, Bardelli A, Tie J, Kopetz S, Rosenfeld N. Liquid biopsies for residual disease and recurrence. Med (N Y) 2(12):1292-1313, 2021. e-Pub 2021. PMID: 35590147.
16. Kanikarla Marie P, Fowlkes NW, Afshar-Kharghan V, Martch SL, Sorokin A, Shen JP, Morris VK, Dasari A, You N, Sood AK, Overman MJ, Kopetz S, Menter DG. The Provocative Roles of Platelets in Liver Disease and Cancer. Front Oncol 11:643815, 2021. e-Pub 2021. PMID: 34367949.
17. Johnson B, Kopetz S. Applying Precision to the Management of BRAF-Mutant Metastatic Colorectal Cancer. Target Oncol 15(5):567-577, 2020. e-Pub 2020. PMID: 32889679.
18. Dragomir MP, Kopetz S, Ajani JA, Calin GA. Non-coding RNAs in GI cancers: from cancer hallmarks to clinical utility. Gut 69(4):748-763, 2020. e-Pub 2020. PMID: 32034004.
19. Calandri M, Siravegna G, Yevich SM, Stranieri G, Gazzera C, Kopetz S, Fonio P, Gupta S, Bardelli A, Veltri A, Odisio BC. Liquid biopsy, a paradigm shift in oncology: what interventional radiologists should know. Eur Radiol. e-Pub 2020. PMID: 32193642.
20. Parseghian CM, Napolitano S, Loree JM, Kopetz S. Mechanisms of Innate and Acquired Resistance to Anti-EGFR Therapy: A Review of Current Knowledge with a Focus on Rechallenge Therapies. Clin Cancer Res 25(23):6899-6908, 2019. e-Pub 2019. PMID: 31263029.
21. Batth IS, Mitra A, Rood S, Kopetz S, Menter D, Li S. CTC analysis: an update on technological progress. Transl Res 212:14-25, 2019. e-Pub 2019. PMID: 31348892.
22. Inoue A, Deem AK, Kopetz S, Heffernan TP, Draetta GF, Carugo A. Current and Future Horizons of Patient-Derived Xenograft Models in Colorectal Cancer Translational Research. Cancers (Basel) 11(9), 2019. e-Pub 2019. PMID: 31500168.
23. Sveen A, Kopetz S, Lothe RA. Biomarker-guided therapy for colorectal cancer: strength in complexity. Nat Rev Clin Oncol. e-Pub 2019. PMID: 31289352.
24. Advani S, Kopetz S. Ongoing and future directions in the management of metastatic colorectal cancer: Update on clinical trials. J Surg Oncol 119(5):642-652, 2019. e-Pub 2019. PMID: 30852840.
25. Menter DG, Davis JS, Broom BM, Overman MJ, Morris J, Kopetz S. Back to the Colorectal Cancer Consensus Molecular Subtype Future. Curr Gastroenterol Rep 21(2):5, 2019. e-Pub 2019. PMID: 30701321.
26. Raghav K, Bailey AM, Loree JM, Kopetz S, Holla V, Yap TA, Wang F, Chen K, Salgia R, Hong D. Untying the gordion knot of targeting MET in cancer. Cancer Treat Rev 66:95-103, 2018. e-Pub 2018. PMID: 29730462.
27. Yamashita S, Chun YS, Kopetz SE, Vauthey JN. Biomarkers in colorectal liver metastases. Br J Surg 105(6):618-627, 2018. e-Pub 2018. PMID: 29579319.
28. Kanikarla-Marie P, Lam M, Sorokin AV, Overman MJ, Kopetz S, Menter DG. Platelet Metabolism and Other Targeted Drugs; Potential Impact on Immunotherapy. Front Oncol 8:107, 2018. e-Pub 2018. PMID: 29732316.
29. Loree JM, Kopetz S. Recent developments in the treatment of metastatic colorectal cancer. Ther Adv Med Oncol 9(8):551-564, 2017. e-Pub 2017. PMID: 28794806.
30. Menter DG, Kopetz S, Hawk E, Sood AK, Loree JM, Gresele P, Honn KV. Platelet "first responders" in wound response, cancer, and metastasis. Cancer Metastasis Rev. e-Pub 2017. PMID: 28730545.
31. Lam M, Roszik J, Kanikarla-Marie P, Davis JS, Morris J, Kopetz S, Menter DG. The potential role of platelets in the consensus molecular subtypes of colorectal cancer. Cancer Metastasis Rev. e-Pub 2017. PMID: 28681242.
32. Kanikarla-Marie P, Lam M, Menter DG, Kopetz S. Platelets, circulating tumor cells, and the circulome. Cancer Metastasis Rev. e-Pub 2017. PMID: 28667367.
33. Lee MS, Menter DG, Kopetz S. Right Versus Left Colon Cancer Biology: Integrating the Consensus Molecular Subtypes. J Natl Compr Canc Netw 15(3):411-419, 2017. e-Pub 2017. PMID: 28275039.
34. Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer 17(2):79-92, 2017. e-Pub 2017. PMID: 28050011.
35. Loree JM, Kopetz S, Raghav KP. Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pie. J Gastrointest Oncol 8(1):199-212, 2017. e-Pub 2017. PMID: 28280626.
36. Batth IS, Mitra A, Manier S, Ghobrial IM, Menter D, Kopetz S, Li S. Circulating Tumor Markers: Harmonizing the yin and yang of CTCs and ctDNA for precision medicine. Ann Oncol. e-Pub 2016. PMID: 27998963.
37. Lee MS, Kopetz S. Current and Future Approaches to Target the Epidermal Growth Factor Receptor and Its Downstream Signaling in Metastatic Colorectal Cancer. Clin Colorectal Cancer 14(4):203-18, 2015. e-Pub 2015. PMID: 26077270.
38. Clarke CN, Kopetz ES. BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies. J Gastrointest Oncol 6(6):660-7, 2015. e-Pub 2015. PMID: 26697199.
39. Chen T, Sun Y, Ji P, Kopetz S, Zhang W. Topoisomerase IIα in chromosome instability and personalized cancer therapy. Oncogene 34(31):4019-31, 2015. e-Pub 2015. PMID: 25328138.
40. Ihle NT, Powis G, Kopetz ES. PI-3-Kinase Inhibitors in Colorectal Cancer (Peer-reviewed Review). Curr Cancer Drug Targets 11(2):190-8, 2011. e-Pub 2011. PMID: 21158718.
41. Kim MP, Park SI, Kopetz S, Gallick GE. Src family kinases as mediators of endothelial permeability: effects on inflammation and metastasis. Cell Tissue Res 1(335):249-59, 2009. e-Pub 2009. PMID: 18815812.

Professional Educational Materials

1. Kopetz ES. Etiology and Management of Bowel Perforation in Patients with Colorectal Cancer” Gastrointestinal Malignancies: Putting Theory Into Practice at M. D. Anderson. M. D. Anderson, 2007.

Editorials

1. Haldar, SD, Kopetz, S. Dual checkpoint blockade for microsatellite instability-high colorectal cancer. The Lancet 405(10476):354-356, 2025. PMID: 39874978.
2. Fedirko V, Kopetz S, Daniel CR. Diverticular disease and cancer risk: More than a gut feeling. Journal of the National Cancer Institute 115(1):12-13, 2023. PMID: 36200895.
3. Lee MS, Kopetz S. Are Homologous Recombination Deficiency Mutations Relevant in Colorectal Cancer?. J Natl Cancer Inst 114(2):176-178, 2022. PMID: 34469539.
4. W-C L, Kopetz S, Wistuba II, Zhang J. Metastasis of cancer: when and how?. Annals of Oncology 28(9):2045–2047, 2017.
5. Morris JS, Kopetz S. Tumor Microenvironment in Gene Signatures: Critical Biology or Confounding Noise?. Clin Cancer Res. PMID: 27334836.
6. Davies MA, Kopetz S. Overcoming resistance to MAPK pathway inhibitors. J Natl Cancer Inst 105(1):9-10, 2013. PMID: 23250957.
7. Morelli MP, Kopetz S. Hurdles and complexities of codon 13 KRAS mutations. J Clin Oncol 30(29):3565-7, 2012. PMID: 22927534.
8. Kopetz S, Lemos R, Powis G. The promise of patient-derived xenografts: the best laid plans of mice and men 18(19):5160-2, 2012. PMID: 22912394.
9. Kopetz S, Abbruzzese J. Barriers to Integrating Gene Profiling for Stage II Colon Cancer. Clinical Cancer Research 15(24), 2009. PMID: 19996205.
10. Eng C, Kopetz S. Commentary: Practice Patterns and Potential Impact on Quality Measurements for a Practicing Physician. Journal of Oncology Practice 5(5):233-5, 2009.
11. Overman M, Kopetz S. Picking the Right Road for Metastatic Colorectal Cancer Patients. Oncology 22(13):1482-3, 2008. PMID: 19227576.
12. Kopetz S, Vauthey JN. Perioperative chemotherapy for resectable hepatic metastases. Lancet 371(9617):963-5, 2008. PMID: 18358910.

Abstracts

1. Takeda M, Yang Z, Theardy MS, Sorokin A, Coker O, Chen S, Vien LT, Bover L, Ying H, Kopetz S, Yao W. Syndecan 1 is a therapeutic target for KRAS-driven pancreatic cancer. AACR Annual Meeting 2024 84(17), 2024. e-Pub 2024.
2. Singh Raghav KP, Xiao L, Lewis C, Zeller BE, Overman MJ, Huey RW, Dasari A, Chang K, Quinn K, YC Shen JP, Parseghian CM, Willis J, Ludford K, Van K Morris II, Wolff RA, Wang XS, Drusbosky L, Kopetz S. A randomized study evaluating tailoring of advanced/metastatic colorectal cancer (mCRC) therapy using circulating tumor DNA (ctDNA): TACT-D. 2024 ASCO Annual Meeting 42(17), 2024. e-Pub 2024.
3. Loree JM, Dasari A, Willis J, Gothwal H, Shaheed M, Singh K, Shaheed H, Mangal R, Gothwal S, Pant A, Overman MJ, Kopetz S, Singh Raghav KP. Racial/ethnic representation and disparities in preclinical cancer models. 2024 ASCO Annual Meeting 42(16), 2024. e-Pub 2024.
4. LaPelusa MB, San Lucas FA, Iorgulescu B, Patel KP, You Y, Foo WC, Maru DM, Kopetz S, Ludford K, Van K Morris II, Overman MJ. Circulating tumor DNA as a predictive biomarker for pathologic response after treatment with neoadjuvant immunotherapy for localized dMMR/MSI-H colorectal cancer. 2024 ASCO Annual Meeting 42(16), 2024. e-Pub 2024.
5. Parikh AR, Chiorean E, Atreya CE, Zheng L, Kopetz S, Spira AI, Spigel DR, Cui Y, Osgood R, Tran R, Morris SR, Ulahannan SV. Updated results from ERAS-007 plus encorafenib and cetuximab (EC) in patients (pts) with EC-naïve metastatic BRAF V600E colorectal cancer (CRC) in the phase 1b/2 HERKULES-3 study. 2024 ASCO Annual Meeting 42(16), 2024. e-Pub 2024.
6. Kopetz S, Boni V, Kato K, Raghav K, Pallis A, Habermehl C, Galipelli S, Courlet P, Rivera I. First-in-human trial of M9140, an anti-CEACAM5 antibody drug conjugate (ADC) with exatecan payload, in patients (pts) with metastatic colorectal cancer (mCRC). 2024 ASCO Annual Meeting 42(16), 2024. e-Pub 2024.
7. Pellatt AJ, Maddalena G, Bent AH, Parseghian CM, Huey RW, Singh Raghav KP, Van K Morris II, Overman MJ, Morelli MP, Willis J, Le P, YC Shen JP, Alfaro K, Aziz K, Kell RJ, Sun R, Kopetz S, Dasari A. A phase II trial of TAS-102 in patients with colorectal cancer with ctDNA-defined minimal residual disease post-adjuvant therapy compared to synthetic control cohort: Results from the MD Anderson INTERCEPT program. 2024 ASCO Annual Meeting 42(16), 2024. e-Pub 2024.
8. Wainberg ZA, Han S, Lee S, Lee K, Kopetz S, Mizrahi J, Hong YS, Ghiringhelli F, Italiano A, Tougeron D, Beagle B, Boakye M, Zhao T, Rhee J, A Nuyten DS, Cecchini M. ARC-9: A randomized study to evaluate etrumadenant based treatment combinations in previously treated metastatic colorectal cancer (mCRC). 2024 ASCO Annual Meeting 42(16), 2024. e-Pub 2024.
9. Eluri M, Sun R, Bubie A, Alshenaifi J, Zhang N, Drusbosky L, Parseghian CM, Singh Raghav KP, Kopetz S. Characterization of mutational signatures demonstrating adaptive mutability post anti-EGFR therapy in a real-world metastatic colorectal cancer cohort. 2024 ASCO Annual Meeting 42(16), 2024. e-Pub 2024.
10. Bahrambeigi V, Lee JJ, Branchi V, Rajapakshe KI, Xu Z, Kui N, Henry JT, Kun W, Stephens BM, Dhebat S, Hurd MW, Sun R, Yang P, Ruppin E, Wang W, Kopetz S, Maitra A, Guerrero PA. Transcriptomic Profiling of Plasma Extracellular Vesicles Enables Reliable Annotation of the Cancer-Specific Transcriptome and Molecular Subtype. AACR Annual Meeting 2024 84(10):1719–1732, 2024. e-Pub 2024.
11. Loree JM, Dasari A, Shaheed M, Gothwal H, Singh K, Shaheed H, Mangal R, Gothwal S, Willis J, Overman MJ, Kopetz S, Singh Raghav KP. Racial and ethnic representation and disparities on clinical guideline panels in oncology. AACR Annual Meeting 2024 84(6), 2024. e-Pub 2024.
12. Hornstein NJ, Wang M, Yousef A, Chowdhury S, Zeineddine F, Zeineddine M, Yousef M, You S, Gunes B, Menter D, Kopetz S, Shen JP. Cell-type-specific gene programs suggest immune and stromal drivers of relapse in colorectal cancer. AACR Annual Meeting 2024 84(6), 2024. e-Pub 2024.
13. Villarreal OE, Lee HM, Tran H, Machado A, Alshenaifi J, Wong CW, Coker O, Minelli R, Peoples M, Martinez AH, Fowlkes N, Kanikarla P, Lin K, Bristow C, Viale A, Marszalek JR, Shen JP, Kopetz S. ASCL2+ tumor cells modulate the response of colorectal cancer to MAPK targeting therapy. AACR Annual Meeting 2024 84(6), 2024. e-Pub 2024.
14. Johnson CW, Terrell EM, Cook J, Shui B, O'Donoghue E, Hull S, Yang MH, Sheth S, Yaeger R, Kopetz S, Morrison DK, Haigis K. Ala59 mutants of KRAS cooperate with Nf1 loss to enhance colon tumorigenesis. AACR Annual Meeting 2024 84(6), 2024. e-Pub 2024.
15. Coker O, Sorokin A, Akhave N, Pan K, Gao F, Liu Z, Kanikarla P, Lee H, Villarreal O, Alshenaifi J, Maddalena G, Mohamed A, Prescod D, Menter D, Chowdury S, Corcoran R, Rai K, Hong D, Kopetz S. YAP-TAZ-TEAD transcriptional program is a prominent driver of acquired resistance to KRASG12C-based therapies in patients with metastatic colorectal cancer. AACR Annual Meeting 2024 84(6), 2024. e-Pub 2024.
16. Whitehead CE, Ziemke EK, Frankowski-McGregor CL, Mumby RA, Chung J, Li J, Osher N, Coker O, Norris M, Kopetz S, Baladandayuthapani V, Hollingshead M, Verma S, Sebolt-Leopold JS. MTX-531, a first-in-class pan-PI3K inhibitor spares hyperinsulinemia yielding durable tumor regressions and resilience to adaptive resistance. AACR Annual Meeting 2024 84(6), 2024. e-Pub 2024.
17. Cho KS, Jiang J, Zhang D, Liu Y, Chen J, Segura RL, Yan X, Pei G, Soto LM, Chu Y, Sinjab AF, Yee C, Kopetz S, Maitra A, Futreal A, Lazar A, Jazaeri AA, Kadara H, Gao J, Li M, Wang L. iStarTLS: Advanced detection and phenotyping of tertiary lymphoid structures. AACR Annual Meeting 2024 84(6), 2024. e-Pub 2024.
18. der Pol YV, Yilma B, Morris VK, Chao C, Harris M, Guinney J, Kopetz S. Molecular characterization of microsatellite stable (MSS) colorectal cancer (CRC) patients with a BRAF V600E mutation. AACR Annual Meeting 2024 84(6), 2024. e-Pub 2024.
19. Villarreal OE, Xiao L, Allam J, Sorokin A, Yuan Y, Kopetz S, Raghav KP. Clinical efficacy and safety of HER2 targeted therapy in patients with metastatic colorectal cancer: A systematic review and meta-analysis. AACR Annual Meeting 2024 84(6), 2024. e-Pub 2024.
20. Peng DH, Tedeschi A, Herdeis L, Schaaf O, Savarese F, Rocchetti F, Popow J, Huber HJ, Wilding B, Treu M, Fuchs J, Bröeker J, Wunberg T, Schischlik F, Lipp J, Williams M, Chandler V, Deckard CE, Ramamoorthy V, Daniele JR, Kopetz S, Kim M, Gibbons DL, Vellano CP, Marszalek JR, Heffernan TP, McConnell D, Pearson M, Kraut N, Rudolph D. KRASmulti inhibitor BI 3706674, an orally bioavailable, direct inhibitor of diverse oncogenic KRAS variants drives tumor regression in KRASG12V-driven preclinical models. AACR Annual Meeting 2024 84(6), 2024. e-Pub 2024.
21. Chu Y, Cho KS, Khanduri I, Zhou T, Jiang J, Liu Y, Yan X, Pei G, Dai Y, Liu Y, Wang R, Jadhav AS, Hernandez S, Kadara H, Solis Soto LM, Kopetz S, Maru DM, Wang L. SpatialCS: A tool to effectively integrate histological annotations and spatial transcriptomics analysis. AACR Annual Meeting 2024 84(6), 2024. e-Pub 2024.
22. Chowdhury S, Ahmed J, Haridas V, Hong DS, Kopetz S, Shen JP. Activating PIK3CA mutations and hedgehog signaling may confer resistance to KRAS inhibition in colorectal cancer. AACR Annual Meeting 2024 84(6), 2024. e-Pub 2024.
23. Negrao MV, Molkentine D, Paula AG, Hover L, Nilsson M, Vokes N, Engstrom L, Calinisan A, Waters L, Briere DM, Hallin J, Blumenschein GR, Skoulidis F, Kopetz SE, Hong DS, Gibbons DL, Olson P, Christensen J, Heymach JV. Impact of KEAP1/STK11 co-mutations and NRF2 signaling on resistance to adagrasib in advanced NSCLC. AACR Annual Meeting 2024 84(6), 2024. e-Pub 2024.
24. Ridinger M, Marie PK, Gao F, Liu Z, Maddalena G, Menter D, Sorokin A, Smeal T, Kopetz S. The PLK1 inhibitor, onvansertib, is active as monotherapy and in combination with cetuximab in RAS wild-type colorectal cancer patient-derived xenografts. AACR Annual Meeting 2024 84(6), 2024. e-Pub 2024.
25. Lee HM, Saw AK, Morris VK, Singh AK, Napolitano S, Sorokin A, Marie PK, Coker O, Villarreal OE, Anvar NE, Rai K, Kopetz S. Elevated H3K27 trimethylation mediates adaptation to DNA demethylation in BRAFV600E-mutated colorectal cancer. AACR Annual Meeting 2024 84(6), 2024. e-Pub 2024.
26. Mohamed AM, Cho KS, Soeung M, Anderson A, Alshenaifi J, Manyam G, Villareal O, Davis J, Norton W, Gao S, Bristow C, Carbone F, Napolitano S, Coker O, Khanduri I, Huang J, Maru DM, Pilato MD, Sun R, Wang L, Menter DG, Genovese G, Draetta G, Fowlkes N, Kopetz S. Anti-CSF1R antibody monotherapy inhibits minimal residual disease in a novel immunocompetent murine colorectal cancer metastasis model. AACR Annual Meeting 2024 84(6), 2024. e-Pub 2024.
27. Dasari A, Yu G, Kopetz S, Puhalla SL, Lucas PC, Halil Sahin IH, Deming DA, Philip PA, Hong TS, Rojas-Khalil Y, Loree JM, Wolmark N, Yothers G, George TJ, Lieu CH. Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-NORTH AMERICA): NRG-GI008. 2024 ASCO Annual Meeting 42(3), 2024. e-Pub 2024.
28. Maddalena G, der Pol YV, Rivers Z, Dasari A, Rogers JE, Guinney J, Kopetz S, Singh Raghav KP. Impact of KRAS codon-specific mutations on survival of patients with metastatic CRC (mCRC) treated with trifluridine-tipiracil (TAS) plus bevacizumab (Bev): A real-world analysis. 2024 ASCO Gastrointestinal Cancers Symposium 42(3), 2024. e-Pub 2024.
29. Pellatt AJ, Maddalena G, Eluri M, Parseghian CM, Aziz K, Alfaro K, Kell RJ, Bent AH, Huey RW, Uppal A, Konishi T, Overman MJ, Morelli MP, Willis J, YC Shen JP, Singh Raghav KP, Newhook TE, Morris VK, Dasari A, Kopetz S. Redefining the prognostic significance of RAS and BRAF V600E mutations on disease free survival in patients with colorectal cancer in the era of ct-DNA defined minimal residual disease: Results from the MD Anderson INTERCEPT Program. 2024 ASCO Gastrointestinal Cancers Symposium 42(3), 2024. e-Pub 2024.
30. Loree JM, Bubie A, Eluri M, Parseghian CM, Overman MJ, Zhang N, Drusbosky L, Kopetz S, Singh Raghav KP. Clinical utility of serial circulating tumor DNA (ctDNA) to identify acquired resistance to anti-EGFR antibodies in metastatic colorectal cancer (mCRC). 2024 ASCO Gastrointestinal Cancers Symposium 42(3), 2024. e-Pub 2024.
31. Higbie V, Shah P, Bent AH, Dasari A, Huey RW, Johnson B, Kee BK, Kopetz S, Lee MS, Ludford K, Morelli MP, Morris VK, Parseghian CM, Singh Raghav KP, YC Shen JP, Willis J, Wolff RA, Overman MJ. Natural history and patterns of progression for dMMR/MSI-H colorectal cancer treated with immune checkpoint blockade: A single center retrospective analysis. 2024 ASCO Gastrointestinal Cancers Symposium 42(3), 2024. e-Pub 2024.
32. Parseghian CM, Lee JK, Quintanilha J, Schrock AB, Graf R, Pasquina L, Sivakumar S, Oxnard GR, Tukachinsky H, Klempner SJ, Kopetz S. Novel potential mechanisms of acquired resistance to anti-EGFR monoclonal antibody (mAb) therapy detected in liquid biopsies (LBx) from patients (pts) with advanced colorectal cancer (CRC). 2024 ASCO Gastrointestinal Cancers Symposium 42(3), 2024. e-Pub 2024.
33. Uppal A, Bhutiani N, YC Shen JP, Alfaro K, Kell RJ, Yousef MM, Yousef AM, Konishi T, Holliday E, Morris VK, Dasari A, Willis J, Newhook TE, Bednarski BK, You Y, Peacock O, Messick C, Das P, Chang GJ, Kopetz S. Association of pathologic nodal status with minimal residual disease after neoadjuvant treatment and resection of locally advanced rectal cancer. 2024 ASCO Gastrointestinal Cancers Symposium 42(3), 2024. e-Pub 2024.
34. White M, Damania A, Alshenaifi J, Sahasrabhojane P, Peacock O, Losh J, Wong MC, Berkova Z, Nguyen ST, Chang GJ, Wargo JA, Ajami NJ, Kopetz S, You Y. Tumoral microbial and pathway alterations associated with young-onset rectal cancer and its response to therapy. 2024 ASCO Gastrointestinal Cancers Symposium 42(3), 2024. e-Pub 2024.
35. Yousef MM, Yousef AM, Fanaeian MM, Chowdhury S, Knafl M, Zeineddine M, Alfaro K, Uppal A, Sun R, Wang W, Singh Raghav KP, Willis J, Kopetz S, YC Shen JP. Understanding causes of racial/ethnic survival disparity in 47,178 patients with colorectal cancer: A quantitative evaluation of molecular, socioeconomic, and clinical covariates. 2024 ASCO Gastrointestinal Cancers Symposium 42(3), 2024. e-Pub 2024.
36. Van K Morris II, Guthrie KA, Kopetz S, Breakstone R, Karasic TB, Hu ZI, Colby S, Fakih M, Gholami S, Gold PJ, Chiorean E, Philip PA. SWOG S2107: Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer. 2024 ASCO Annual Meeting 42(3), 2024. e-Pub 2024.
37. Overman MJ, Yothers G, Jacobs SA, Sanoff HK, Cohen DJ, Guthrie KA, Henry NL, Ganz PA, Kopetz S, Lucas PC, Blanke CD, Hong TS, Wolmark N, Hochster HS, George TJ, Rocha Lima CMSP. Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC)—NRG-GI004/SWOG-S1610. 2024 ASCO Gastrointestinal Cancers Symposium 42(3), 2024. e-Pub 2024.
38. Maddalena G, Pellatt AJ, Eluri M, Parseghian CM, Aziz K, Alfaro K, Kell RJ, Bent AH, Huey RW, Uppal A, Konishi T, Overman MJ, Morelli MP, Willis J, YC Shen JP, Singh Raghav KP, Newhook TE, Morris VK, Dasari A, Kopetz S. INTERCEPT Program of circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) in colorectal cancer (CRC): Results from a prospective clinical cohort. 2024 ASCO Gastrointestinal Cancers Symposium 42(3), 2024. e-Pub 2024.
39. Lieu CH, Yu G, Kopetz S, Puhalla SL, Lucas PC, Sahin IH, Deming DA, Philip PA, Hong TS, Rojas-Khalil Y, Loree JM, Wolmark N, Yothers G, George TJ, Dasari A. NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-NORTH AMERICA). 2024 ASCO Gastrointestinal Cancers Symposium 42(3), 2024. e-Pub 2024.
40. Kasi PM, Rivero S, Aushev VN, Langer N, Wang CG, Cannon TL, Berim LD, Feinstein T, Grothey A, McCollom JW, Kalmadi SR, Zakari A, Dayyani F, Gravenor D, Meyer JM, Sharif S, Jurdi AA, Liu MC, Aleshin A, Kopetz S. Patient-reported outcomes from the BESPOKE CRC study. 2024 ASCO Gastrointestinal Cancers Symposium 42(3), 2024. e-Pub 2024.
41. Kasi PM, Aushev VN, Ensor J, Langer N, Wang CG, Cannon TL, Berim LD, Feinstein T, Grothey A, McCollom JW, Kalmadi SR, Zakari A, Dayyani F, Gravenor D, Meyer JM, Sharif S, Jurdi AA, Liu MC, Aleshin A, Kopetz S. Circulating tumor DNA (ctDNA) for informing adjuvant chemotherapy (ACT) in stage II/III colorectal cancer (CRC): Interim analysis of BESPOKE CRC study. 2024 ASCO Gastrointestinal Cancers Symposium 42(3), 2024. e-Pub 2024.
42. Bhutiani N, Johnson B, Kopetz S, White M, Willis J, Morris VK, Chang GJ, Uppal A. Immune checkpoint blockade combined with targeted therapies to provide disease control in mismatch repair-proficient colorectal cancer with peritoneal metastases. 2024 ASCO Gastrointestinal Cancers Symposium 42(3), 2024. e-Pub 2024.
43. Takeda M, Sorokin A, Theardy M, Coker O, Kopetz S, Ying H, Draetta G, DePinho RA, Yao W. Targeting Syndecan1 to overcome acquired resistant to KRAS inhibitor in gastrointestinal cancer. AACR 84(2), 2024.
44. Kopetz S, Yoshino T, Kim TW, Wasan HS, Cutsem EV, Ciardiello F, Maughan TS, Eng C, Yaeger R, Desai J, Zhang X, Usari T, Mori A, Tabernero J. BREAKWATER: An open-label, multicenter, randomized, phase 3 study, with a safety lead-in (SLI), of first-line (1L) encorafenib (E) + cetuximab (C) ± chemotherapy (CT) vs standard-of-care (SOC) CT for BRAF V600E-mutant metastatic colorectal cancer (mCRC). 2023 ASCO Annual Meeting 41(16), 2023. e-Pub 2023.
45. Morris VK, Yothers G, Kopetz S, Puhalla SL, Lucas PC, Iqbal A, Boland PM, Deming DA, Scott AJ, Lim HJ, Jacobs SA, Hong TS, Wolmark N, George TJ. Phase II results of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA) phase II/III study. 2024 ASCO Gastrointestinal Cancers Symposium 41(16), 2023. e-Pub 2023.
46. Sorokin A, Marie PK, Gao F, Liu Z, Menter D, Kopetz S. A novel PDX-based 2-stage screening platform can identify active drug combinations against KRAS-mutated colorectal cancer. AACR Annual Meeting 2023 83(8), 2023. e-Pub 2023.
47. Johnson B, Haymaker C, Morris VK, Dasari A, Higbie VS, Shen JP, Parseghian C, Morelli MP, Huey R, Lee MS, Willis J, Raghav KP, Yuan Y, Zebala J, DePinho RA, Kopetz S, Overman M. A phase I/II trial of a CXCR1/2 inhibitor in combination with anti-PD-1 for circulating tumor DNA (ctDNA) positive & refractoryRAS-mutated microsatellite stable (MSS) colorectal cancer. AACR Annual Meeting 2023 83(8), 2023. e-Pub 2023.
48. Guo S, Cheng X, Koval A, Ji S, Liang Q, Li Y, Owen LA, Kim IK, Weinstein J, Kopetz S, Shen JP, DeAngelis MM, Chen R, Wang W. Integration with benchmark data of paired bulk and single-cell RNA sequencing data substantially improves the accuracy of bulk tissue deconvolution. AACR Annual Meeting 2023 83(7), 2023. e-Pub 2023.
49. Ding S, Marie PK, Zhang R, Bohn A, Moseley RM, Baro N, Brown D, Pittman K, Paduch M, Hsu D, Kopetz S, Shen X. Evaluating targeted therapy combination for refractory colorectal cancer using MicroOrganoSpheres (MOS). AACR Annual Meeting 2023 83(7), 2023. e-Pub 2023.
50. Mohamed AM, Soeung M, Alshenaifi J, Fowlkes N, Manyam G, Davis J, Anderson A, Norton W, Deem AK, Gao S, Khanduri I, Bistow C, Carbone F, Napolitano S, Huang J, Maru DM, Menter DG, Draetta GF, Genovese G, Kopetz S. Recapitulating metastatic colorectal cancer in somatic mutation models for investigating the tumor immune microenvironment in minimal residual disease. AACR Annual Meeting 2023 83(7), 2023. e-Pub 2023.
51. Lee HM, Sorokin A, Marie PK, Chowdhury S, Singh A, Anderson A, Alshenaifi JY, Meric-Bernstam F, Rai K, Kopetz S. Combining bromodomain and extraterminal (BET) protein inhibitor treatment with standard MAPK inhibitors improved MAPK signaling inhibition in colorectal cancer. AACR Annual Meeting 2023 83(7), 2023. e-Pub 2023.
52. Jiang Y, Yu K, Montierth MD, Ji S, Shin SJ, Guo S, Cao S, Tang Y, Kopetz S, Msaouel P, Wang JR, Kimmel M, Loo PV, Zhu H, Wang W. Pan-cancer analysis of intra-tumor heterogeneity in 9,116 cancers using a novel regularized likelihood model. AACR Annual Meeting 2023 83(7), 2023. e-Pub 2023.
53. Lee HM, Sorokin A, Marie PK, Chowdhury S, Singh A, Anderson A, Alshenaifi JY, Meric-Bernstam F, Rai K, Kopetz S. Combining bromodomain and extraterminal (BET) protein inhibitor treatment with standard MAPK inhibitors improved MAPK signaling inhibition in colorectal cancer. AACR Annual Meeting 2023 83(7), 2023. e-Pub 2023.
54. Rocha Lima CMSP, Yothers G, Puhalla SL, Sanoff HK, Cohen DJ, Guthrie KA, Henry NL, Ganz PA, Kopetz S, Lucas PC, Blanke CD, Jacobs SA, Hong TS, Wolmark N, Hochster HS, George TJ, Overman MJ. NRG-GI004/SWOG-S1610: Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC). 2023 ASCO Gastrointestinal Cancers Symposium 41(4), 2023. e-Pub 2023.
55. Cohen SA, Kasi PM, Aushev VN, Hanna DL, Botta GP, Sharif S, Georgios I Laliotis MD, PhD, Sharma VR, Alqahtani A, Chandana SR, Kang S, Chakrabarti S, Somer BG, Kasi A, Dayyani F, Malla M, Jurdi AA, Liu MC, Aleshin A, Kopetz S. Kinetics of postoperative circulating cell-free DNA and impact on minimal residual disease detection rates in patients with resected stage I-III colorectal cancer. J Clin Oncol 2023 ASCO GI Cancers Symposium 41(suppl 4), 2023. e-Pub 2023.
56. Morris VK, Guthrie KA, Kopetz S, Breakstone R, Karasic TB, Hu ZI, Bellasea S, Fakih M, Gholami S, Gold PJ, Philip PA. Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer: SWOG S2107. J Clin Oncol 2023 ASCO GI Cancers Symposium 41(suppl 4), 2023. e-Pub 2023.
57. Kopetz S, Kasper S, Rivera F, Tournigand C, Cheng Y, Deshpande P, D'Alessio D, Angelozzi NA, da Silva ABP, Segal NH. Patient-reported outcomes (PROs) and biomarker assessments in daNIS-3, a phase II platform study of NIS793 (anti–TGF-β monoclonal antibody) and other investigational drug combinations with standard of care (SOC) vs SOC alone in patients (pts) with second-line metastatic colorectal cancer (mCRC). J Clin Oncol 2023 ASCO GI Cancers Symposium 41(suppl 4), 2023. e-Pub 2023.
58. Hecht J, Kopetz S, Welling T, Morelli MP, Molina JR, Kirtane K, Oberstein PE, Greenwald DR, Lin Y, Mardiros A, Beutner K, Lozac'hmeur A, Salahudeen A, Liechty KB, Vong J, Ng EW, Maloney DG, Go WY, Welch JS, Simeone DM. Prospective BASECAMP-1 experience in patients with gastrointestinal (GI) cancer: Identifying patients with human leukocyte antigen (HLA) loss of heterozygosity (LOH) for a future therapeutic trial exploiting LOH as a tumor vulnerability. J Clin Oncol 2023 ASCO GI Cancers Symposium 41(suppl 4), 2023. e-Pub 2023.
59. Kopetz S, Bekaii-Saab TS, Yoshino T, Chung C, Zhang X, Tabernero J. SEAMARK: Randomized phase 2 study of pembrolizumab + encorafenib + cetuximab vs pembrolizumab alone for first-line treatment of BRAF V600E–mutant microsatellite instability–high (MSI-H)/mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC). J Clin Oncol 2023 ASCO GI Cancers Symposium 41(suppl 4), 2023. e-Pub 2023.
60. Salem ME, Kopetz S, Tabernero J, Sinicrope FA, Chalabi M, Tie J, Kadakia KC, George TJ, Mauer E, Macera L, Chao CY, Lonardi S, Cutsem EV, Andre T, Overman MJ. Comprehensive characterization of KRAS mutations and inter-relation with primary tumor location in colorectal cancers. J Clin Oncol 41(suppl 4), 2023. e-Pub 2023.
61. Ding S, Marie PK, Zhang R, Baro N, Brown DW, Bohn A, Pittman K, Paduch M, Hsu SD, Kopetz S, Shen X. Identifying targeted therapy combination for refractory colorectal cancer using micro-organospheres. J Clin Oncol 2023 ASCO GI Cancers Symposium 41(suppl 4), 2023. e-Pub 2023.
62. Kopetz S, Yoshino T, Kim TW, Yaeger R, Desai J, Wasan HS, Cutsem EV, Maughan T, Eng C, Tie J, Elez E, Lonardi S, Zhang X, Chung C, Usari T, Nicholz T, Murphy DA, Tabernero J, Ciardiello F. BREAKWATER safety lead-in (SLI): Encorafenib (E) + cetuximab (C) + chemotherapy for BRAFV600E metastatic colorectal cancer (mCRC). J Clin Oncol 2023 ASCO GI Cancers Symposium 41(suppl 4), 2023. e-Pub 2023.
63. Lieu CH, Lin Y, Kopetz S, Jacobs SA, Lucas PC, Sahin IH, Deming DA, Philip PA, Hong TS, Rojas-Khalil Y, Loree JM, Wolmark N, Yothers G, George TJ, Dasari A. NRG GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US). J Clin Oncol 2023 ASCO GI Cancers Symposium 41(suppl 4), 2023. e-Pub 2023.
64. Barnett R, Gnerre S, Willis J, Overman MJ, Singh Raghav KP, Parseghian CM, Dasari A, Morelli MP, Johnson B, Eluri M, Drusbosky L, Kopetz S, Morris VK. ctDNA-based fusion detection for advanced colorectal cancer with a partner-agnostic assay. J Clin Oncol 2023 ASCO GI Cancers Symposium 41(suppl 4), 2023. e-Pub 2023.
65. Saeed A, Barnett R, Lou E, da Silva LM, Cho MT, Lieu CH, Fakih M, Kopetz S, Loree JM, Gholami S. A plasma-based analysis and genomic landscape of patients with high tumor mutational burden (TMB-H), microsatellite stable (MSS) colorectal cancer (CRC). J Clin Oncol 2023 ASCO GI Cancers Symposium 41(suppl 4), 2023. e-Pub 2023.
66. Uppal A, White M, Chang GJ, Zeineddine FA, Zeineddine MA, Yousef AM, Scally C, Fournier KF, Newhook TE, You Y, Willis J, Kopetz S, YC Shen JP. Tumor mutations associated with outcomes in colorectal peritoneal metastases. J Clin Oncol 2023 ASCO GI Cancers Symposium 41(suppl 4), 2023. e-Pub 2023.
67. Singh Raghav KP, Guthrie KA, Kopetz S, Tan BR, Denlinger CS, Fakih M, Overman MJ, Dasari A, Corum LR, Hicks LG, Patel M, Esparaz BT, Ali Kazmi SM, Alluri N, Colby S, Gholami S, Gold PJ, Chiorean E, Hochster HS, Philip PA. A randomized phase 2 study of trastuzumab and pertuzumab (TP) compared to cetuximab and irinotecan (CETIRI) in advanced/metastatic colorectal cancer (mCRC) with HER2 amplification: SWOG S1613. J Clin Oncol 2023 ASCO GI Cancers Symposium 41(suppl 4), 2023. e-Pub 2023.
68. Kopetz S, Cutsem EV, Kuboki Y, Johnson B, Katakabe T, He M, Archuadze S, Shen L. A phase Ia/Ib, open-label, dose escalation study of the TRAILR2 agonist BI 905711 in combination with chemotherapy (CT) in patients (pts) with advanced GI cancers. J Clin Oncol 2023 ASCO GI Cancers Symposium 41(suppl 4), 2023. e-Pub 2023.
69. Janak A, Peacock O, White M, Guraieb-Trueba M, Nguyen ST, Alshenaifi J, Kopetz S, Johnson B, Smith GL, Chang GJ, You Y. Internet-based assessment tools for predicting colorectal cancer risk: How do they communicate individualized risk to the young adult?. J Clin Oncol 2023 ASCO GI Cancers Symposium 41(suppl 4), 2023. e-Pub 2023.
70. Nunez SK, Young CD, Griffen TL, Kopetz S, Lillard JW. Co-expressed gene networks in CRC CMS1 subtype. Cancer Res 2022 American Association for Cancer Research 82(suppl 12), 2022. e-Pub 2022.
71. Khan S, Wiegand J, Zhang P, Hu W, Thummuri D, Budamagunta V, Hua N, Jin L, Allegra CJ, Kopetz ES, Zajac-Kaye M, Kaye FJ, Zheng G, Zhou D. A BCL-XL PROTAC degrader DT2216 synergizes with KRASG12C inhibitors for effectively treating KRASG12C-mutated cancers. Cancer Res 2022 American Association for Cancer Research 82(suppl 12), 2022. e-Pub 2022.
72. Lee HM, Napolitano S, Sorokin A, Woods MN, Chowdhury S, Alshenaifi JY, Singh AK, Shen JP, Meric-Bernstam F, Rai K, Kopetz S. Bromodomain and extraterminal (BET) protein inhibition sensitize BRAFV600E colorectal cancer to standard targeted therapies. Cancer Res 2022 American Association for Cancer Research 82(suppl 12), 2022. e-Pub 2022.
73. Waizenegger IC, Lu H, Thamer C, Savarese F, Gerlach D, Rudolph D, Vellano CP, Marotti M, Heymach J, Kopetz S, Heffernan TP, Marszalek JR, Petronczki MP, Hofmann MH, Kraut N. Trial in progress: Phase 1 study of BI 1823911, an irreversible KRASG12C inhibitor targeting KRAS in its GDP-loaded state, as monotherapy and in combination with the pan-KRAS SOS1 inhibitor BI 1701963 in solid tumors expressing KRASG12C mutation. Cancer Res 2022 American Association for Cancer Research 82(suppl 12), 2022. e-Pub 2022.
74. Korkut A, Li X, Kong E, Yan G, Dereli Z, Bozorgui B, Imanirad P, Elnaggar J, Luna A, Menter D, Pilié P, Yap T, Kopetz S, Sander C. Precision combination therapies based on recurrent oncogenic co-alterations. Cancer Res 2022 American Association for Cancer Research 82(suppl 12), 2022. e-Pub 2022.
75. Lenz H, Prenen H, Cutsem EV, Kössler T, Mayol J, Trapani F, Tihy M, Rubbia-Brandt L, Toso C, Bogenrieder T, Belnoue E, Derouazi M, Kopetz S. ATP128 vaccine with ezabenlimab promotes antigen-specific immune responses in stage IV colorectal cancer in the KISIMA-01 phase 1b trial. Cancer Res 2022 American Association for Cancer Research 82(suppl 12), 2022. e-Pub 2022.
76. Gopalan A, Gallup TD, Wood S, Maldonado J, Margain C, Esnaola NF, Kim MP, Kopetz E, Yun K. A novel 3D culture platform for precision medicine. Cancer Res 2022 American Association for Cancer Research 82(suppl 12), 2022. e-Pub 2022.
77. Gouda MA, Duose DY, Lapin M, Zalles S, Huang HJ, Xi Y, Zheng X, Aldesoky AI, Alhanafy AM, Shehata MA, Wang J, Kopetz S, Meric-Bernstam F, Wistuba II, Luthra R, Janku F. Mutation-agnostic detection of colorectal cancer-specific cell-free DNA using targeted methylation sequencing. Cancer Res 2022 American Association for Cancer Research 82(suppl 12), 2022. e-Pub 2022.
78. Minussi DC, Wang J, Schalck A, Yan Y, Wu H, Peng C, Hu M, Sei E, Edgerton M, Chen H, Contreras A, Hui D, Damodaran S, Kopetz S, Lim B, Navin N. Resolving clonal substructure from single cell genomic data in primary and metastatic tumors using CopyKit. Cancer Res 2022 American Association for Cancer Research 82(suppl 12), 2022. e-Pub 2022.
79. Chowdhury S, Gupta R, Haridas V, Zeineddine MA, Kopetz S, Shen JP. Consensus molecular subtypes (CMS) of colorectal cancer predict anti-EGFR response irrespective of tumor sidedness. Cancer Res 2022 American Association for Cancer Research 82(suppl 12), 2022. e-Pub 2022.
80. Lenz H, Koessler T, Oberstein P, Cutsem EV, Kim S, Fritsch R, Prenen H, Morse M, Gani D, Derouazi M, Bogenrieder T, Kopetz S. KISIMA-01: A first-in-human trial of the heterologous prime-boost vaccine ATP128/VSV-GP128 with ezabenlimab (BI 754091) in patients with stage IV colorectal cancer. Cancer Res 2022 American Association for Cancer Research 82(suppl 12), 2022. e-Pub 2022.
81. Salem ME, Andre T, El-Refai SM, Kopetz S, Tabernero J, Sinicrope FA, Tie J, George TJ, VanCutsem E, Mauer E, Lonardi S, Overman MJ, Foureau D. Impact of RAS mutations on immunologic characteristics of the tumor microenvironment (TME) in patients with microsatellite instability-high (MSI-H) or mismatch-repair–deficient (dMMR) colorectal cancer (CRC). J Clin Onco 2022 ASCO Annual Meeting 40(suppl 16), 2022. e-Pub 2022.
82. Parseghian CM, Sun R, Woods MN, Napolitano S, Alshenaifi J, Willis J, Nunez SK, Sorokin A, Marie PK, Singh Raghav KP, Morris VK, YC Shen JP, Sanchez EV, Rehn M, Ang A, Troiani T, Kopetz S. Resistance mechanisms to anti-EGFR therapy in RAS/RAF wildtype colorectal cancer varies by regimen and line of therapy. J Clin Oncol 2022 ASCO Annual Meeting 40(suppl 16), 2022. e-Pub 2022.
83. Loree JM, Topham JT, Kennecke HF, Feilotter H, Lee YS, Virk S, Kopetz S, Duose DY, Manyam GC, Morris JS, Maru DM, Renouf D, Jonker DJ, Tu D, O'Callaghan CJ, Chen EX. Impact of consensus molecular subtyping (CMS) on survival in the CO.26 trial of durvalumab plus tremelimumab versus best supportive care (BSC) in metastatic colorectal cancer (mCRC). J Clin Oncol 2022 ASCO Annual Meeting 40(suppl 16), 2022. e-Pub 2022.
84. Singh Raghav KP, Ou F, Venook AP, Innocenti F, Sun R, Lenz H, Kopetz S. Circulating tumor DNA dynamics on front-line chemotherapy with bevacizumab or cetuximab in metastatic colorectal cancer: A biomarker analysis for acquired genomic alterations in CALGB/SWOG 80405 (Alliance) randomized trial. JCO 2022 ASCO Gastrointestinal Cancers Symposium 40(suppl 4), 2022. e-Pub 2022.
85. Villarreal O, Zeineddine FA, Chacko R, Parseghian CM, Johnson B, Willis J, Lee MS, Morris VK, Dasari A, Singh Raghav KP, Overman MJ, You Y, Wang Y, Maru DM, YC Shen JP, Kopetz S. Outcomes of IBD-associated colorectal cancer and implications in early-onset colorectal cancer. JCO 2022 ASCO Gastrointestinal Cancers Symposium 40(suppl 4), 2022. e-Pub 2022.
86. Bhamidipati D, Singh Raghav KP, Morris VK, Kopetz S, Kee BK, Johnson B, Willis J, Dasari A, Morelli MP, Parseghian CM, Lee MS, Le P, YC Shen JP, Ludford K, Overman MJ. Prognostic role of systemic inflammatory markers in patients with metastatic MSI-h/dMMR colorectal cancer receiving immunotherapy. J Clin Oncol 2022 ASCO Annual Meeting 40(suppl), 2022. e-Pub 2022.
87. Bent AH, Maru DM, Vauthey J, Dasari A, Johnson B, Kee BK, Parseghian CM, Menter D, Overman MJ, Morris VK, Fan P, Koyama K, Maeda N, Kopetz S, Singh Raghav KP. HER3 expression in metastatic colorectal cancer: Defining the clinicomolecular profile of an emerging target. J Clin Oncol 2022 ASCO Annual Meeting 40(suppl 16), 2022. e-Pub 2022.
88. Kopetz S, Yoshino T, Kim TW, Desai J, Yaeger R, Cutsem EV, Ciardiello F, Wasan HS, Maughan T, Zhang Y, Usari T, Chung C, Zhang X, Tabernero J. BREAKWATER safety lead-in (SLI): Encorafenib + cetuximab (EC) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC). JCO 2022 ASCO Gastrointestinal Cancers Symposium 40(suppl 4), 2022. e-Pub 2022.
89. Parseghian CM, Sanchez EV, Sun R, Eluri M, Morris VK, Johnson B, Morelli MP, Overman MJ, Willis J, Huey R, Singh Raghav KP, Dasari A, Kee BK, Wolff RA, YC Shen JP, Kopetz S. Phase 2 study of anti-EGFR rechallenge therapy with panitumumab with or without trametinib in advanced colorectal cancer. J Clin Oncol 40(suppl. 16), 2022. e-Pub 2022.
90. Rocha Lima CMSP, Yothers G, Jacobs SA, Sanoff HK, Cohen DJ, Guthrie KA, Henry NL, Ganz PA, Kopetz S, Lucas PC, Blanke CD, Hong TS, Wolmark N, Hochster HS, George TJ, Overman MJ. Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC)—NRG-GI004/SWOG-S1610. J Clin Oncol 2022 ASCO Annual Meeting 40(suppl 16), 2022. e-Pub 2022.
91. Kopetz S. ctDNA as a Tool to Detect Minimal Residual Disease After Surgery, 2022. e-Pub 2022.
92. Kopetz S, Grothey A, Yaeger R, Ciardiello F, Desai J, Kim TW, Maughan T, Cutsem EV, Wasan HS, Yoshino T, Edwards ML, Golden A, Gollerkeri A, Tabernero J. BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cet) ± chemotherapy for first-line treatment (tx) of BRAF V600E-mutant (BRAFV600) metastatic colorectal cancer (mCRC). JCO 2022 ASCO Gastrointestinal Cancers Symposium 40(suppl 4), 2022. e-Pub 2022.
93. Dasari A, Lin Y, Kopetz S, Jacobs SA, Lucas PC, Sahin IH, Deming DA, Philip PA, Hong TS, Rojas-Khalil Y, Wolmark N, Yothers G, George TJ, Lieu CH. Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US): NRG-GI008. J Clin Onco 2022 ASCO Annual Meeting 40(suppl 16), 2022. e-Pub 2022.
94. Johnson B, Yang D, Dada HI, Drusbosky L, Kopetz S. Comprehensive landscape of BRAF variant classes, clonalities, and comutations in metastatic colorectal cancer using ctDNA profiling. JCO 2022 ASCO Gastrointestinal Cancers Symposium 40(suppl 4), 2022. e-Pub 2022.
95. Simmons K, Kee BK, Singh Raghav KP, Johnson B, Kopetz S, Willis J, Dasari A, Sanchez EV, Ludford K, Parseghian CM, Lee MS, Le P, YC Shen JP, Overman MJ, Morris VK. Clinical outcomes following termination of immunotherapy due to long-term benefit in MSI-H colorectal cancer. J Clin Oncol 2022 ASCO Annual Meeting 40(suppl 16), 2022. e-Pub 2022.
96. Dasari A, Abdelrahim M, Acoba JD, Alluri KC, Dragovich T, Ali Kazmi SM, Musher BL, Sun R, Wong L, You Y, Zaiden RA, Kopetz S. Minimal residual disease assessment in colorectal cancer (MiRDA-C). JCO 2022 ASCO Gastrointestinal Cancers Symposium 40(suppl 4), 2022. e-Pub 2022.
97. Woods MN, Falco VD, Prisco C, Martini G, Guerrera LP, Belli V, Troiani T, Morris VK, YC Shen JP, Lee HM, Villarreal O, Sorokin A, Marie PK, Ciardiello F, Kopetz S, Napolitano S. Encorafenib, cetuximab, and cytotoxic chemotherapy combinations in BRAFV600E CRC murine models. JCO 2022 ASCO Gastrointestinal Cancers Symposium 40(suppl 4), 2022. e-Pub 2022.
98. Salem ME, Kopetz S, El-Refai SM, Tabernero J, Sinicrope FA, Tie J, George TJ, VanCutsem E, Mauer E, Lonardi S, Andre T, Overman MJ, Foureau D. Comparative analysis of microsatellite instability-high (MSI-H) BRAF V600E-mutated versus MSI-H BRAF wild type colorectal cancers (CRC), including tumor microenvironment (TME), associated genomic alterations, and immunometabolomic biomarkers. J Clin Oncol 2022 ASCO Annual Meeting 40(suppl 16), 2022. e-Pub 2022.
99. Kopetz S, Murphy DA, Pu J, Yaeger R, Ciardiello F, Desai J, Cutsem EV, Wasan HS, Yoshino T, Elez E, Golden A, Zhu Z, Zhang X, Tabernero J. Evaluation of baseline BRAF V600E mutation in circulating tumor DNA and efficacy response from the BEACON study. JCO 2022 ASCO Gastrointestinal Cancers Symposium 40(suppl 4), 2022. e-Pub 2022.
100. Nusrat M, Syed MA, Katkhuda R, Parra ER, Wistuba II, Kong P, Koehne A, Dasari A, Overman MJ, Menter D, Kopetz S. The immune impact of PI3K-AKT pathway inhibition in colorectal cancer. JCO 2022 ASCO Gastrointestinal Cancers Symposium 40(suppl 4), 2022. e-Pub 2022.
101. Johnson B, Kopetz S, Hwang H, Yuan Y, DePinho RA, Zebala J, Overman MJ. STOPTRAFFIC-1: A phase I/II trial of SX-682 in combination with nivolumab for refractory RAS-mutated microsatellite stable (MSS) metastatic colorectal cancer (mCRC). J Clin Oncol 2022 ASCO Annual Meeting 40(suppl 16), 2022. e-Pub 2022.
102. Kopetz S, Morris VK, Alonso-Orduña V, Garcia-Alfonso P, Reboredo M, Montes AF, Maurel J, Paez D, Reinacher-Schick AC, Höhler T, Carrasco J, Galligan BM, Manning L, Preußner L, Tureci Ö, Sahin U. A phase 2 multicenter, open-label, randomized, controlled trial in patients with stage II/III colorectal cancer who are ctDNA positive following resection to compare efficacy of autogene cevumeran versus watchful waiting. J Clin Onco 2022 ASCO Annual Meeting 40(supply 16), 2022. e-Pub 2022.
103. Kopetz S, Morris VK, O'Neil B, Bridgewater JA, Graham J, Parkes EE, Saunders MP, Asken E, Goodwin L, Phillips C, Robertson J, Tilston C, Woodcock S, Cook N. A multi-arm, phase 2, open-label study to assess the efficacy of RXC004 as monotherapy and in combination with nivolumab in patients with ring finger protein 43 (RNF43) or R-spondin (RSPO) aberrated, metastatic, microsatellite stable colorectal cancer following standard treatments. J Clin Oncol 2022 ASCO Annual Meeting 40(suppl 16), 2022. e-Pub 2022.
104. Negrao MV, Morelli MP, Jazaeri AA, Johnson B, Kebriaei P, Deninger D, Groot ED, Collinson-Pautz MR, Demars NA, Holland JS, Heymach J, Baffa R, Kopetz S. First-in-human phase 1/2 study of autologous T cells engineered using the Sleeping Beauty System transposon/transposase to express T-cell receptors (TCRs) reactive against cancer-specific mutations in patients with advanced solid tumors. J Clin Oncol 2022 ASCO Annual Meeting 40(suppl 16), 2022. e-Pub 2022.
105. Johnson B, Yang D, Dada HI, Morris VK, Wang X, Dasari A, Singh Raghav KP, Kee BK, YC Shen JP, Huey R, Lee MS, Parseghian CM, Le P, Morelli MP, Willis J, Wolff RA, Drusbosky L, Overman MJ, Kopetz S. RAS co-mutation and early onset disease represent an aggressive phenotype of atypical (non-V600) BRAF mutant metastatic colorectal cancer. J Clin Oncol 2022 ASCO Annual Meeting 40(suppl 16), 2022. e-Pub 2022.
106. Kopetz S, Bekaii-Saab TS, Yoshino T, Chung C, Zhang X, Tabernero J. SEAMARK: Randomized phase 2 study of pembrolizumab + encorafenib + cetuximab versus pembrolizumab alone for first-line treatment of BRAF V600E-mutant and microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC). J Clin Oncol 2022 ASCO Annual Meeting 40(suppl 16), 2022. e-Pub 2022.
107. Morris VK, Parseghian CM, Escano M, Johnson B, Singh Raghav KP, Dasari A, Huey R, Overman MJ, Willis J, Lee MS, Wolff RA, Kee BK, Le P, Margain C, Gallup D, Tam A, Foo WC, Xiao L, Yun K, Kopetz S. Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable (MSS), BRAFV600E metastatic colorectal cancer. J Clin Oncol 2022 ASCO Annual Meeting 40(suppl 16), 2022. e-Pub 2022.
108. Lee MS, Zemla TJ, Ciombor KK, McRee AJ, Akce M, Dakhil SR, Jaszewski BL, Ou F, Bekaii-Saab TS, Kopetz S. A randomized phase II trial of MEK and CDK4/6 inhibitors vesus tipiracil/trifluridine (TAS-102) in metastatic KRAS/NRAS mutant (mut) colorectal cancer (CRC). JCO 2022 ASCO Gastrointestinal Cancers Symposium 40(suppl 4), 2022. e-Pub 2022.
109. Amaria RN, Vining DJ, Kopetz S, Overman MJ, Javle MM, Antonoff M, Tzeng CD, Wolff RA, Pant S, Lito K, Rangel KM, Wilson L, Fellman BM, Haymaker CL, Yuan Y, Forget M, Hwu P, Bernatchez C, Jazaeri AA. Efficacy and safety of autologous expanded tumor infiltrating lymphocytes (TILs) in multiple solid tumors. J Clin Oncol 2022 ASCO Annual Meeting 40(suppl 16), 2022. e-Pub 2022.
110. Naing A, Mamdani H, Barve MA, Johnson ML, Morgensztern D, Olszanski AJ, Wolff RA, Pant S, Chaney MF, Adebanjo T, Fan J, Kim RD, Kopetz S. Efficacy and safety of NT-I7, long-acting interleukin-7, plus pembrolizumab in patients with advanced solid tumors: Results from the phase 2a study. J Clin Onco 2022 ASCO Annual Meeting 40(suppl 16), 2022. e-Pub 2022.
111. Hecht J, Kopetz S, Patel SP, Welling T, Morelli MP, Borad MJ, Molina JR, Kirtane K, Lin Y, Fan-Port M, Mardiros A, Beutner K, Lozac'hmeur A, Lau D, Liechty KB, Vong J, Ng E, Maloney DG, Go WY, Simeone DM. Next generation sequencing (NGS) to identify relapsed gastrointestinal (GI) solid tumor patients with human leukocyte antigen (HLA) loss of heterozygosity (LOH) for future logic-gated CAR T therapy to reduce on target off tumor toxicity. JCO 2022 ASCO Gastrointestinal Cancers Symposium 40(suppl 4), 2022. e-Pub 2022.
112. Simeone DM, Hecht J, Patel SP, Morelli MP, Kirtane K, Borad MJ, Maus MV, Sunwoo JB, Welling T, Lin Y, Garon EB, Kopetz S, Locke FL, Liechty KB, Lozac'hmeur A, Beutner K, Ng EW, Go WY, Maloney DG, Molina JR. BASECAMP-1: Leveraging human leukocyte antigen (HLA) loss of heterozygosity (LOH) in solid tumors by next-generation sequencing (NGS) to identify patients with relapsed solid tumor for future logic-gated Tmod CAR T-cell therapy. J Clin Oncol 2022 ASCO Annual Meeting 40(suppl 16), 2022. e-Pub 2022.
113. Coker O, Sorokin A, Gale K, Gao F, Shen JP, Kwong L, Wu J, Lee HM, Woods M, Villareal O, Kopetz S. Oncogenic KRASG12C dependency in colorectal cancer. Cancer Res 2021 American Association for Cancer Research 81(suppl 13), 2021. e-Pub 2021.
114. Zhang X, Hoffman KL, Li F, Irajizad E, Browman G, Basen-Engquist K, Hanash S, Scheet P, Okhuysen PC, Kopetz S, Petrosino J, Daniel CR. Beans to Enrich the Gut microbiome vs. Obesity's Negative Effects: First results from the BE GONE Trial in high-risk colorectal patients. Cancer Res 2021 American Association for Cancer Research 81(suppl 13), 2021. e-Pub 2021.
115. Li F, White MG, Davis J, Hoffman KL, Menter D, Ajami N, Zhang X, Morris JS, Jenq RR, Petrosino J, Wargo JA, Kopetz S, Daniel CR. Tumor microbiota profiles are associated with molecular subtype and survival in colorectal cancer patients. Cancer Res 2021 American Association for Cancer Research 81(suppl 13), 2021. e-Pub 2021.
116. Lee HM, Napolitano S, Morris II VK, Rai K, Shen JP, Davis JS, Maru DM, Overman MJ, Wu J, Coker O, Woods MN, Villarreal O, Kopetz S. Epigenetic regulation of the Wnt-signaling pathway in CIMP-H BRAFV600E mCRC. J Clin Oncol, 2021 Gastrointestinal Cancers Symposium 39(suppl 3), 2021. e-Pub 2021.
117. Strickler JH, F-S O, Bekaii-Saab TS, Parseghian CM, Cercek A, Ng K, Sanchez FA, Bruggeman S, Larson JJ, Finley GG, Hubbard JM, Wu C, H-J L, Kopetz S, Corcoran RB. PULSE: A randomized phase II open label study of panitumumab rechallenge versus standard therapy after progression on anti-EGFR therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC). J Clin Oncol, 2021 Gastrointestinal Cancers Symposium 39(suppl 3), 2021. e-Pub 2021.
118. Morris VK, Raghav PS, Dasari A, Overman MJ, Kee BK, Johnson B, Parseghian CM, Shen JP, Huey R, Raymond VM, Duose DY, Luthra R, Hong DS, Janku F, Kopetz S. Utility of circulating tumor DNA in the clinical management of patients with BRAFV600E metastatic colorectal cancer. J Clin Oncol, 2021 Gastrointestinal Cancers Symposium 39(suppl 3), 2021. e-Pub 2021.
119. Kopetz S, Grothey A, Ciardiello F, Desai J, Kim TW, Maughan T, Cutsem EV, Wasan HS, Yaeger R, Yoshino T, Gollerkeri A, Edwards M, Lizaso MR, Tabernero J. Global BRAF testing practices in metastatic colorectal cancer. J Clin Oncol 2021 Gastrointestinal Cancers Symposium 39(3_suppl), 2021. e-Pub 2021.
120. Taku N, You Y, Ludmir EB, Smith GL, Rodriguez-Bigas MA, Chang GJ, Skibber JM, Koong AC, Minsky BD, Holliday EB, Koay EJ, Dasari A, Taniguchi CM, Bednarski BK, Morris VK, Overman MJ, Kopetz S, Singh Raghav KP, Das P. Clinical outcomes following definitive treatment of young-onset, locally advanced rectal cancer: A single institution experience. J Clin Oncol 2021 ASCO Annual Meeting 39(suppl. 15), 2021. e-Pub 2021.
121. Lee HM, Napolitano S, Morris VK, Rai K, YC Shen JP, Davis JS, Maru DM, Overman MJ, Wu J, Coker O, Woods MN, Villarreal O, Kopetz S. Epigenetic regulation of the Wnt-signaling pathway in CIMP-H BRAFV600E mCRC. J Clin Onco 2021 Gastrointestinal Cancers Symposium 39(suppl. 3), 2021. e-Pub 2021.
122. Morris VK, Lam M, Wang X, Overman MJ, Johnson B, Kee BK, Wolff RA, Dasari A, Zorrilla IR, Tam A, Maru DM, Kopetz S. Phase II trial of bintrafusp alfa in patients with metastatic MSI-H cancers following progression on immunotherapy. J Clin Onco 2021 Gastrointestinal Cancers Symposium 39(3_suppl), 2021. e-Pub 2021.
123. Singh Raghav KP, Yoshino T, Taniguchi H, Tejpar S, Vogel A, Wainberg ZA, Yamaguchi K, Kanai M, Liu Y, Mekan S, Pudussery G, Qiu Y, Kopetz S. An open-label, phase II study of patritumab deruxtecan (HER3-DXd, U3-1402) in patients (pts) with previously treated advanced/metastatic colorectal cancer (CRC). J Clin Onco 2021 Gastrointestinal Cancers Symposium 39((suppl 3), 2021. e-Pub 2021.
124. Yu J, Singh Raghav KP, Parikh AR, Hanna D, Marino E, Raymond VM, Nagy R, Zhang N, Corcoran RB, Kopetz S, Strickler JH, Lang K. Real-world genomic and treatment landscape in advanced colorectal cancer identifies treatment differences pre- and post-ctDNA genomic profiling. J Clin Oncol 2021 Gastrointestinal Cancers Symposium 39(suppl. 3), 2021. e-Pub 2021.
125. C-F C, Y-M Y, K-H Y, Desai J, Price TJ, Tebbutt N, Tabernero J, Velez L, Trevino TL, Grothey A, Yaeger R, Gollerkeri A, Maharry K, Kopetz S. Management of adverse events associated with encorafenib plus cetuximab in patients with BRAF V600E mutant metastatic colorectal cancer (BEACON CRC Study). Annals of Oncology 31(S6):S1276, 2020. e-Pub 2020.
126. Ileana Dumbrava EE, Huang HJ, Stuckett A, Madwani K, Adat A, Hong DS, Piha-Paul SA, Subbiah V, Karp DD, Fu S, Naing A, Tsimberidou AM, Moulder S, Koenig K, Barcenas CH, Kee B, Fogelman D, Kopetz S, Meric-Bernstam F, Janku F. PIK3CA mutations in plasma cell-free DNA predict survival and treatment outcomes in patients with advanced cancers. Mol Cancer Res 2020 American Association for Cancer Research 18(suppl 10), 2020. e-Pub 2020.
127. Nusrat M, Hong D, Piha-Paul SA, Subbiah V, Rodon J, Tsimberidou A, Adat A, Wang Y, Overman M, Kopetz S, Meric-Bernstam F, Janku F. Activating mutations of phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) gene confer sensitivity to PD-L1 checkpoint inhibition in metastatic adenocarcinoma patients. Mol Cancer Res 2020 American Association for Cancer Research 18(suppl 10), 2020. e-Pub 2020.
128. Parikh A, Gugel EG, Smolyakova N, M-H J, Toms N, Lin Y, Kim JS, Kopetz S. A meta-analysis of efficacy and safety of cetuximab with biweekly vs. weekly dosing. Annals of Oncology 31(S4):S435, 2020. e-Pub 2020.
129. Napolitano S, Carbone F, Menter DG, Davis JS, Troiani T, Syed MA, Ciardiello F, Kopetz S, Genovese G. Somatic mosaic model of colorectal cancer for translational immune cancer research. Annals of Oncology 31(S4):S448, 2020. e-Pub 2020.
130. Davis JS, Kanikarla P, Yu PL, Gagea M, Fang D, Sebastian M, Yang P, Hawk E, Dashwood R, Lichtenberger LM, Menter D, Kopetz S. Sulindac plus phospholipid is effective for polyp reduction and safer than sulindac alone. Cancer Res 2020 American Association for Cancer Research 80(suppl 16), 2020. e-Pub 2020.
131. Bhamidipati D, Verma A, Maru DM, Sui D, Mathew G, Lang W, Posadas JF, Hein JP, Kopetz S, Futreal A, Wistuba II, Lee J, Overman MJ, Tam AL. Analysis of 1151 prospective research biopsies: Factors influencing tumor yield across patients and biopsy cores. Cancer Res 2020 American Association for Cancer Research 80(suppl 16), 2020. e-Pub 2020.
132. Sahni N, McGrail DJ, Garnett J, Yin J, Dai H, H Shih DJ, Peng G, Menter D, Yates MS, Kopetz S, Lu K, Broaddus R, Mills GB, Lin SY. Proteome instability is an immunogenic therapeutic vulnerability in mismatch repair deficient cancer. Cancer Res 2020 American Association for Cancer Research 80(suppl 16), 2020. e-Pub 2020.
133. A GrotheyKopetz S, Yaeger R, Van Cutsem E, Wasan H, Desai J, Ciardiello F, Yoshino T, Maharry K, Christy-Bittel J, Gollerkeri A, Tabernero J. Encorafenib plus cetuximab with or without binimetinib for BRAFV600E metastatic colorectal cancer (mCRC): Relationship between carcinoembryonic antigen (CEA) and clinical outcomes from BEACON CRC. Annals of Oncology 31(S3):S243, 2020. e-Pub 2020.
134. Velez L, Trevino T, Kopetz S, Grothey A, Yaeger R, Gollerkeri A, Maharry K, Tabernero J. Management of adverse events associated with encorafenib plus cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer (The BEACON CRC Study). Annals of Oncology 31(S3):S224, 2020. e-Pub 2020.
135. Nusrat M, Roszik J, Holla V, Cai T, Hong M, Coker O, Johnson B, Ahnert JR, Janku F, S <, Shaw KR, Meric-Bernstam F, Hong DS. Therapeutic vulnerabilities among KRAS G12C mutant (mut) advanced cancers based on co-alteration (co-alt) patterns. J Clin Oncol, 2020 ASCO Virtual Scientific Program 38(15_suppl), 2020. e-Pub 2020.
136. Kasi PM, Dayyani F, Morris VK, Kopetz S, Parikh AR, Starr JS, Cohen S, Grothey A, Lieu CH, O'Hara MH, Loranger K, Westbrook L, Sharma S, Krinshpun S, Hook N, Zimmermann B, Billings PR, Aleshin A. Tumor-informed assessment of molecular residual disease and its incorporation into practice for patients with early and advanced-stage colorectal cancer (CRC-MRD Consortia). J Clin Oncol, 2020 ASCO Virtual Scientific Program 38(15_suppl), 2020. e-Pub 2020.
137. Korphaisarn K, Lam M, Loree JM, Ruiz E, Aguiar S, Kopetz S. Consensus molecular subtypes in colorectal cancer differ by geographic region. J Clin Oncol, 2020 ASCO Virtual Scientific Program 38(15_suppl), 2020. e-Pub 2020.
138. Sarshekeh AM, Roszik J, Manyam GC, Advani SM, Willis J, Shen JP, Morris J, Davis JS, Ajani JA, Maru DM, Overman MJ, Kopetz S. ARID1A mutation to define an immunologically active subgroup in patients with microsatellite-stable colorectal cancer. J Clin Oncol, 2020 Gastrointestinal Cancers Symposium 38(suppl 4), 2020. e-Pub 2020.
139. CMSP RL, Yothers G, Jacobs SA, Sanoff HK, Cohen DJ, Guthrie KA, Henry NL, Ganz PA, Kopetz S, Lucas PC, Blanke CD, Wolmark N, Hochster HS, George TJ, Overman MJ. A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer (mCRC): Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study (NRG- GI004/SWOG-S1610). J Clin Oncol, 2020 Gastrointestinal Cancers Symposium 38(suppl 4), 2020. e-Pub 2020.
140. Napolitano S, Carbone F, Menter DG, Troiani T, Genovese G, Kopetz S. Immune competent somatic mosaic model of colorectal cancer. Annals of Oncology 30(Supplement 5), 2019. e-Pub 2019.
141. Tabernero J, Grothey A, Cutsem E, Yaeger R, Wasan H, Yoshino T, Desai J, Ciardiello F, Loupakis F, Hong Y, Steeghs N, Guren T, Arkenau H, García-Alfonso P, Gollerkeri A, Pickard M, Maharry K, Christy-Bittel J, Anderson L, Kopetz S. Encorafenib plus cetuximab with or without binimetinib for BRAF V600E–mutant metastatic colorectal cancer: Expanded results from a randomized, 3-arm, phase III study vs the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC). Annals of Oncology 30(Supplement 5), 2019. e-Pub 2019.
142. Matrone N, Napolitano S, Belli V, Barra G, Giunta EF, De Falco V, Terminiello M, Vitiello PP, Ciardiello D, Turano M, Furia M, Muddassir AS, Kopetz S, Martinelli E, Ciardiello F, Troiani T. Triple blockade of EGFR, MEK and PD-L1 as effective antitumor treatment in PD-L1 overexpressing, MEK inhibitor resistant colon cancer cells. Annals of Oncology 30(Supplement 5), 2019. e-Pub 2019.
143. Tabernor J, Grothey A, Van Cutsem E, Yaeger R, Harpreet W, Yoshino T, Desai J, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren T, Arkenau H, Garcia-Alfonsi P, Elez E, Gollerkeri A, Maharry K, Christy-Bittel J, S|| K. Encorafenib plus Cetuximab as a New Standard of Care for Previously-Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses, 2019. e-Pub 2019.
144. Kopetz S, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, Desai J, Ciardiello F, Gollerkeri A, Maharry K, Loupakis F, Hong Y, Steeghs N, Guren T, Arkenau H, Garcıa Alfonso P, Sandor V, Christy-Bittel J, Anderson L, Tabernero J. BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E–mutant metastatic colorectal cancer. Annals of Oncology 30(Suppl 4):iv154, 2019. e-Pub 2019.
145. Parseghian, C M, Willis, J, Morris, V K, Raghav, K P S, Dasari, A, Raymond, V M, Kopetz, S. Identifying anti-EGFR (EGFRi) response subgroups using evidence of ctDNA selective pressure. Journal of Clinical Oncology 37(15 Suppl), 2019. e-Pub 2019.
146. Henry J, Loree JM, Strickler JH, Singh Raghav KP, Morris VK, Raymond VM, Lanman RB, Yaeger R, Corcoran RB, Overman MJ, Kopetz S. Quantifying the evolution of tumor architecture using serial circulating tumor DNA. J Clin Oncol 37(suppl 4; abstr 600), 2019. e-Pub 2019.
147. Alifrangis L, Schoemacker R, Ostergaard Skartved NJ, Hald R, Düring M, Montagut C, Argiles G, Kopetz||B S, Horak ID, Kragh M, Wade JR. Population pharmacokinetics (popPK) of Sym004 to evaluate the effect of intrinsic and extrinsic factors on exposure in metastatic colorectal cancer (mCRC). J Clin Oncol 37(suppl 4; abstr 496), 2019. e-Pub 2019.
148. Tannenbaum D, Singh Raghav KP, Horn RA, Overman MJ, Eng C, Kopetz S, Johnson B, Morris VK, Parseghian CM, Chang GJ, Rogers JE, Parker S, Angeles Lopez-Olivo MDL, Dasari A. Systematic review of three decades of clinical trials in metastatic colorectal cancer: Making lemonade out of lemons?. J Clin Oncol 37(suppl 4; abstr 656), 2019. e-Pub 2019.
149. Singh Raghav KP, Yaeger R, Loree JM, Dasari A, Morris VK, Kee BK, Raymond VM, Nagy RJ, Lanman RB, Strickler JH, Corcoran RB, Overman MJ, Kopetz S. Comprehensive landscape of gene amplifications (amps) in tissue and circulating tumor DNA (ctDNA) in metastatic colorectal cancer (mCRC). J Clin Oncol 37(suppl 4; abstr 604), 2019. e-Pub 2019.
150. Johnson B, Loree JM, Morris VK, Dasari A, Pant S, Raghav KPS, Kopetz S. Activity of EGFR inhibition in atypical (non-V600E) BRAF-mutated metastatic colorectal cancer. J Clin Oncol 37(Suppl 4; abstr 596), 2019. e-Pub 2019.
151. Kopetz S, Grothey A, Yaeger R, Cuyle PA, Huijberts S, M Schellens JH, Elez E, Fakih M, Viladot CM, Peeters M, Desai J, Yoshino T, Ciardiello F, Wasan HS, Maharry K, Christy-Bittel J, Gollerkeri A, Cutsem EV, Tabernero J. Updated results of the BEACON CRC safety lead-in: Encorafenib (ENCO) + binimetinib (BINI) + cetuximab (CETUX) for BRAFV600E-mutant metastatic colorectal cancer (mCRC). J Clin Oncol 37(suppl 4; abstr 688), 2019. e-Pub 2019.
152. Lee JJ, Yothers G, Jacobs SA, Sanoff HK, Cohen DJ, Guthrie KA, Henry NL, Ganz PA, Kopetz <, Lucas PC, Allegra CJ, Blanke CD, Wolmark N, Hochster HS, George TJ, Overman MJ. Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study (NRG- GI004/SWOG-S1610): A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer (mCRC). J Clin Oncol 37(suppl 4; abstr TPS728), 2019. e-Pub 2019.
153. Overman MJ, Lonardi S, Mark Wong KY, Lenz H, Gelsomino F, Aglietta M, Morse M, Cutsem EV, McDermott RS, Hill AG, Sawyer MB, Hendlisz A, Neyns B, Svrcek M, Atasoy A, Zhao H, Lei M, Kopetz S. Nivolumab (NIVO) + low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up. J Clin Oncol 37(suppl 4; abstr 635), 2019. e-Pub 2019.
154. Loree JM, Dowers A, Tu D, O'Callaghan CJ, Edelstein D, Quinn H, Jonker DJ, Karapetis C, Price TJ, Zalcberg JR, Moore MJ, Waring PM, Kennecke HF, Hamilton SR, Kopetz S. Expanded RAS and BRAF V600 testing as predictive biomarkers for single agent cetuximab in the randomized phase III CO.17 trial. J Clin Oncol 37(suppl 4; abstr 537), 2019. e-Pub 2019.
155. Laeufle R, Arnold D, Kopetz S, Straub J, Bruns R, Massimini G, Debenedetto R, Linke R, Elez Fernandez E, Tabernero J. Patient selection for targeting integrin with abituzumab in patients with metastatic colorectal cancer (mCRC): A retrospective analysis of the randomized phase I/II Poseidon study. Annals of Oncology 29(Suppl 8), 2018. e-Pub 2018.
156. Parseghian CM, Loree JM, Morris VK, Pereira AAL, Vilar Sanchez E, Kee BK, Raghav KPS, Dasari A, Wu J, Raymond VM, Banks K, Talasaz AA, Lanman RB, Overman MJ, Kopetz S. Anti-EGFR resistant clones decay exponentially after progression: Implications for anti-EGFR rechallenge. J Clin Oncol 36(Suppl), 2018. e-Pub 2018.
157. Pereira AAL, Lam M, Kanikarla Marie P, Raghav KPS, Morris VK, Brown H, Windham J, Duose DY, Overman MJ, Vilar Sanchez E, Wistuba II, Kipp P, Janku F, Sinha S, Kopetz S. Circulating tumor DNA (ctDNA) as an early marker to monitor clinical benefit of regorafenib and TAS-102 in patients with metastatic colorectal cancer (mCRC). J Clin Oncol 36(Suppl), 2018. e-Pub 2018.
158. Fujii S, Magliocco AM, Valtorta E, Kim J, Okamoto W, Kim JE, Sawada K, Nakamura Y, Torri V, Kopetz S, Park WY, Tsuchihara K, Kim TW, Raghav KPS, Siena S, Yoshino T. International harmonization of diagnostic criteria for HER2-amplified metastatic colorectal cancer and application of targeted next-generation sequencing panel as a diagnostic method. J Clin Oncol 36(Suppl), 2018. e-Pub 2018.
159. Nusrat M, Oh J, Jiang ZQ, Dasari A, Fogelman DR, Kee BK, Menter D, Raghav KPS, Morris VK, Wu J, Meric-Bernstam F, Morris J, Overman MJ, Kopetz S. Proteomic profiling of phosphatidylinositol 3-kinase (PI3K) altered metastatic colorectal cancer (mCRC) after protein kinase B (Akt) inhibition: Insulin like growth factor 1 receptor (IGF1R) mediates adaptive resistance. J Clin Oncol 36(Suppl), 2018. e-Pub 2018.
160. Poulsen TT, Kragh M, Ding C, Pedersen MW, Lindsted T, Blondal T, Dienstmann R, Montagut C, Horak ID, Kopetz S, Tabernero J. Circulating tumor DNA profiling to identify patients with metastatic colorectal cancer with improved overall survival following Sym004 treatment. J Clin Oncol 36(Suppl), 2018. e-Pub 2018.
161. Lee JJ, Yothers G, Jacobs SA, Sanoff HK, Cohen DJ, Guthrie KA, Henry NL, Ganz PA, Kopetz S, Lucas PC, Allegra CJ, Blanke CD, Wolmark N, Hochster HS, George TJ, Overman MJ. Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study (NRG- GI004/SWOG-S1610): A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer. J Clin Oncol 36(Suppl), 2018. e-Pub 2018.
162. Sarshekeh AM, Loree JM, Manyam GC, Pereira AAL, Raghav KPS, Lam M, Davis JS, Dasari A, Morris VK, Menter D, Eng C, Broaddus R, Routbort M, Luthra R, Maru DM, Overman MJ, Meric-Bernstam F, Kopetz S. The characteristics of ARID1A mutations in colorectal cancer. J Clin Oncol 36(Suppl), 2018. e-Pub 2018.
163. Wang Y, Loree JM, Yu C, Tschautscher M, Briggler AM, Overman MJ, Broaddus R, Meric-Bernstam F, Jones JC, Balcom J, Kipp B, Kopetz S, Grothey A. Distinct impacts of KRAS, NRAS and BRAF mutations on survival of patients with metastatic colorectal cancer. J Clin Oncol 36(Suppl), 2018. e-Pub 2018.
164. Clifton K, Raymond VM, Dasari A, Raghav KPS, Parseghian CM, Pereira AAL, Loree JM, Yaeger R, Strickler JH, Corcoran JB, Lanman RB, Kopetz S, Morris VK. Actionable fusions in colorectal cancer using a cell-free circulating tumor DNA (ctDNA) assay, 2018. e-Pub 2018.
165. Margalit O, Mamtani R, Kopetz S, Yang YX, Lawrence YR, Abu-Gazala S, Reiss KA, Golan T, Halpern N, Aderka D, Giantonio BJ, Shacham-Shmueli E, Boursi B. Refining the use of adjuvant oxaliplatin in clinical stage II or III rectal adenocarcinoma. J Clin Oncol 36(Suppl), 2018. e-Pub 2018.
166. Overman MJ, Jaimovich A, Kennedy D, Tan M, Gavino D, Mortimer S, Chudova D, Talasaz AA, Odegaard J, Kopetz S. A priori filtering of post-operative (post-op) circulating tumor DNA (ctDNA) to predict recurrence in post-metastasectomy colorectal cancer patients (CRC pts) without knowledge of tumor genotype.. J Clin Oncol 36(Suppl), 2018. e-Pub 2018.
167. Lam M, AAl P, Loree JM, Advani SM, Overman MJ, Johnson A, Holla V, Khotskaya Y, Sanchez NS, Meric-Bernstam F, Kopetz S, Pant S. Effect of matched therapy in metastatic colorectal cancer on progression free survival in the phase I setting. J Clin Oncol 36(Suppl), 2018. e-Pub 2018.
168. Lam M, Pereira AAL, Marie PK, Davis JS, Yu RX, Morris J, Manyam GC, Broom BM, Maru DM, Katkhuda R, Menter D, Kopetz S. Consensus molecular subtypes (CMS), markers of systemic inflammation (SI) and clinicopathological parameters in colorectal cancer (CRC). J Clin Oncol 36(Suppl), 2018. e-Pub 2018.
169. Raghav KPS, McDonough SL, Tan BR, Denlinger CS, Magliocco AM, Choong NW, Sommer N, Scappaticci FA, Campos D, Guthrie KA, Kopetz S, Fakih M, Hochster HS. A randomized phase II study of trastuzumab and pertuzumab (TP) compared to cetuximab and irinotecan (CETIRI) in advanced/metastatic colorectal cancer (mCRC) with HER2 amplification: S1613. J Clin Oncol 36(Suppl), 2018. e-Pub 2018.
170. Kopetz S, Spira AI, Wertheim M, Kim E, Tan BR, Lenz HJ, Nikolinakos P, Rich P, Smith DA, Helwig C, Dussault I, Ojalvo L, Gulley JL. M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with heavily pretreated CRC: Preliminary results from a phase I trial. 2018 Gastrointestinal Cancers Symposium 36(suppl 4S), 2018. e-Pub 2018.
171. Raghav KPS, Loree JM, Morris J, Manuel S, Crosby S, Meric-Bernstam F, Menter D, Raymond V, Lanman RB, Talasaz AA, Kopetz S. Detection and description of ERBB2 amplification using circulating cell free tumor DNA (ctDNA) genomic analysis in metastatic colorectal cancer (mCRC). 2018 Gastrointestinal Cancers Symposium 36(suppl 4S), 2018. e-Pub 2018.
172. Mehrvarz Sarshekeh A, Loree J, Lima Pereira AA, Raghav KPS, Lam M, Advani SM, Davis JS, Dasari A, Morris VK, Menter D, Eng C, Shaw KR, Broaddus R, Routbort M, Luthra R, Maru DM, Overman MJ, Meric-Bernstam F, Kopetz S. The rate of novel actionable mutations in standard of care NGS panel testing in gastrointestinal malignancies. 2018 Gastrointestinal Cancers Symposium 36(suppl 4S), 2018. e-Pub 2018.
173. Lima Pereira AA, Loree JM, Davis JS, Lam M, Morris VK, Overman MJ, Raghav KPS, Kee BK, Fogelman DR, Vilar Sanchez E, Shureiqi I, Eng C, Manuel S, Crosby S, Wolff RA, Lanman RB, Talasaz AA, Janku F, Kopetz S. Predictors for detecting circulating tumor DNA (ctDNA) in metastatic colorectal cancer (mCRC). 2018 Gastrointestinal Cancers Symposium 36(suppl 4S), 2018. e-Pub 2018.
174. Loree JM, Strickler JH, Lima Pereira AA, Lam M, Raghav KPS, Morris VK, Menter D, Banks K, Nagy RJ, Raymond V, Overman MJ, Talasaz AA, Lanman RB, Kopetz S. Serial monitoring of ctDNA to highlight mutation profiles in colorectal cancer. 2018 Gastrointestinal Cancers Symposium 36(suppl 4S), 2018. e-Pub 2018.
175. Willauer AN, Loree JM, Lima Pereira AA, Lam M, Raghav KPS, Morris VK, Menter D, Shaw KR, Broaddus R, Meric-Bernstam F, Wang Y, Overman MJ, Kopetz S. Clinical and molecular characterization of early-onset colorectal cancer patients with inflammatory bowel disease. 2018 Gastrointestinal Cancers Symposium 36(suppl 4S), 2018. e-Pub 2018.
176. Cutsem EV, Cuyle PJ, Huijberts S, Yaeger R, Schellens JHM, Elez E, Tabernero J, Fakih M, Montagut C, Peeters M, Desai J, Yoshino T, Ciardiello F, Wasan HS, Kopetz S, Maharry K, Christy-Bittel J, Gollerkeri A, Grothey A. BEACON CRC study safety lead-in (SLI) in patients with BRAFV600E metastatic colorectal cancer (mCRC): Efficacy and tumor markers. 2018 Gastrointestinal Cancers Symposium 36(suppl 4S), 2018. e-Pub 2018.
177. Patel M, Loree JM, Taggart MW, Malpica A, Matamoros A, Kopetz S, Varadhachary GR, Fournier KF, Royal RE, Raghav KPS. Malignant peritoneal mesothelioma: Clinicopathological features, prognostic factors, and survival outcomes. 2018 Gastrointestinal Cancers Symposium 36(suppl 4S), 2018. e-Pub 2018.
178. Bendell JC, Kopetz S, Middleton MR, Eves PT, Bozon V, Boyd AP, Schellens JHM. Phase 1b/2 study of binimetinib (BINI) in combination with nivolumab (NIVO) or NIVO plus ipilimumab (IPI) in patients (pts) with previously treated microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) with RAS mutation. 2018 Gastrointestinal Cancers Symposium 36(suppl 4S), 2018. e-Pub 2018.
179. Overman MJ, Bergamo F, McDermott RS, Aglietta M, Chen F, Gelsomino F, Wong M, Morse M, Van Cutsem E, Hendlisz A, Neyns B, Moss RA, Zhao H, Cao ZA, Kamble S, Kopetz S, Andre T. Nivolumab in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): Long-term survival according to prior line of treatment from CheckMate-142. 2018 Gastrointestinal Cancers Symposium 36(suppl 4S), 2018. e-Pub 2018.
180. Kopetz S, Spira, AI, Wertheim M, Kim E, Tan BR, Lenz HJ. A bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with heavily pretreated CRC: Preliminary results from a phase I trial. Journal of Clinical Oncology 36(4suppl):764, 2018. e-Pub 2018.
181. Nusrat M, Roszik J, Katkhuda R, Menter D, Raghav KPS, Morris VK, Sharma P, Allison JP, Blando JM, Maru DM, Overman MJ, Kopetz S. Association of phosphatidylinositol 3-kinase (PI3K) pathway activation with increased immune checkpoint expression in colorectal cancer (CRC) patients. 2018 Gastrointestinal Cancers Symposium 36(suppl 4S), 2018. e-Pub 2018.
182. Vicente D, Mizuno T, Loehrer A, Limani P, Kopetz S, Vauthey JN. Association of SMAD4 gene mutation with incidence of peritoneal involvement in unresectable metastatic colorectal cancer. 2018 Gastrointestinal Cancers Symposium 36(suppl 4S), 2018. e-Pub 2018.
183. Andre T, Lonardi S, Wong M, Lenz HJ, Gelsomino F, Aglietta M, Morse M, Van Cutsem E, McDermott RS, Hill AG, Sawyer MB, Hendlisz A, Neyns B, Svrcek M, Moss RA, Ledeine JM, Cao ZA, Kamble S, Kopetz S, Overman MJ. Nivolumab + ipilimumab combination in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): First report of the full cohort from CheckMate-142. 2018 Gastrointestinal Cancers Symposium 36(Suppl 4S), 2018. e-Pub 2018.
184. Lam M, Lima Pereira AA, Loree JM, Advani SM, Overman MJ, Bailey A, Johnson A, Holla VK, Sanchez NS, Khotskaya Y, Meric-Bernstam F, Kopetz S. Effect of matched therapy in metastatic colorectal cancer on progression free survival in the phase I setting. 2018 Gastrointestinal Cancers Symposium 36(suppl 4S), 2018. e-Pub 2018.
185. Willis J, Morelli MP, Morris VK, Loree J, Lam M, Lima Pereira AA, Raghav KPS, Kee BK, Vilar Sanchez E, Eng C, Manuel S, Crosby S, Wolff RA, Lanman RB, Talasaz AA, Janku F, Overman MJ, Kopetz S. Impact of microsatellite instability (MSI) on tumor clonal evolution in metastatic colorectal cancer (mCRC). 2018 Gastrointestinal Cancers Symposium 36(suppl 4S), 2018. e-Pub 2018.
186. Kopetz S, Zagonel V, Overman MJ, McDermott R, Morse MA, Chen FL, Lee J, Moss RA, Ling L, Greenfield A, Greenawalt D, Cao ZA. Microbiome Analyses in Patients with Previously Treated, Deficient DNA Mismatch Repair/Microsatellite Instability-High Metastatic Colorectal Cancer Treated with Nivolumab +/- Ipilimumab: CheckMate 142, Bristol Myers Squibb, 2017. e-Pub 2017.
187. Morris V, Sorokin A, Blum M, Korphaisarn K, Estrella J, Faoro L, Wang M, Hamilton S, Kapoun AM, Kopetz S. RSPO3 overexpression is a characteristic feature of signet ring gastrointestinal malignancies 17(1S), 2017. e-Pub 2017.
188. Capasso A, Lang J, Pitts TM, Lieu CH, Kopetz S, Davis SL, Jordan K, Bagby SM, Messersmith WA, Pelanda R, Eckhardt SG. Humanized patient-derived xenografts (PDXs) recapitulate clinical responses in microsatellite stable (MSS) and unstable (MSI-H) colorectal cancer (CRC) 17(1S), 2017. e-Pub 2017.
189. Dumbrava EI, Balaji K, Raghav K, Javle M, Blum-Murphy M, Sajan B, Kopetz S, Broaddus R, Routbort M, Pant S, Tsimberidou A, Subbiah V, Hong DS, Ahnert JR, Shaw K, Piha-Paul S, Meric-Bernstam F. Targeting HER2 (ERBB2) amplification identified by next-generation sequencing (NGS) in patients with advanced or metastatic solid tumors 17(1S), 2017. e-Pub 2017.
190. Andre T, Overman MJ, Lonardi S, Aglietta M, McDermott R, Wong KYM, Morse M, Hendlisz A, Moss RA, J-M L, Tang H, Cao ZA, Kopetz S. Analysis of tumor PD-L1 expression and biomarkers in relation to clinical activity in patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) 1 ipilimumab (IPI): CheckMate 142. Annals of Oncology 28(Suppl 5, v163), 2017. e-Pub 2017.
191. Huijberts S, Schellens JHM, Fakih M, Peeters M, Kopetz S, Grothey A, Cutsem EV, Wasan HS, Desai J, Ciardiello F, Yoshino T, Maharry K, Gollerkeri A, Tabernero J. BEACON CRC (binimetinib [BINI], encorafenib [ENCO], and cetuximab [CTX] combined to treat BRAF-mutant metastatic colorectal cancer [mCRC]): A multicenter, randomized, open-label, three-arm phase III study of ENCO plus CTX plus or minus BINI vs irinotecan (IRI)/CTX or infusional 5-fluorouracil/folinic acid/IRI (FOLFIRI)/CTX with a safety lead-in of ENCO + BINI + CTX in patients (Pts) with BRAFV600E mCRC. J Clin Oncol 35(Suppl), 2017. e-Pub 2017.
192. Andre T, Lonardi S, Wong KYM, Morse M, McDermott RS, Hill AG, Hendlisz A, Lenz HJ, Leach JW, Moss RA, Cao ZA, Ledeine JM, Chan E, Kopetz S, Overman MJ. Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 study. J Clin Oncol 35(suppl), 2017. e-Pub 2017.
193. Overman MJ, Vauthey JN, Aloia TM, Conrad C, Chun YS, Lima Pereira AA, Jiang Z, Crosby S, Wei S, Raghav KPS, Morris VK, Tan M, Maslan A, Talasaz AA, Mortimer S, Kopetz S. Circulating tumor DNA (ctDNA) utilizing a high-sensitivity panel to detect minimal residual disease post liver hepatectomy and predict disease recurrence. J Clin Oncol 35(suppl), 2017. e-Pub 2017.
194. Adam L, Fowler J, Wu W, Yu Y, Wang H, San Lucas FA, Huff C, Kopetz S, Scheet P, Overman MJ. DNA sequencing of the small bowel adenocarcinomas to identify targetable ErbB2 mutations, 2017. e-Pub 2017.
195. Kopetz S, Lonardi S, McDermott RS, Aglietta M, Hendlisz A, Morse M, Leach JW, Neyns B, Chan E, Chen F, Wong KYM, Lee JJ, Garcia-Alfonso P, Hill AG, Lenz HJ, Desai J, Moss RA, Cao ZA, Overman MJ, Andre T. Concordance of DNA mismatch repair deficient (dMMR)/microsatellite instability (MSI) assessment by local and central testing in patients with metastatic CRC (mCRC) receiving nivolumab (nivo) in CheckMate 142 study. J Clin Oncol 35(suppl), 2017. e-Pub 2017.
196. Loree JM, Miron B, Holla V, Overman MJ, Lima Pereira AA, Lam M, Morris VK, Raghav KPS, Routbort M, Shaw KR, Burck N, Sharivkin R, Edelheit O, Meric-Bernstam F, Vidne M, Tarcic G, Kopetz S. Not all RAS mutations created equal: Functional and clinical characterization of 80 different KRAS and NRAS mutations. J Clin Oncol 35(suppl), 2017. e-Pub 2017.
197. Korphaisarn K, Chou CK, Xia W, Clarke C, Davis JS, Liao HW, Crosby S, Manuel S, Wu J, Menter D, Hung CM, Kopetz S. Arginine methylation of EGFR in circulating tumor cells: A new biomarker for predicting resistance to anti-EGFR agents, 2017. e-Pub 2017.
198. Kopetz S, McDonough SL, Morris II VK, Lenz HJ, Magliocco AM, Atreya CE, Diaz Jr LA, Joseph Allegra C, Wang SE, Hanyoung Lieu C, Eckhardt SG, Semrad TJ, Kaberle K, Guthrie KA, Hochster HS. Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406). 2017 Gastrointestinal Cancers Symposium 35(suppl), 2017. e-Pub 2017.
199. Reilley M, Basu S, Katkhuda R, Patterson N, Chen T, Blando JM, Menter D, Maru DM, Allison JP, Kopetz S, Sharma P, Overman MJ. Prognostic implications of TAMs in colorectal cancer hepatic metastases, 2017. e-Pub 2017.
200. Nusrat M, Manyam GC, Loree JM, Lam M, Overman MJ, Maru DM, Routbort M, Morris J, Kopetz S. Molecular characterization of TP53 mutations and copy number change in colorectal cancers, 2017. e-Pub 2017.
201. Parseghian C, Patnana M, Bhosale P, Hess K, Kopetz S, Overman M, Naing A, Piha-Paul S, Subbiah V, Hong D, Le H. Evaluating for pseudoprogression in colorectal and pancreatic tumors treated with immunotherapy. ESMO World Congress on GI Cancer 2017 28(suppl_3), 2017. e-Pub 2017.
202. Moehrmann L, Huang HJ, Hong DS, Tsimberidou AM, Fu S, Piha-Paul SA, Subbiah V, Karp DD, Naing A, Krug A, Enderle D, Priewasser T, Noerholm M, Eng C, Kopetz S, Skog J, Meric-Bernstam F, Janku F. Liquid biopsies of plasma exosomal nucleic acids, plasma cell-free DNA, and survival of patients with advanced cancers. J Clin Oncol 35(suppl), 2017. e-Pub 2017.
203. Janku F, De Groot JF, Javle MM, Penas-Prado M, Shroff RT, Luthra R, Banks K, Lanman RB, Conley AP, Broaddus R, Davies MA, Kopetz S, Yung WKA, Heymach J, Fu S, Shaw KR, Meric-Bernstam F. Simultaneous molecular alterations in solid tumors with IDH1 or IDH2 mutations. J Clin Oncol 35(suppl), 2017. e-Pub 2017.
204. Chun YS, Mehran RJ, Tzeng CD, Kee BK, Dasari A, Sepesi B, Conrad C, Aloia TA, Kopetz S, Vauthey J. LUNA: A randomized phase II trial of liver resection plus chemotherapy or chemotherapy alone in patients with unresectable lung and resectable liver metastases from colorectal adenocarcinoma, 2017. e-Pub 2017.
205. Dumbrava EEI, Brusco L, Daniels MS, Wathoo C, Shaw KR, Lu KH, Zheng X, Strong LC, Litton JK, Arun B, Eterovic AK, Routbort M, Piha-Paul SA, Subbiah V, Hong DS, Kopetz S, Mendelsohn J, Mills GB, Chen K, Meric-Bernstam F. Prevalence of incidental germline pathogenic (PV) and likely pathogenic (LPV) variants in hereditary cancer-related genes identified in matched tumor/normal sequencing of advanced solid tumors. J Clin Oncol 35(suppl), 2017. e-Pub 2017.
206. Capasso A, Lang J, Pitts TM, Davis SL, Lieu C, Kopetz S, Bagby S, Francoeur P, Tentler JJ, Slansky J, Pelanda R, Eckhardt G. Development and validation of humanized mice models implanted with patient derived colorectal cancer xenografts 17(13S), 2017. e-Pub 2017.
207. Loree JM, Korphaisarn KK, Lam M, Morris VK, Raghav KP, Overman MJ, Eng C, Dasar A, Kee BK, Fogelman D, Wolff RA, Shaw K, Broaddus R, Routbort MJ, Luthra R, Maru DM, Menter DG, Meric-Bernstam F, Kopetz S. APCWT/RASWT/BRAFWT tumors represent an under recognized poor prognostic group of right sided colorectal cancer 77(13S), 2017. e-Pub 2017.
208. Inoue A, Salimian Rizi B, Carugo A, Seth S, Bristow C, Genovese G, Viale A, Menter DG, Kopetz S, Draetta GF. Identifying selective vulnerabilities in colorectal cancer molecular subtypes using in vivo functional genomic screens 77(13S), 2017. e-Pub 2017.
209. Kheder E, Huang HJ, Wu A, Hong DS, Piha-Paul SA, Karp DD, Fu S, Subbiah V, Tsimberidou AM, Naing A, Diab A, Javle M, Kopetz S, Sood AK, Kurie JM, Meric-Bernstam F, Gleeson M, Janku F. Detection of circulating antibodies against KRAS in patients with advanced cancers 77(13S), 2017. e-Pub 2017.
210. Janku F, Barzi A, Sartore-Bianchi A, Fujii T, Cassingena A, Siravegna G, Karp DD, Piha-Paul SA, Subbiah V, Tsimberidou AM, Huang HJ, Veronese S, Di Nicolantonio F, Erlander MG, Luthra R, Kopetz S, Meric-Bernstam F, Siena S, Lenz HJ, Bardelli A. Mutation enrichment next-generation sequencing for quantitative detection of KRAS mutations in urine cell-free DNA from patients with advanced colorectal and other cancers. J Clin Oncol 35(suppl 4S), 2017. e-Pub 2017.
211. Korphaisarn K, Morris VK, Overman MJ, Fogelman DR, Shureiqui I, Kee BK, Wolff RA, Eng C, Menter D, Hamilton SR, Dasari A, Raghav KPS, Mehta TR, Manuel S, Kopetz S. Signet ring cell colorectal cancer: Genomic insights into a rare subpopulation of colorectal adenocarcinoma. J Clin Oncol 35(suppl 4s), 2017. e-Pub 2017.
212. Overman MJ, Lonardi S, Leone F, McDermott RS, Morse MA, Wong KYM, Neyns B, Leach JL, Garcia Alfonso P, Lee JJ, Hill A, Lenz HJ, Desai J, Moss RA, Cao ZA, Ledeine JM, Tang H, Kopetz S, Andre T. Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: Update from CheckMate 142. J Clin Oncol 35(suppl 4S), 2017. e-Pub 2017.
213. Sorokin A, Bitner L, Wu J, Menter D, Kopetz S, Morris VK. Antitumor activity of panRAF inhibition in BRAF V600E metastatic colorectal cancer. J Clin Oncol 35(Suppl 4s), 2017. e-Pub 2017.
214. Strickler JH, Banks KC, Nagy RJ, Lanman RB, Talasaz AA, Corcoran RB, Kopetz S. Blood-based genomic profiling of circulating cell-free tumor DNA (ctDNA) in 1397 patients (pts) with colorectal cancer (CRC). J Clin Oncol 35(suppl 4S), 2017. e-Pub 2017.
215. Loree JM, Lam M, Morris J, Overman MJ, Raghav KPS, Eng C, Dasari A, Kee BK, Fogelman DR, Wolff RA, Jiang Z, Davis JS, Shaw KR, Broaddus R, Routbort M, Luthra R, Maru DM, Menter D, Meric-Bernstam F, Kopetz S. RAS heterogeneity as a prognostic marker in metastatic colorectal cancer. J Clin Oncol 35(suppl 4S), 2017. e-Pub 2017.
216. Lee MS, Advani SM, Morris J, Jiang ZQ, Manyam GC, Menter D, McIntosh Broom B, Eng C, Overman MJ, Maru DM, Hamilton SR, Kopetz S. Association of primary (1°) site and molecular features with progression-free survival (PFS) and overall survival (OS) of metastatic colorectal cancer (mCRC) after anti-epidermal growth factor receptor (αEGFR) therapy. J Clin Oncol 34(Suppl), 2016. e-Pub 2016.
217. Korphaisarn K, Overman MJ, Fogelman DR, Kee BK, Raghav KPS, Shureiqui I, Wolff RA, Patel K, Shaw KR, Eng C, Maru DM, Routbort M, Meric-Bernstam F, Kopetz S, Morris VK, Vilar-Sanchez E, Manuel S, Dasari A. Association of FBXW7 missense mutations (mt) with unfavorable prognosis in metastatic colorectal cancer (mCRC) patients (pts). J Clin Oncol 34(suppl), 2016. e-Pub 2016.
218. Dasari A, Overman MJ, Fogelman DR, Kee BK, Menter D, Raghav KPS, Morris VK, Oh J, Wu J, Jiang Z, Tian F, Adam L, Brimer M, Morris J, Meric-Bernstam F, Kopetz S. A phase II and co-clinical study of an AKT inhibitor in patients (pts) with biomarker-enriched, previously treated metastatic colorectal cancer (mCRC). J Clin Oncol 34(suppl), 2016. e-Pub 2016.
219. Shin US, You YN, Price BA, Rodriguez-Bigas MA, Skibber JM, Maru DM, Taggart MW, Kopetz S, Eng C, Minsky BD, Das P, Krishnan S, Chang GJ. Is the neutrophil-lymphocyte ratio (NLR) a predictive and prognostic factor in rectal cancer patients treated with neoadjuvant chemoradiation (nCRT)?. J Clin Oncol 34(suppl), 2016. e-Pub 2016.
220. Morris VK, Wu J, Adam L, Tian F, Gagea M, Hong DS, Menter D, Kopetz S. Role of MEK inhibition in improving anti-tumor responses in xenograft models of BRAF-mutated metastatic colorectal cancer. J Clin Oncol 34(suppl 4S), 2016. e-Pub 2016.
221. Lee CE, Burnham Lanman R, Banks KC, Nagy RJ, Mortimer S, Simon DA, Chudova D, Eltoukhy H, Talasaz A, Lastra E, Kopetz S, Strickler JH. Identification of novel EGFR ectodomain mutations based on a large database of clinical circulating cell-free DNA sequencing tests. J Clin Oncol 34(suppl), 2016. e-Pub 2016.
222. Raghav KPS, Overman MJ, Yu R, Meric-Bernstam F, Menter D, Kee BK, Muranyi A, Singh S, Routbort M, Chen K, Shaw KR, Shanmugam K, Maru DM, Fakih M, Kopetz S. HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer. J Clin Oncol 34(suppl), 2016. e-Pub 2016.
223. Reilley M, Blando JM, Katkhuda R, Menter D, Sharma P, Allison JP, Kopetz S, Maru DM, Overman JM. Immunologic profiling of consensus molecular subtype (CMS) stratified colorectal cancer (CRC) primary and liver metastectomy specimens: Implications for immune targeting of proficient mismatch repair CRC. J Clin Oncol 34(suppl), 2016. e-Pub 2016.
224. Clarke C, Korphaisarn K, Jiang Z, Crosby S, Davis DW, Wu W, Raghav KPS, Overman MJ, Morris VK, Kee BK, Eng C, Fogelman DR, Navin N, Kopetz S. Antibody-independent isolation and characterization of circulating tumor cells using dielectrophoresis: Fluid flow fractionation in metastatic colorectal cancer. J Clin Oncol 34(Suppl), 2016. e-Pub 2016.
225. Overman MJ, Kopetz S, McDermott RS, Leach J, Lonardi S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson MD, Moss RA, Lin CS, Goldberg M, Andre T. Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results. J Clin Oncol 34(Suppl), 2016. e-Pub 2016.
226. Madwani K, Huang HJ, Shelton DN, Fu S, Tsimberidou AM, Piha-Paul SA, Naing A, Hong DS, Karp DD, Andrews DL, Cabrilo G, Kopetz ES, Luthra R, Kee BK, Eng C, Morris VK, Karlin-Neumann GA, Meric-Bernstam F, Janku F. Quantity of KRAS mutations in cell-free DNA is associated with survival of patients with advanced cancers 76(14S), 2016. e-Pub 2016.
227. Fujii T, Vibat CRT, Karp DD, Piha-Paul SA, Subbiah V, Tsimberidou AM, Fu S, Hong DS, Huang HJ, Madwani K, Andrews DL, Hancock S, Naing A, Luthra R, Kee BK, Kopetz S, Erlander MG, Melnikova V, Meric-Bernstam F, Janku F. Circulating tumor DNA assay performance for detection and monitoring of KRAS mutations in urine from patients with advanced cancers 76(14S), 2016. e-Pub 2016.
228. Sanchez-Espiridion B, White L, Mishra L, Raju GS, Kopetz S, Gu J, Ye Y, Wu X, Liang D. Global and targeted metabolomic profiling of colorectal cancer progression 76(14S), 2016. e-Pub 2016.
229. Lin SH, Raju GS, Huff C, Gu J, Chen JS, Kopetz S, Menter DG, Hawk E, Mishra L, y Y, Wu X. Mutational landscape of colorectal adenomas reveals potential signatures for progression 76(14S), 2016. e-Pub 2016.
230. Thierry AR, El Messaoudi S, Mollevi C, Pastor B, Sanchez C, Raoul JL, Guimbaud R, Pezet D, Artru P, Mathonnet M, De La Fouchardiere C, Borg C, Assenat E, Bouche O, Gavoille C, Kopetz S, Ychou M. Clinical validation of circulating DNA analysis for the detection of point mutations and of the longitudinal metastatic colorectal patient follow up for detecting emergence of resistance to targeted therapy 76(14S), 2016. e-Pub 2016.
231. Kopetz S. Opportunities for integration of PDX models into clinical trials, 2016. e-Pub 2016.
232. Sarshekeh AM, Overman MJ, Kee BK, Fogelman DR, Dasari A, Raghav KPS, Vilar Sanchez E, Manuel S, Shureiqui I, Wolff RA, Patel K, Luthra R, Shaw KR, Eng C, Maru DM, Routbort M, Meric-Bernstam F, Kopetz S. Demographic, tumor characteristics, and outcomes associated with SMAD4 mutation in colorectal cancer. J Clin Oncol 34(suppl 4S), 2016. e-Pub 2016.
233. Gulhati P, Singh Raghav KP, Shroff RT, Varadhachary GR, Kopetz S, Javle MM, Qiao W, Wang H, Morris J, Wolff RA, Overman MJ. Phase II study of bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater. J Clin Oncol 34(suppl 4S), 2016. e-Pub 2016.
234. Subbiah V, Hong DS, Amini B, Piha-Paul S, Fernandez JG, Fu S, Tsimberidou AM, Naing A, Janku F, Karp DD, Overman M, Eng C, Kopetz S, Meric-Bernstam F, Falchook GS. Phase I dose escalation study of the oral multi-kinase VEGF inhibitor regorafenib and the anti-EGFR monoclonal antibody cetuximab in patients with advanced solid tumors including colorectal cancer. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics 14(12 Suppl 2), 2015. e-Pub 2015.
235. Shaw KR, Kopetz S, Holla V, Litzenburger BC, Kinyua W, Sajan B, Lee JJ, Broaddus R. Prospective evaluation of two-phase NGS platform coupled to active precision oncology decision support in the therapeutic management of patients with advanced cancers. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics 14(12 Suppl 2), 2015. e-Pub 2015.
236. Morris V, Janku F, Huang H, Fu S, Overman M, Piha-Paul S, Subbiah V, Kee B, Tsimbierdou A, Fogelman D, Shurieqi I, Manuel S, Scamardo A, Lanman R, Sommer N, Hong D, Kopetz S. Circulating cell-free DNA as a marker for response and resistance to BRAF and EGFR inhibition in BRAF-mutated metastatic colorectal cancer 14(12S2), 2015. e-Pub 2015.
237. Subbiah IW, Janku F, Tsimberidou AM, Naing A, Subbiah V, Wheler JJ, Zinner R, Eng C, Overman MJ, Kopetz S, Hong DS. Concurrent aberrations in the Wnt, MAPK and PI3K pathways identified through next generation sequencing of relapsed refractory colorectal adenocarcinoma (CRC): Implications for future therapeutic trials 75(15S), 2015. e-Pub 2015.
238. Davis JS, Advani S, Banfield E, Overman M, Jiang ZQ, Manuel S, Daniel C, Chang S, Kopetz S. Demographics of colorectal cancer patients vary by aspirin use 75(15S), 2015. e-Pub 2015.
239. Morelli MP, Overman M, Vilar E, Morris V, Fogelman D, Shureiqi I, Garret C, Kanwal R, Eng C, Kee B, Manuel S, Wolff R, Sebisanovic D, Sew L, Zapanta A, Shiller B, Mei G, Eltoukhy H, Talasaz AA, Kopetz S. Prospective clinical application of circulating cell-free DNA sequencing in metastatic colorectal cancer 75(15S), 2015. e-Pub 2015.
240. Advani SM, Lee MS, Overman MJ, Fogelman D, Kee BK, Manuel SD, Davis J, Morris VK, Clarke CN, Daniel CR, Menter DG, Hamilton SR, Maru DM, Kopetz S. Correlation of CpG island methylation with clinical and pathologic characteristics in metastatic colorectal cancer patients 75(15S), 2015. e-Pub 2015.
241. Daniel CR, Shu X, Ye Y, Gu J, Raju GS, Kopetz S, Wu X. Severe obesity and colorectal cancer patient survival 75(15S), 2015. e-Pub 2015.
242. Tu H, Pu X, Daniel-MacDougall C, Melkonian SC, Ye Y, Raju GS, Kopetz S, Wu X. Body mass index, weight gain, and physical activity during adulthood in relation to colorectal cancer risk 75(15S), 2015. e-Pub 2015.
243. Guinney J, Dienstmann R, Wang X, de Reynies A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, Bot B, Morris JS, Simon I, Gerster S, Fessler E, de Sousa e Melo F, Missiaglia E, Ramay H, Barras D, Homicsko K, Maru D, Manyam G, Broom B, Boige V, Laderas T, Salazar R, Gray JW, Tabernero J, Bernards R, Friend S, Laurent-Puig P, Medema JP, Sadanandam A, Wessels L, Delorenzi M, Kopetz S, Vermeulen L, Tejpar S. Consensus molecular subtyping through a community of experts advances unsupervised gene expression-based disease classification and facilitates clinical translation 75(15S), 2015. e-Pub 2015.
244. Meric-Bernstam F, Brusco L, Daniels MS, Strong LC, Shaw KR, Lu KH, Qi Y, Lara-Guerra H, Litton JK, Zhao H, Eterovic AK, Arun B, Routbort M, Janku F, Davies MA, Kopetz S, Mendelsohn J, Mills GB, Chen K. Prevalence of incidental actionable germline mutations in 1,000 advanced cancer patients on a prospective somatic genomic profiling program. J Clin Oncol 33(suppl), 2015. e-Pub 2015.
245. Hong DS, Morris VK, El Osta BE, Fu S, Overman MJ, Piha-Paul SA, Subbiah V, Kee BK, Tsimberidou AM, Zinner R, Fogelman DR, Bellido J, Shureiqi I, Meric-Bernstam F, Kopetz S. Phase Ib study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated metastatic colorectal cancer and advanced cancers. J Clin Oncol 33(suppl), 2015. e-Pub 2015.
246. Janku F, Vibat CRT, Falchook GS, Huang HJ, Hong DS, Piha-Paul SA, Subbiah V, Ramzanali NM, Hancock S, Naing A, DaKarp DD, Nitti G, Cabrilo G, Luthra R, Patel SP, Overman MJ, Kopetz S, Erlander MG, Melnikova V, Meric-Bernstam F. Low frequency KRAS G12/13 mutations in urine cell-free (cf) DNA from patients with BRAF V600E-mutant advanced cancers. J Clin Oncol 33(suppl), 2015. e-Pub 2015.
247. Kopetz S, Litzenburger B, Kinyua W, Sajan B, Subbiah V, Zinner R, Wheler JJ, Hong DS, Tsimberidou AM, Overman MJ, Pagliaro LC, Busaidy NL, Westin SN, Glisson BS, Heymach J, Meric-Bernstam F, Shaw KR, Lee JJ, Broaddus R. Prospective evaluation of a 409-gene next generation sequencing platform to facilitate genotype-matched clinical trial enrollment. J Clin Oncol 33(suppl), 2015. e-Pub 2015.
248. Raghav KPS, Tang C, Morelli MP, Amin HM, Chen K, Manyam GC, Broom BM, Talasaz A, Overman MJ, Shaw KR, Meric-Bernstam F, Maru DM, Eng C, Hong DS, Kopetz S. Multiple independent methods fail to confirm MET amplification rate reported in literature for metastatic colorectal cancer (mCRC). J Clin Oncol 33(suppl 3), 2015. e-Pub 2015.
249. Overman MJ, Kee BK, Fogelman DR, Eng C, Vilar Sanchez E, Shroff RT, Dasari A, Wolff RA, Morris J, Kopetz S. A phase II study of nab-paclitaxel in refractory CIMP-high metastatic colorectal cancer. J Clin Oncol 33(suppl), 2015. e-Pub 2015.
250. Kwatampora L, Clarke C, Silva A, Zorba Y, Williams MD, Broaddus R, Clayman GL, El-Naggar AK, Gagel RF, Grubbs EG, Habra MA, I-Nan Hu M, Jimenez C, Kopetz S, Lee JE, StevSherman SI, Vassilopoulou-Sellin R, Waguespack S, Perrier ND, Busaidy NL. Recurrent parathyroid carcinoma and the need for molecular profiling to aid in prognostication and therapeutics. J Clin Oncol 33(suppl), 2015. e-Pub 2015.
251. Morris VK, Morelli MP, Janku F, Overman MJ, Kee BK, Fogelman DR, Vilar Sanchez E, Shureiqi I, Garrett CR, Raghav KPS, Eng C, Manuel S, Wolff RA, Eltoukhy H, Lanman RB, Talasaz AA, Kopetz S. Clinical utility of a circulating cell-free DNA assay for clinical trial enrollment in refractory metastatic colorectal cancer patients. J Clin Oncol 33(suppl), 2015. e-Pub 2015.
252. Lee MS, Clarke C, Jiang Z, Manyam GC, Tian F, Lu Y, Morris J, Broom BM, Menter D, Vilar Sanchez E, Shureiqi I, Raghav KPS, Eng C, Chang GJ, Simon I, Bernards R, Mills GB, Overman MJ, Maru DM, Kopetz S. Proteomic signatures of colorectal cancer to identify distinct and reproducible subgroups and to reflect prognosis. J Clin Oncol 33(suppl), 2015. e-Pub 2015.
253. Morelli MP, Overman MJ, Kee BK, Vilar Sanchez E, Morris VK, Fogelman DR, Janku F, Garrett CR, Shureiqi I, Raghav KPS, Eng C, Manuel S, Wolff RA, Eltoukhy H, Lanman RB, Talasaz AA, Kopetz S. Predictors of clonal evolution in metastatic colorectal cancer patients. J Clin Oncol 33(suppl), 2015. e-Pub 2015.
254. Lee MS, Clarke C, Jiang ZQ, Manyam GC, Tian F, Lu Y, Morris J, Broom BM, Menter D, Vilar Sanchez E, Shureiqi I, Raghav KPS, Eng C, Chang GJ, Simon I, Bernards R, Mills GB, Overman MJ, Maru DM, Kopetz S. Proteomic signatures of colorectal cancer to identify distinct and reproducible subgroups independent of oncogenic mutations. J Clin Oncol 33(suppl 3), 2015. e-Pub 2015.
255. Clarke C, Lee MS, Manyam GC, Jiang ZQ, Tian F, Lu Y, Morris J, Broom BM, Menter D, Vilar Sanchez E, Raghav KPS, Eng C, Chang GJ, Overman MJ, Maru DM, Kopetz S. Proteomic features of colorectal cancer independently predict relapse-free survival. J Clin Oncol 33(suppl 3), 2015. e-Pub 2015.
256. Bedard PL, Davies MA, Kopetz S, Flaherty KT, Shapiro G, Luke JJ, Spreafico A, Wu B, Gomez C, Cartot-Cotton S, Mazuir F, Micallef S, Demers B, Juric D. First-in-human phase I trial of the PI3Kb-selective inhibitor SAR260301 in patients with advanced solid tumors (NCT01673737). J Clin Oncol 33(suppl), 2015. e-Pub 2015.
257. Subbiah IM, Janku F, Tsimberidou AM, Naing A, Subbiah V, Wheler JJ, Zinner R, Eng C, Overman MJ, Kopetz S, Palmer GA, Hong DS. Next-generation sequencing of advanced, relapsed colorectal adenocarcinoma (CRC) to reveal mutations affecting Wnt, MAPK and PI3K pathway signaling: Emergence of novel combinatorial strategies. J Clin Oncol 33(suppl 3), 2015. e-Pub 2015.
258. Morris VK, James B, Tian F, Jiang ZQ, Overman MJ, Maru DM, Menter D, Powis G, Kopetz S. Acquired mutations in MAPK signaling pathway following initial pharmacological response in BRAF-mutated metastatic colorectal cancer (mCRC). J Clin Oncol 33(suppl 3), 2015. e-Pub 2015.
259. Kopetz S, McDonough S, Morris VK, Lenz HJ, Magliocco AM, Atreya CE, Diaz LA, Allegra CJ, Lieu CH, Eckhardt SG, Semrad TJ, Kaberle K, Guthrie K, Hochster HS. S1406: Randomized phase II study of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (mCRC). J Clin Oncol 33(suppl 3), 2015. e-Pub 2015.
260. Conte B, George B, Dasari A, Overman MJ, Estrella J, Jiang Z, Machado K, Mello CL, Ferrarotto R, Hoff PM, Yao JC, Rashid A, Kopetz S. Colorectal high-grade neuroendocrine carcinoma: A single institution experience. J Clin Oncol 32(suppl 3), 2014. e-Pub 2014.
261. Liu X, George GC, Tsimberidou AM, Naing A, Wheler JJ, Kopetz S, Fu S, Piha-Paul SA, Eng C, Falchook GS, Janku F, Garrett CR, Karp DD, Kurzrock R, Zinner R, Raghav KPS, Subbiah V, Meric-Bernstam F, Hong DS, Overman MJ. Rechallenge with anti-EGFR–based therapy in metastatic colorectal cancer: Impact of intervening time interval and prior anti-EGFR response 32(5s), 2014. e-Pub 2014.
262. Dienstmann R, Guinney J, Delorenzi M, De Reynies A, Roepman P, Sadanandam A, Vermeulen L, Schlicker A, Missiaglia E, Soneson C, Marisa L, Homicsko K, Wang X, Simon I, Laurent-Puig P, Wessels LFA, Medema JP, Kopetz S, Friend SH, Tejpar S. Colorectal Cancer Subtyping Consortium (CRCSC) identification of a consensus of molecular subtypes 32(5s), 2014. e-Pub 2014.
263. Satelli A, Brownlee Z, Kopetz S, Overman M, Meng QH, Li S. A universal marker for the detection of epithelial-mesenchymal transitioned circulating tumor cells and their prognostic relevance in epithelial cancers. Proceedings of the 105th Annual Meeting of the American Association for Cancer Research, 2014. e-Pub 2014.
264. Hong DS, Morris VK, Fu S, Overman MJ, Piha-Paul SA, Kee BK, Zinner R, Fogelman DR, Mistry R, Shureiqi I, Meric-Bernstam F, Kopetz S. Phase 1B study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated advanced cancers and metastatic colorectal cancer 32(5s), 2014. e-Pub 2014.
265. Lee MS, Lieu CH, Overman MJ, Eng C, Morris J, Jiang Z, Morelli MP, Heymach J, Tran HT, Kopetz S. Association of prior treatment with anti-EGFR monoclonal antibodies with downregulation of circulating TRAIL and upregulation of EGFR and VEGF family ligands in metastatic colorectal cancer. J Clin Oncol 32(suppl 3), 2014. e-Pub 2014.
266. Pereira AAL, De Mendonga Rego FJ, Morris VK, Overman MJ, Eng C, Garrett CR, Ferrarotto R, Lee MS, Jiang Z, Hoff PM, Vauthey J, Vilar Sanchez E, Maru DM, Kopetz S. Association between KRAS mutation and lung metastasis in advanced colorectal cancer. J Clin Oncol 32(suppl 3), 2014. e-Pub 2014.
267. Morelli MP, Overman MJ, Vilar Sanchez E, Morris VK, Shureiqi I, Garrett CR, Fogelman DR, Raghav KPS, Kee BK, Deaton L, Eng C, Wolff RA, Sebisanovic D, Siew L, Zapanta A, Mei G, Schiller B, Eltoukhy H, Talasaz AA, Kopetz S. Frequency of concurrent gene mutations and copy number alterations in circulating cell-free DNA (cfDNA) from refractory metastatic CRC patients 32(5s), 2014. e-Pub 2014.
268. San Lucas FA, Fowler J, Kopetz S, Vilar E, Scheet P. Drug repositioning with a bioinformatics platform that integrates the TCGA, cMap and CCLE. Proceedings of the 105th Annual Meeting of the American Association for Cancer Research, 2014. e-Pub 2014.
269. Kopetz S, Overman MJ, Chen K, Lucio-Eterovic AK, Kee BK, Fogelman DR, Dasari A, Raghav KPS, Vilar Sanchez E, Phillips J, Shureiqi I, Garrett CR, Wolff RA, Patel K, Aldape KD, Luthra R, Routbort M, DM, Meric-Bernstam F, Eng C. Mutation and copy number discordance in primary versus metastatic colorectal cancer (mCRC) 32(5s), 2014. e-Pub 2014.
270. Lee MS, Overman MJ, Maru DM, Jiang Z, Manuel S, Eng C, Kee BK, Fogelman DR, Garrett CR, Advani SM, Sanchez EV, Shureiqi I, Wolff RA, Hamilton SR, Kopetz S. Association of CpG island methylator phenotype (CIMP) with inferior progression-free survival with anti-EGFR monoclonal antibody therapy in metastatic colorectal cancer 32(5s), 2014. e-Pub 2014.
271. Overman MJ, Eng C, Kee BK, Fogelman DR, Shroff RT, Fark C, Moinova H, Lutterbaugh J, Issa JJ, Markowitz SD, Kopetz S. A phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer. J Clin Oncol 32(suppl 3), 2014. e-Pub 2014.
272. Hassabo HM, Sahin IH, Kazmi SMA, Al Mutar SS, Gomes DBD, Pini TM, Vilar Sanchez E, Dasari A, Kopetz S, Overman MJ, Eng C, Kee BK, Vauthey J, Hassan M, Garrett CR. Associations between patient (pt) colorectal cancer (CRC) tumor KRAS and BRAF mutation (mut) status and overall survival (OS). J Clin Oncol 32(suppl 3), 2014. e-Pub 2014.
273. Morris VK, Overman MJ, Kee BK, Fogelman DR, Eng C, Dasari A, Shroff RT, Deaton L, Manuel S, Garrett CR, Vilar Sanchez E, Pini TM, Shureiqi I, Mills GB, Hamilton SR, Wolff RA, Meric-Bernstam F, Abbruzzese JL, Maru DM, Kopetz S. Efficiency of biomarker screening for enriched metastatic colorectal cancer trials: The ATTACC program experience. J Clin Oncol 32(suppl 3), 2014. e-Pub 2014.
274. Eng C, Bendell JC, Kopetz S, Tarco E, Xiao L, Ying J, Wang X, Phillips J, Sportelli P, Meric-Bernstam F. Impact of PI3K aberrations on efficacy of perifosine (P), x-PECT: A phase III randomized study of P plus capecitabine (PC) versus placebo plus capecitabine (C) in refractory metastatic colorectal cancer (mCRC) patients 32(5s), 2014. e-Pub 2014.
275. Corcoran RB, Atreya CE, Falchook GS, Infante JR, Hamid O, Messersmith WA, Daud A, Kwak EL, Ryan D, Kurzrock R, Sun P, Cunningham EA, Orford KW, Motwani M, Bai Y, Patel K, Venook AP, Kopetz S. Phase 1-2 trial of the BRAF inhibitor dabrafenib (D) plus MEK inhibitor trametinib (T) in BRAF V600 mutant colorectal cancer (CRC): Updated efficacy and biomarker analysis 32(5s), 2014. e-Pub 2014.
276. Gomes DBD, Hassabo HM, Al Mutar SS, Sahin IH, Rogers J, Nguyen DV, Bolonesi RM, Pini TM, Dasari A, Kopetz S, Overman MJ, Eng C, Kee BK, Hassan M, Garrett CR. MD Anderson experience with off-study regorafenib in patients with advanced colorectal cancer. J Clin Oncol 32(suppl 3), 2014. e-Pub 2014.
277. Chen T, Zhao H, Mao Y, Qi Y, Eterovic AK, Mills Shaw KR, Moulder SL, Davies MA, Degroot JF, Kopetz SE, Meric-Bernstam F, Mills GB, Chen K. Identifying cancer driver mutations in clinical sequencing data. Proceedings of the 105th Annual Meeting of the American Association for Cancer Research, 2014. e-Pub 2014.
278. Shah MS, Fogelman DR, Daniel-MacDougall C, Raghav KPS, Heymach J, Tran HT, Jiang Z, Kopetz S. Il-8 as an underutilized prognostic factor in metastatic colorectal cancer. J Clin Oncol 32(suppl 3), 2014. e-Pub 2014.
279. San Lucas FA, Kopetz S, Scheet PA, Vilar Sanchez E. Discovering new targeted therapies for BRAF mutant-like colorectal cancers. J Clin Oncol 31(suppl), 2013. e-Pub 2013.
280. Kopetz S, Jiang Z, Overman MJ, Rosenberg R, Salazar R, Tabernero J, Stork L, Li Y, Simon I, Chang GJ, Maru DM. Genomic classifier (ColoPrint) to predict outcome and chemotherapy benefit in stage II and III colon cancer patients. J Clin Oncol 31(suppl), 2013. e-Pub 2013.
281. Morris VK, Overman MJ, Maru DM, Kopetz S. Progression-free survival in metastatic, BRAF-mutated colorectal cancer. J Clin Oncol 31(suppl 4), 2013. e-Pub 2013.
282. Lieu CH, Varella-Garcia M, Xu LG, Jiang Z, Eckhardt SG, Messersmith WA, Maru DM, Kopetz S. Increased gene copy number and amplification of FGF2 and FGFR1 in metastatic colorectal cancer. J Clin Oncol 31(suppl 4), 2013. e-Pub 2013.
283. Morelli MP, Overman MJ, Dasari A, Kazmi SMA, Vilar Sanchez E, Eng C, Kee BK, Deaton L, Garrett CR, Diehl F, Angenendt P, Kopetz S. Heterogeneity of acquired KRAS and EGFR mutations in colorectal cancer patients treated with anti-EGFR monoclonal antibodies. J Clin Oncol 31(suppl), 2013. e-Pub 2013.
284. Jiang Z, Deaton L, Neishaboori N, Vauthey JN, Overman MJ, Maru DM, Kopetz S. Molecular characteristics of complete PTEN loss in metastatic colorectal cancer. J Clin Oncol 31(suppl 4), 2013. e-Pub 2013.
285. Salazar R, Roepman P, Tabernero J, Schlicker A, Majewski I, Moreno V, Rosenberg R, Kopetz S, Wessels LFA, Bernards R, Simon I. Association of colorectal cancer intrinsic subtypes with prognosis, chemotherapy response, deficient mismatch repair, and epithelial to mesenchymal transition (EMT). J Clin Oncol 31(suppl), 2013. e-Pub 2013.
286. Kopetz S, Jiang Z, Overman MJ, Dreezen C, Tian S, Li Y, Simon I, Chang GJ, Maru DM. Genomic classifiers (ColoPrint/MSI-Print) predict outcome and chemotherapy benefit in stage II and III colon cancer patients. J Clin Oncol 31(suppl 4), 2013. e-Pub 2013.
287. Corcoran RB, Falchook GS, Infante JR, Hamid O, Messersmith WA, Daud A, Kwak EL, Ryan DP, Kurzrock R, Atreya CE, Luan J, Sun P, Schaeffer M, Motwani M, Bleam MR, Moy CH, Patel K, Orford KW, Kopetz S, Venook AP. Pharmacodynamic and efficacy analysis of the BRAF inhibitor dabrafenib (GSK436) in combination with the MEK inhibitor trametinib (GSK212) in patients with BRAFV600 mutant colorectal cancer (CRC). J Clin Oncol 31(suppl), 2013. e-Pub 2013.
288. Raghav KPS, Wang W, Overman MJ, Kopetz S. MET overexpression as a hallmark of the epithelial-mesenchymal transition (EMT) phenotype in colorectal cancer. J Clin Oncol 31(suppl 4), 2013. e-Pub 2013.
289. Morris VK, Overman MJ, Eng C, Vilar Sanchez E, Morelli MP, Jiang Z, Luthra R, Maru DM, Meric-Bernstam F, Kopetz S. Clinicopathologic features of KRAS-mutated colorectal tumors vary by site of mutation. J Clin Oncol 31(suppl), 2013. e-Pub 2013.
290. Dasari A, Gao H, Deaton L, Overman MJ, Hauch S, Kopetz S, Reuben, JM. Association of mesenchymal phenotype in circulating tumor cells with poor prognosis in metastatic colorectal cancer. J Clin Oncol 31(suppl), 2013. e-Pub 2013.
291. Overman MJ, Kopetz S, Wong S, Tie J, Kosmider S, Jacob A, Vilar E, Gibbs P, Desai J, Tran B. Survival Outcomes in Metastatic Colorectal Cancer (CRC) with High-Level Microsatellite Instability (MSI-H). Annals of Oncology 30(Supplement 9), 2012. e-Pub 2012.
292. Corcoran RB, Falchook GS, Infante JR, Hamid O, Messersmith WA, Kwak EL, Ryan DP, Kurzrock R, Brenner AA, Luan J, Sun P, Allred AJ, Little SM, Patel L, Kopetz S, Venook AP. BRAF V600 mutant colorectal cancer (CRC) expansion cohort from the phase I/II clinical trial of BRAF inhibitor dabrafenib (GSK2118436) plus MEK inhibitor trametinib (GSK1120212) 30, 2012. e-Pub 2012.
293. Raghav KPS, Kalil K, Ferrarotto R, George B, Eng C, Garrett CR, Loyer E, Hoff PM, Charnsangavej C, Kopetz S, Overman MJ. Effect of bevacizumab on rate of oxaliplatin-induced thrombocytopenia and splenomegaly 30, 2012. e-Pub 2012.
294. Das P, Eng C, Rodriguez-Bigas MA, Chang GJ, Skibber JM, Maru D, Munsell MF, Clemons MV, Kopetz S, Garrett CR, Shureiqi I, Krishnan S, Delclos ME, Crane CH. Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal adenocarcinoma: A phase I trial. J Clin Oncol 30(suppl 4), 2012. e-Pub 2012.
295. Shah NN, Lieu CH, Ivan C, Overman MJ, Shimizu M, Morris J, Tran H, Heymach J, Calin G, Kopetz S. Prognostic effects of circulating markers of epithelial mesenchymal transition (EMT) in metastatic colorectal cancer patients, 2012. e-Pub 2012.
296. Overman MJ, George B, Kalil K, Ferrarotto R, Eng C, Garrett CR, Loyer E, Hoff PM, Charnsangavej C, Kopetz S. Use of bevacizumab to reduce the rate of oxaliplatin-induced thrombocytopenia and splenomegaly. J Clin Oncol 30(Suppl 4), 2012. e-Pub 2012.
297. Kesmodel SB, Ellis LM, Lin E, Chang GJ, Abdalla EK, Kopetz S, Vauthey J, Rodriguez-Bigas MA, Curley SA, Feig BW. Complication rates following hepatic surgery in patients receiving neoadjuvant bevacizumab (BV) for colorectal cancer (CRC) liver metastases, 2012. e-Pub 2012.
298. Chen ZY, Lieu CH, Jiang ZQ, Eng C, Vauthey JN, Chang GJ, Qiao W, Morris J, Hong DS, Hoff PM, Tran HT, Heymach J, Overman MJ, Kopetz S. Correlation of specific cytokine profiles with high blood neutrophil-to-lymphocyte ratio and outcome in metastatic colorectal cancer 30, 2012. e-Pub 2012.
299. Chang GJ, Park IJ, Eng C, You YN, Kopetz S, Overman MJ, Rodriguez-Bigas MA, Skibber JM. Exploratory analysis of adjuvant chemotherapy benefits after preoperative chemoradiotherapy and radical resection for rectal cancer 30, 2012. e-Pub 2012.
300. Chen Z, Overman MJ, Garrett CR, Jiang ZQ, Wolff RA, Abbruzzese JL, Eng C, Kopetz S. Systematic survey of therapeutic trials for metastatic colorectal cancer. J Clin Oncol 30(suppl 4), 2012. e-Pub 2012.
301. Chang GJ, Park IJ, Eng C, You Y, Kopetz S, Overman MJ, Rodriguez-Bigas MA, Skibber JM. Exploratory analysis of adjuvant chemotherapy benefits after preoperative chemoradiotherapy and radical resection for rectal cancer. J Clin Oncol 30(suppl), 2012. e-Pub 2012.
302. Shah NN, Lieu CH, Ivan C, Overman MJ, Shimizu M, Morris J, Tran HT, Heymach J, Calin G, Kopetz S. Prognostic effects of circulating markers of epithelial mesenchymal transition (EMT) in metastatic colorectal cancer patients. J Clin Oncol 30(suppl 4), 2012. e-Pub 2012.
303. Park IJ, Eng C, You Y, Kopetz S, Rodriguez-Bigas MA, Overman MJ, Skibber JM, Chang GJ. Exploratory analysis of adjuvant chemotherapy effects after preoperative chemoradiotherapy and radical resection for rectal cancer. J Clin Oncol/ 2012 Gastrointestinal Cancers Symposium 30(suppl 4), 2012. e-Pub 2012.
304. Morris VK, Parikh N, Overman MJ, Jiang ZQ, Maru DM, Elvin D, Kopetz S, Gallick GE. Relationship of Src activity and prior oxaliplatin on outcomes after hepatectomy for metastatic colorectal cancer 30, 2012. e-Pub 2012.
305. Overman MJ, Eng C, Kee BK, Fogelman DR, Fark C, Hippert R, Holter S, Issa JP, Hamilton SR, Kopetz S. A phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory metastatic colorectal cancer 30, 2012. e-Pub 2012.
306. Mao M, Tsao L, Dayyani F, Gopal V, Nanda Y, Mills G, Bollag G, Davies M, Gallick G, Kopetz S. Resistance to BRAF inhibition in BRAF V600E colorectal cancer is associated with PI3K/AKT activation and hypermethylation:LB-228, 2011. e-Pub 2011.
307. Lieu CH, Tran HT, Fiorentino S, Jiang Z, Mao M, Overman MJ, Eng C, Ellis LM, Heymach J, Kopetz S. Relative impact of chemotherapy with or without bevacizumab on cytokines and angiogenic factors (CAFs) in metastatic colorectal cancer. J Clin Oncol 29((suppl 4; abstr 401)), 2011. e-Pub 2011.
308. George B, You Y, Viswanathan C, Wen S, Baladandayuthapani V, Overman MJ, Kee BK, Kopetz S, Eng C, Garrett CR. Survival advantage associated with palliative oophorectomy in patients with metastatic colorectal cancer (CRC) to the ovaries (mCRC-O): A single institution retrospective analysis. J Clin Oncol 29((suppl 4; abstr 539)), 2011. e-Pub 2011.
309. Jiang Z, Mehta TR, You YN, Chang GJ, Eng C, Overman MJ, Maru M, Hamilton SR, Kopetz S. Association of PTEN loss and local recurrence in stage II-III colon cancer. J Clin Oncol 29((suppl 4; abstr 399)), 2011. e-Pub 2011.
310. Kopetz S, Tran HT, Cunningham D, Mookerjee B, Pike L, Jurgensmeier J, Heymach J. Association of circulating cytokine and angiogenic factors (CAFs) with outcomes to second-line FOLFOX plus bevacizumab or cediranib in metastatic colorectal cancer. J Clin Oncol 29((suppl 4; abstr 406)), 2011. e-Pub 2011.
311. Hassabo H, Hassan M, George B, Wen S, Baladandayuthapani V, Kopetz S, Fogelman DR, Kee BK, Eng C, Garrett CR. Retrospective evaluation of patients with colorectal cancer (CRC) and type II non-insulin-dependent diabetes (NIDDM). J Clin Oncol 29((suppl 4; abstr 507)), 2011. e-Pub 2011.
312. Lieu CH, Tran HT, Jiang Z, Mao M, Overman MJ, Eng C, Morris J, Ellis LM, Heymach J, Kopetz S. The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer 29, 2011. e-Pub 2011.
313. Lieu CJ, Tran HT, Fiorentino S, Jiang Z, Mao M, Overman MJ, Eng C, Ellis LM, Heymach J, Kopetz S. Relative impact of chemotherapy with or without bevacizumab on cytokines and angiogenic factors (CAFs) in metastatic colorectal cancer 29, 2011. e-Pub 2011.
314. Hassabo HM, Hassan M, George B, Wen S, Baladandayuthapani V, Kopetz S, Fogelman DR, Kee BK, Eng C, Garrett CR. Survival advantage associated with metformin usage in patients with colorectal cancer (CRC) and type II noninsulin-dependent diabetes (NIDDM) 29, 2011. e-Pub 2011.
315. George B, Estrella J, Machado L, Ferrarotto R, Hoff PM, Rashid A, Kopetz S. High-grade neuroendocrine carcinomas (HGNECs) of the colon and rectum: A single-institution retrospective analysis 29, 2011. e-Pub 2011.
316. Jiang Z, Mehta TR, You YN, Chang GJ, Eng C, Overman MJ, Maru D, Hamilton SR, Kopetz S. Association of PTEN loss and local recurrence in stage II-III colon cancer 29, 2011. e-Pub 2011.
317. Hassabo H, Hassan M, George B, Wen S, Baladandayuthapani V, Kopetz S, Fogelman DR, Kee BK, Eng C, Garrett CR. Retrospective evaluation of patients with colorectal cancer (CRC) and type II non-insulin-dependent diabetes (NIDDM) 29, 2011. e-Pub 2011.
318. Chang G, Maru D, Agarwal A, Schlette E, Wolff R, Rodriguez-Bigas M, You N, Feig B, Kopetz S, Skibber J, Eng C. Histopathologic responses in primary tumors of patients with metastatic colorectal carcinoma after neoadjuvant systemic chemotherapy alone, 2010. e-Pub 2010.
319. Kopetz S, Desai J, Chan E, Hecht JR, O'Dwyer PJ, Lee RJ, Nolop KB, Bhattacharya S, Saltz L. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors, 2010. e-Pub 2010.
320. Tran B, Kopetz S, Jeanne T, Gibbs P, Jiang ZQ, Lieu CH, Agarwal A, Maru DM, Sieber O, Desai J. Distinct Differences in Sites of Metastatic Disease May Contribute to Poorer Outcomes Observed in Patients with BRAF Mutant Colorectal Cancers, 2010. e-Pub 2010.
321. Tran B, Kopetz S, Tie J, Gibbs P, Jiang Z, Lieu CH, Agarwal A, Maru D, Sieber O, Desai J. Differences in sites of metastatic disease and outcomes observed in patients with BRAF mutant colorectal cancers 28, 2010. e-Pub 2010.
322. Boonsirikamchai P, Maru DM, Chun YS, Kaur H, Kopetz S, Loyer EM. New CT Findings of Response and Recurrence Independent of Change in Tumor Size in Colorectal Liver Metastasis Treated with Bevacizumab. presented at the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), Chicago, 2009. e-Pub 2009.
323. Kopetz S, Hoff P, Eng C, Overman MJ, Glover KY, Chang DZ, Wolff RA, Abbruzzese JL, Ellis LM, Heymach JV. Levels of angiogenic cytokines prior to disease progression in metastatic colorectal cancer patients treated with bevacizumab:292, 2009. e-Pub 2009.
324. Chun YS, Kopetz S, Palavecino M, Zorzi D, Curley SA, Abdalla EK, Vauthey JN. Proposal of new staging in advanced colorectal cancer:304, 2009. e-Pub 2009.
325. Sankhala K, Takimoto C, Mita A, Xiong H, Rodon JA, Adinin R, Burns K, Toko T, Arakawa K, Kopetz S. Two Phase I, Pharmacokinetic (PK) and Pharmacodynamic (PD) Studies of TAS-109, a novel nucleoside analogue with 14 days and 7 days continuous infusion (CI) schedules, 2008. e-Pub 2008.
326. Eng C, Kopetz S, Morris J, Malik Z, Stewart D, Chang H, Ohinata A, Abbruzzese J, Gallick G. Phase II study of the novel oral Src-kinase inhibitor, AZD0530, in previously treated advanced colorectal cancer patients:LB-76, 2008. e-Pub 2008.
327. Kopetz S, Wolff R, Eng C, Henry L, Glover K, Chang D, Overman M, Gallick G, Abbruzzese J. Phase IB study of Src inhibitation with dasatinib in combination with 5-fluorouracil, leuvocorin, oxaliplatin (FOLFOX) and cetuximab in metastatic colorectal cancer:LB-69, 2008. e-Pub 2008.
328. Kopetz S, Mita MM, Sankhala KK, Moseley J, Sherman BM, Bradley CR, Tolcher AW. First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors, 2008. e-Pub 2008.
329. Politano S, Pathak P, Hoff PM, Charnsangavej C, Overman MJ, Loyer E, Vauthey J, Wallace MJ, Wolff RA, Kopetz S. The use of 5-fluorouracil and oxaliplatin (FOLFOX) for colorectal cancer is associated with the development of splenomegaly and thrombocytopenia, 2008. e-Pub 2008.
330. Kopetz S, Shah AN, Gallick GE. Src Continues Aging: Current and Future Clinical Directions:7232, 2007. e-Pub 2007.
331. Kopetz S. Phase II study of infusional 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer, 2007. e-Pub 2007.
332. Chang D, Zhu K, Kopetz S, Voo K, Li Y, Hwu P, Radvanyi L, Abbruzzese JL. Presence of survivin-specific cytotoxic T-lymphocytes (CTLs) in pancreatic cancer patients, and specific killing of human pancreatic carcinoma cells in vitro by survivin-specific CTLs, 2007. e-Pub 2007.
333. Kopetz S, Wu J, Davies M, Johnson F, Donato N. Synergistic effects of combination therapy with anti-EGFR and anti-Src therapy in vitro in colon cancer, 2007. e-Pub 2007.
334. Kopetz S, Wu J, Davies M, Parikh N, Johnson F, Gallick G, Donato N. Synergistic activity of Src and EGFR inhibitors in colon cancer, 2007. e-Pub 2007.
335. Kopetz S, Wu J, Johnson F, Donato N. Anti-tumor effects of combination therapy with anti-EGFR and anti-Src therapy in colorectal cancer:B51, 2006. e-Pub 2006.
336. Hoff PM, Eng C, Adinin RB, Wolff RA, Lin E, Kopetz S, Rodney A, Chang DZ, Abbruzzese JL. Preliminary results from a phase II study of FOLFIRI plus bevacizumab as first-line treatment for metastatic colorectal cancer (mCRC), 2006. e-Pub 2006.
337. Kopetz S, Dang J, Overman M, Phan L, Feig B, Patel D, Wolff RA, Eng CA, Abbruzzese JL, Hoff P. Bevacizumab toxicity and efficacy are unaffected by regimen or resection status: A single institution retrospective study, 2006. e-Pub 2006.
338. Dhillon N, Kopetz S, Del Fabbro E, Reddy S, Bruera E. The Establishment Of A Palliative Care Consult Team In A Comprehensive Cancer Center, 2005. e-Pub 2005.
339. Elez E, Yoshino T, Shen L, Lonardi S, Cutsem EV, Eng C, Kim TW, Wasan HS, Desai J, Ciardiello F, Yaeger R, Maughan TS, Van K Morris II, Wu C, Usari T, Laliberte RJ, Dychter SS, Zhang X, Tabernero J, Kopetz S. First-line encorafenib + cetuximab + mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer. 2025 ASCO Annual Meeting 43(17).
340. Morris V, Quintanilha J, Elvin J, Graf R, Kopetz S. Clinical relevance of tumor fraction assessment from circulating tumor DNA in metastatic colorectal cancer. 2025 ASCO Gastrointestinal Cancers Symposium 43(4).
341. Pan K, Baig Y, Willis J, Dasari A, Bent AH, Higbie V, Huey RW, Kee BK, Lee MS, Parseghian C, Morelli MP, Shen JP, Kopetz S, Morris VK. Phase I/II trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAFV600E metastatic colorectal cancer following progression on prior BRAF+EGFR targeted therapies. 2025 ASCO Gastrointestinal Cancers Symposium 43(4).
342. Bhutiani N, Chiang YJ, Uppal A, Konishi T, White M, Vauthey JN, Kopetz S, Overman MJ, Chang GJ, Tran Cao H. Patterns of metastatic spread and survival outcomes for stage IV left-sided colon vs. rectal cancers: A real-world analysis. 2025 ASCO Gastrointestinal Cancers Symposium 43(4).
343. LaPelusa MB, Qiao W, Iorgulescu B, Lucas FAS, Patel K, Bhamidipati D, Thomas JV, You YN, Foo WC, Maru DM, Thirumurthi S, Morris VK, Kopetz S, Overman MJ, Ludford K. Prognostic value of circulating tumor DNA for progression-free survival in patients with locally advanced dMMR/MSI-H colorectal cancer managed without surgery. 2025 ASCO Gastrointestinal Cancers Symposium 43(4).
344. Yousef MM, Yousef AM, Alfaro K, Maddalena G, Fanaeian MM, Knafl M, Roy P, Vetere G, Bhutiani N, Goldstein D, Uppal A, White M, Fournier KF, Helmink BA, Singh Raghav KP, Dasari A, Overman MJ, Zhao D, Kopetz S, YC Shen JP. Utilizing an automated, high-throughput platform to generate comprehensive clinical & molecular datasets to enable a real-world evidence approach for improving care of patients with gastrointestinal malignancies. 2025 ASCO Gastrointestinal Cancers Symposium 43(4).
345. Maddalena G, Perissinotto E, Intini R, Morris V, Bergamo F, Newhook T, Lonardi S, Kopetz S. Challenges in patient selection for surgical options in V600E BRAF–mutated metastatic colorectal cancer. 2025 ASCO Gastrointestinal Cancers Symposium.
346. Shah PK, Aushev VN, Ensor J, Sanchez SA, Wang CG, Cannon TL, Berim LD, Feinstein T, Grothey A, McCollom JW, Kalmadi SR, Zakari A, Dayyani F, Gravenor D, Liu MC, Jurdi AA, Aleshin A, Meyer JM, Sharif S, Kopetz S. Circulating tumor DNA for detection of molecular residual disease (MRD) in patients (pts) with stage II/III colorectal cancer (CRC): Final analysis of the BESPOKE CRC sub-cohort. 2025 ASCO Gastrointestinal Cancers Symposium 43(4).
347. Arrondo E, Iida N, Hashimoto T, Ozaki H, Shibuki T, Imai M, Fujisawa T, Nakamura Y, Bando H, Kopetz S, Shen JP, Yoshino T. Molecular characteristics and prognostic impact of GNAS mutations in colorectal cancer: An international collaborative study between United States and Japan. 2025 ASCO Gastrointestinal Cancers Symposium 43(4).
348. Higbie V, LaPelusa MB, Shah P, Childress M, Gasco A, An A, Bent AH, Kee BK, Kopetz S, Le P, Morris VK, Pant S, Parseghian C, Shen JP, Wolff RA, Overman MJ. Serial monitoring of circulating tumor DNA as a marker of response to immune checkpoint blockade in MSI-H gastrointestinal tumors. 2025 ASCO Gastrointestinal Cancers Symposium 43(4).
349. Li H, Kopetz S, Yin Y, Peng J, Keenan H. A real-world study of treatment patterns among patients (pts) with metastatic colorectal cancer (mCRC) receiving third-line (3L) or fourth-line (4L) treatment in the US. 2025 ASCO Gastrointestinal Cancers Symposium 43(64).
350. Pant S, Smaglo BG, Huey RW, Haldar SD, Morelli MP, Willis J, Xiao L, Yuan Y, Attanasio S, Shah R, Citron F, Zhao D, Kopetz S, Maitra A, Welsch D, Sheth R, Bhosale P, Wolff RA, Viale A. A phase 1b dose escalation trial of gemcitabine and nab-paclitaxel in combination with lixumistat in patients with advanced pancreatic cancer. 2025 ASCO Gastrointestinal Cancers Symposium 43(4).
351. Overman MJ, Yothers G, Puhalla SL, Sanoff HK, Cohen DJ, Guthrie KA, Ganz PA, Kopetz S, Lucas PC, Blanke CD, Jacobs SA, Hong TS, Wolmark N, Hochster HS, George TJ, Lima CM. Colorectal cancer metastatic dMMR immunotherapy (COMMIT) study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer 9NRG-GI004/SWOG-S1610). 2025 ASCO Gastrointestinal Cancers Symposium 43(4).
352. Lieu CH, Yu G, Kopetz S, Puhalla SL, Lucas PC, Sahin IH, Deming DA, Philip PA, Hong TS, Rojas-Khalil Y, Loree JM, Wolmark N, Yothers G, George TJ, Dasari A. NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-North America). 2025 ASCO Gastrointestinal Cancers Symposium 43(4).
353. Yaeger R, Uboha NV, Klempner SJ, Bekaii-Saab TS, Sabari JK, Barve MA, Saltzman JN, Peguero JA, Paulson AS, Jänne PA, Pelster M, Cruz-Correa M, Kim AMK, Hu N, Ahmad HA, Kopetz S. Adagrasib (Ada) + cetuximab (Cetux) for KRASG12C-mutated metastatic colorectal cancer (mCRC): Longer follow-up analysis from KRYSTAL-1. 2025 ASCO Gastrointestinal Cancers Symposium 43(4).
354. Morelli MP, Basar R, Marin D, Huey RW, Banerjee PP, Willis J, Morris VK, Rafei H, Dasari A, Kee BK, Zeller BE, Diao S, Menter D, Shpall EJ, Kopetz S, Rezvani K. A phase Ib study of immunotherapy with ex-vivo pre-activated and expanded CBNK cells in combination with cetuximab, in patients with colorectal cancer (CRC) with minimal residual disease (MRD): Final report. 2025 ASCO Gastrointestinal Cancers Symposium 43(4).
355. Lim AM, Lin K, Abdelfattah N, Parseghian C, Morelli MP, Willis J, Huey RW, Higbie V, Bent AH, Eluri M, Kee BK, Wolff RA, Singh Raghav KP, Dasari A, Overman MJ, YC Shen JP, Kopetz S, Van K Morris II. Clinicopathologic features of complement activation signatures in colorectal cancer. 2025 ASCO Annual Meeting 43(16).
356. Vetere G, Sun R, Van K Morris II, Dasari A, Kee BK, YC Shen JP, Willis J, Morelli MP, Sorokin A, Marie PK, Wolff RA, Overman MJ, Singh Raghav KP, Sanchez EV, Huey RW, Higbie V, Le P, Baig Y, Kopetz S, Parseghian C. Open-label phase Ib/II study of cetuximab (CET) plus LY3214996 with or without abemaciclib in patients (pts) with anti-EGFR-refractory metastatic colorectal cancer (mCRC). 2025 ASCO Annual Meeting 43(16).
357. Dasari A, Mazard T, Cohen R, Elez E, Tarazona N, Borg C, Rinaudo P, Chêne L, Fagerberg J, Schmoll HJ, Cervantes A, Tabernero J, Kopetz S. Survival of patients (pts) with microsatellite stable/mismatch repair proficient (MSS/pMMR) metastatic colorectal carcinoma (mCRC) treated with EO4010 + nivolumab (EO/N). 2025 ASCO Annual Meeting 43(16).
358. Vinocha A, Dasari A, Li JJ, Thomas JV, Kopetz S, Hu ZI, Shen JP, Raghav KP, Overman MJ. Brain metastasis in patients with primary gastrointestinal malignancy on anti-HER2 therapy. 2025 ASCO Annual Meeting 43(16).
359. Xavier CB, Kang L, Le H, Kahle M, Tsimberidou MA, Naing A, Dumbrava EE, Ahnert JR, Pohlmann PR, Piha-Paul SA, Fu S, Champiat S, Yap TA, Tang TY, Kopetz S, Meric-Bernstam F, Hong DS. Colorectal cancer with gene fusions: Navigating the genomic landscape and treatment selection in a phase I unit. 2025 ASCO Annual Meeting 43(16).
360. Osterlund E, Maddalena G, Pellatt AJ, Eluri M, Parseghian C, Aziz K, Alfaro K, Kell RJ, Manyam GC, Konishi T, Overman MJ, Morelli MP, Willis J, YC Shen JP, Singh Raghav KP, Newhook TE, Dasari A, Maitra A, Van K Morris II, Kopetz S. Biologic correlates of circulating tumor DNA (ctDNA) shedding in the INTERCEPT colorectal cancer (CRC) study. 2025 ASCO Annual Meeting 43(16).
361. Bent AH, Parseghian C, Morris VK, Kee BK, Huey RW, Morelli MP, Shen JP, Jernigan K, Fernandez A, Harrison C, Horodecky K, Dasari A, Alfaro K, Aziz K, Kell RJ, Kopetz S. DAILY: A prospective single arm study evaluating the impact of vitamin D, aspirin, exercise, and diet in colorectal cancer patients with ctDNA-defined minimal residual disease. 2025 ASCO Annual Meeting 43(16).
362. Dasari A, Yu G, Kopetz S, Puhalla SL, Lucas PC, Sahin IH, Deming DA, Philip PA, Hong TS, Rojas-Khalil Y, Loree JM, Wolmark N, Yothers G, George TJ, Lieu CH. Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-NORTH AMERICA): NRG-GI008. 2025 ASCO Annual Meeting 43(16).
363. Amaria R, Kopetz S, Morelli M, Blumenschein G, Altan M, Sanber K, Jazaeri A, Davies M, Diab A, Glitza I, McQuade J, Ikeguchi A, Tawbi H, Bernatchez C, Forget M, Haymaker C, Wong K, Tobin E, Benson M, Truppel-Hartmann A. A phase 1/2 study of KSQ-004EX: Autologous tumor infiltrating lymphocytes, engineered to inactivate genes encoding SOCS1 and Regnase-1, in patients with select advanced solid tumors. 2025 ASCO Annual Meeting 43(16).
364. Kopetz S. Minimal Residual Disease Detection and Intervention: Challenges and Opportunities. 2024 ASCO Annual Meeting.

Book Chapters

1. Yu, IS, Advani, S, Kopetz, S. Initial Systemic Chemotherapy for Metastatic Colorectal Cancer, 279-286, 2022.
2. Dasari A, Johnson B, Parseghian C, Raghav K, Kopetz S. Colorectal Cancer. In: The MD Anderson Manual of Medical Oncology. 3rd, 2020.
3. Heymach JV, Zurita-Saavedra A, Kopetz S, Cascone T, Nilsson M. Tumor angiogenesis. In: Holland-Frei Cancer Medicine, 2017.
4. Hong DS, Kopetz ES, George GC. Colorectal Cancer (Adenocarcinoma). In: Handbook of Targeted Cancer Therapy. Wolters Kluwer Health, 2015.
5. Bhadkamkar N, Crane CH, Rodriguez-Bigas M, Kopetz S, Eng C. Colorectal Cancer. In: The MD Anderson Manual of Medical Oncology. 2nd, 2011.
6. Kopetz S. Targeted Therapy in Cancer. In: Targeted Therapy for Colorectal Cancer. Humana Press, 101-24, 2008.
7. Hoff PMG, Kopetz S. Systemic Therapy for Non-operable Colorectal Cancer Metastases. In: Liver Metastases. Springer, 51-8, 2008.
8. Kopetz S, Hoff P. Management Issues in Patients Presenting with Stage IV Colorectal Cancer. In: Advanced Therapy in Surgical Oncology. Decker Press, 281-91, 2006.
9. Kopetz S, Raber M, Abbruzzese J. Colorectal, Anal, and Unknown Primary Cancer (electronic web update). In: Cancer Medicine, 2006.

Letters to the Editor

1. Pasquereau-Kotula E, Nigro G, Dingli F, Loew D, Poullet P, Xu Y, Kopetz S, Davis J, Peduto L, Robbe-Masselot C, Sansonetti P, Trieu-Cuot P, Dramsi S. Author Correction: Global proteomic identifies multiple cancer-related signaling pathways altered by a gut pathobiont associated with colorectal cancer. Scientific reports 13: 17676, 2023.
2. Raghav K, Kopetz S, Yuan Y. Reply to Y. Yu et al. Journal of Clinical Oncology 41: 1495-1496, 2023.
3. Sun, H, Cao, S, Mashl, RJ, Mo, CK, Zaccaria, S, Wendl, MC, Davies, S, Bailey, MH, Primeau, T, Hoog, J, Mudd, JL, Dean, DA, Patidar, R, Chen, L, Wyczalkowski, MA, Jayasinghe, R, Rodrigues, FM, Terekhanova, NV, Li, Y, Lim, KH, Wang-Gillam, A, Van Tine, BA, Ma, C, Aft, R, Fuh, KC, Schwarz, JK, Roth, JA, Tapia, C, Yang, F, Akcakanat, A, Chen, H, Dai, B, Gibbons, DL, Ha, MJ, Jensen, VB, Kim, M, Kopetz, S, Menter, DG, Meraz, I, Sorokin, A, Wang, J, Westin, SN, Xi, Y, Yap, TA, Yennu Nanda, VG, Zhang, X, Zheng, X, Davies, MA, Fang, B, Meric-Bernstam, F. Author Correction. Nature communications 13, 2022.
4. Vauthey JN, Zorzi D, Kopetz S, Abdalla EK, Kishi Y, Blazer DG. Colorectal Hepatic Metastases: Adjuvant Chemotherapy and Survival Reply. J Clin Oncol 27: E20-E21, 2009.
5. Vauthey JN, Zorzi D, Kopetz S, Abdalla EK, Kishi Y, Blazer DG, III. Reply to Colorectal hepatic metastases: adjuvant chemotherapy and survival by D. Gallagher et al. J Clin Oncol 27: e20-1, 2009.
6. Kopetz S, Abbruzzese JL. Hidden Biases in an Observational Study of Bevacizumab Beyond Progression. J Clin Oncol 27: 1732-3, 2009.
7. Overman M, Kopetz S. First-Line Therapeutic Strategies in Metastatic Colorectal Cancer The Davies/Goldberg Article Reviewed. Oncology, New York-New York 22: 1482-1483, 2008.